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ABSTRACT 
 
Men who have sex with men (MSM) in the United States continue to 
experience disproportionate HIV disease burden.  Historically, most HIV prevention 
research has focused on reducing sexual risk behaviors through individual-level 
behavior change interventions.  To date, behavioral interventions have not reduced 
HIV incidence among MSM and combination prevention approaches that package 
behavioral interventions with additive biomedical or structural interventions are now 
recommended.  The last meta-analysis of HIV behavioral interventions for MSM was 
conducted in 2008.  Since then sixteen new rigorous trials have been identified.  New 
evidence and new recommendations justify an updated meta-analysis to identify the 
most promising and relevant features of behavioral interventions to be used in new 
combination approaches.  This study aimed to calculate an updated effect size for 
MSM-specific HIV behavioral interventions, identify moderators of effect size, 
examine cumulative effect sizes over time, and describe trials that addressed more 
than one behavioral outcome (“integrated interventions”).   Systematic review and 
meta-analysis evaluated effects of 34 randomized controlled trials for 17,872 US 
MSM conducted between 1989 and 2014.  Behavioral interventions reduced the odds 
of sexual risk behavior by 14 percent (OR=.859, 95% CI [0.790, 0.933], p<.001).  
Findings suggest behavioral interventions are still somewhat effective to reduce sexual 
risk behavior, but the effect size was smaller than effect sizes observed in earlier meta-
analyses. Cumulative meta-analysis further demonstrated that intervention effects 
gradually declined over time.  From 1991 to 2014, the magnitude of the effect size 
decreased by 19.5 percent (OR=.719-.859).   Reasons for effect size decline are not 
 clear, but HIV prevention fatigue, inclusion criteria that focus on very high-risk MSM, 
choice of comparison condition, and underpowered primary trials likely contribute to 
effect size shrinkage.  Statistical homogeneity restricted this study’s objective to 
reliably detect moderators of effect [Q(33)=39.35, p=.207; I2=16.14].  All moderators 
hypothesized a priori were not significant.  Post-hoc moderator analyses found 
intervention effects to be moderated by age (p<.001), peer delivery (p=.002), 
community-level interventions (p=.032), HIV status (p=.019), education (p=.023), 
evidence-level (p=.076), retention (p=.09), and MSM subgroup (p=.09).  Nine trials 
were identified that addressed at least one additional problem behavior other sexual 
risk behavior; six trials addressed substance use and three trials addressed HIV testing.  
In conclusion, this study provides new evidence that behavioral interventions have 
become less effective over time.  Development of new combination prevention 
packages presents an opportune time to improve and update behavioral interventions.  
HIV prevention research would benefit from frequent research synthesis to monitor 
effect sizes, identify the most effective intervention components, retire outdated 
intervention components, and identify gaps in current research.  To our knowledge, 
this is the first meta-analysis of HIV behavioral interventions to demonstrate effect 
size shrinkage for HIV behavioral interventions using cumulative meta-analysis.  
Routine cumulative meta-analysis should be included in research synthesis protocols 
to examine and explain effect size shift as new evidence is accumulated. 
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CHAPTER 1: INTRODUCTION 
Statement of the Problem 
 
 The first United States (US) cases of human immunodeficiency virus (HIV) 
were reported in 1981.  Within a few years, about 50 percent of gay men living in San 
Francisco were infected with HIV (Wohlfeiler & Ellen, 2007).  There were no HIV 
medications, and no government-funded HIV prevention programs.  Communities 
mobilized through grassroots organizing to distribute information and educational 
materials to gay men.  Pamphlets, brochures, and media explained that HIV was a 
preventable, sexually transmitted infection.  Social norms changed in the gay 
community and men modified their sexual practices to avoid HIV infection.  
Widespread reductions in sexual risk behavior curbed HIV incidence and rates 
plummeted (Wohlfeiler & Ellen, 2007).  
The majority of HIV prevention research since has focused on reducing sexual 
risk behavior to replicate the community-level behavior change seen in the 1980s.   
However, behavior change associated with the early HIV crisis slowly eroded over 
time, and it is unrealistic to expect similar effects in today’s mature epidemic 
(Wohlfeiler & Ellen, 2007).  While HIV behavioral interventions have demonstrated 
efficacy in reducing sexual risk behavior in small groups of gay, bisexual, and other 
men who have sex with men (referred to as men who have sex with men [MSM] in 
CDC surveillance systems), effects of interventions are limited by reach and dose and 
are not sustained over time.  To date, no funded HIV behavioral intervention has 
reduced HIV incidence among US MSM.  Behavioral interventions, while still 
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necessary, are no longer sufficient for MSM (Coates, 2013).  As the HIV epidemic 
among US MSM becomes more complex and challenging to control, additional 
strategies that can enhance individual-level behavior change interventions are needed. 
Combination HIV prevention packages that benefit from combining partially-
effective behavioral, biomedical, and structural interventions are now recommended.  
Combination approaches aim to identify the most effective components of each 
intervention and rationally combine them.  Scale up of combination approaches 
presents an opportune time to review the state of the science of behavioral 
interventions and identify the most promising and relevant intervention features.  The 
last meta-analysis of HIV behavioral interventions for MSM was published in 2008 
(Johnson et al., 2008).  Since 2008, sixteen rigorous intervention trials have been 
published.  An updated systematic review was published in 2013 (Higa et al., 2013), 
but did not include a meta-analysis.  An updated systematic review with meta-analysis 
to calculate an updated effect size and identify factors associated with effectiveness is 
needed to inform the development of new behavioral interventions.   
Epidemiology of HIV among US MSM 
Prevention and control of HIV continues to be a major public health challenge 
in the United States (Frieden, Foti, and Mermin, 2015).  The Centers for Disease 
Control and Prevention (CDC) estimates 1.1 million people are infected with HIV 
(CDC, 2013a).  About 1 in 6 of people infected with HIV do not know they are 
infected, and are at higher risk of transmitting their infection to others (CDC, 2013a; 
Marks, Crepaz, & Janssen, 2006).  HIV incidence has been stable at about 50,000 new 
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HIV infections each year (CDC, 2012).  However, US MSM continue to experience 
disproportionate HIV disease burden compared to other risk groups.   
In 2010, 63 percent all persons diagnosed with HIV were MSM (CDC, 2012).  
MSM make up about 4 percent of males in the US, but accounted for 78 percent of all 
males diagnosed with HIV (CDC, 2012; CDC 2014a).  MSM are 44 times more likely 
to be infected with HIV than heterosexual males (Purcell et al., 2012).  Further, MSM 
is the only US risk group where new infections have increased.  From 2008 to 2010, 
new infections among MSM significantly increased by 12 percent with the steepest 
increase (22 percent) among younger MSM aged 13-24 years.  Young black MSM 
comprise more new HIV infections than any other demographic group (CDC, 2014a), 
highlighting a complex epidemic fueled by racial and economic disparities.   
MSM of all races and ethnicities also have poorer health outcomes at each 
stage of HIV care (e.g. HIV testing, linkage to care, retention in care, adherence to 
HIV medications, and viral suppression).  Poor care outcomes result in greater HIV 
risk because MSM may be unaware of their infection and/or have viral loads high 
enough for transmission to sexual partners.  In 2010, 78 percent of MSM diagnosed 
with HIV were linked to care, 51 percent were retained in HIV care, 49 percent 
received antiretroviral therapy, and only 42 percent achieved viral suppression (Singh 
et al., 2014).  In a 2011 study of MSM in 21 major US cities, 18 percent of MSM were 
found to be infected with HIV.  One-third of HIV-positive MSM did not know they 
were infected (Wejnert et al., 2013).   
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Complex HIV Risk Environment for MSM 
Since the beginning of the epidemic, HIV prevention research has been 
challenged to demonstrate highly effective interventions for US MSM.  The social 
context can quickly evolve making previously effective interventions less relevant.  
Additionally, MSM-specific HIV epidemics differ from other groups due to multi-
factorial risk environments. Biological, social, and structural factors interact to create 
transmission dynamics that accelerate rapid and efficient transmission of HIV through 
sexual networks (Beyrer et al, 2012; Johnson et al., 2010; Sullivan et al., 2012).   
Disproportionate HIV disease burden is driven primarily by the high per-act 
transmission probability of HIV infection from each encounter of unprotected anal sex 
(Baggeley, White, & Boiley, 2010; Beyrer, 2012; Vittinghoff et al., 1999; Patel et al., 
2014).  In other words, higher background prevalence of HIV increases the likelihood 
that sexual risk behavior will result in infection among MSM (CDC, 2014a).   
Higher biological risk is further compounded by person-level factors such as 
having multiple sexual partners, frequency of unprotected anal sex, substance use prior 
to or before sex, and incident sexually transmitted infection (STI) (Koblin et al., 
2006).  Other factors that influence HIV transmission include social or structural 
determinants that impact the environment people live in.  Stigma and homophobia, 
gaps in comprehensive health care, and poor access to condoms and/or HIV testing 
challenge HIV prevention norms and create additional stressors for vulnerable MSM 
(Altman et al., 2012; Kaufman, Cornish, Zimmerman, & Johnson, 2014; Mayer et al., 
2012).  Finally, community-level factors such as higher community viral load due to 
undiagnosed HIV infection or poor adherence to HIV medications can vary by sexual 
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network (e.g. male sex workers, homeless MSM, substance-using MSM), and make 
some communities more vulnerable to HIV exposure and infection (Das et al., 2010; 
Mayer et al., 2014).   
Combination Prevention Interventions 
HIV risk and transmission dynamics among MSM may be too complex to be 
effectively addressed by behavioral interventions alone.  MSM who intentionally 
engage in high-risk sexual practice (despite knowledge of the risks) may require 
additional strategies including, but not limited to, individual behavior change.  While 
newer biomedical interventions are likely to be more effective than behavioral 
interventions, they also are not sufficient to prevent HIV if implemented without 
behavioral interventions (Coates, 2013).  “Combination prevention interventions” are 
assumed to maximize prevention through the additive effects of partially-effective 
behavioral, biomedical, and structural interventions (Cohen et al., 2013; Dieffenbach 
& Fauci, 2011; Kurth, Celum, Baeten, Vermund, & Wasserheit, 2011 Sullivan et al., 
2012;).   
UNAIDS (2010) defines combination HIV prevention as: 
“The strategic, simultaneous use of different classes of prevention activities 
(biomedical, behavioral, social/structural) that operate on multiple levels 
(individual, relationship, community, societal), to respond to the specific needs 
of particular audiences and modes of HIV transmission, and to make efficient 
use of resources through prioritizing, partnership, and engagement of affected 
communities.”  
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Combination approaches are now recommended in the National HIV/AIDS Strategy 
and in the President’s Emergency Plan for AIDS Relief (US Department of State, 
2013;  The White House, 2010).  To advance new combination approaches, the most 
effective components of currently available biomedical, structural, and behavioral 
interventions need to be identified.  Combination prevention packages can then be 
tailored to disrupt the primary drivers of HIV infection in specific populations or 
sexual networks.   
Biomedical Interventions 
 Biomedical interventions for MSM take advantage of scientific advances 
using antiretroviral therapy (ART) as prevention and hold high promise to curb HIV 
transmission.  Biomedical interventions, if scaled up, are estimated to have greater 
impact on HIV incidence than behavioral interventions - especially for high-risk MSM 
resistant to individual behavior change.  Recommended biomedical interventions for 
US MSM include pre- and post-exposure prophylaxis (PrEP and PEP, respectively) 
for uninfected MSM, initiation of ART as “treatment as prevention” (TasP) for HIV-
positive MSM, as well as expedited treatment of incident STI.  PrEP and TasP are the 
most promising biomedical strategies based on estimated efficacy, however they are 
relatively recent interventions and are expected to require behavioral components to 
optimize adherence, and decrease sexual risk (Cohen et al., 2010; Cohen, et al., 2013; 
Grant et al., 2010).   
Structural Interventions 
Structural interventions aim to influence the environmental variables 
associated with risk and create environments that promote HIV prevention norms 
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(Kaufman et al., 2014).  There is less evidence for these interventions due to 
challenges in evaluating slow, structural-level change, yet their hypothesized 
contribution to health equity and disruption of key social drivers of HIV risk support 
their role in combination approaches (Grossman, Purcell, Rotherum-Borus, & 
Veniegas, 2011; Kaufman, et al., 2014; Kurth, Celum, Baeten, Vermund, & 
Wasserheit, 2011).  Examples of structural interventions include condom distribution 
programs, syringe exchange programs, comprehensive health care, and policy changes 
to reduce institutional discrimination against lesbian, gay, bisexual, and transgendered 
individuals (Breyer et al., 2012; Kaufman et al., 2014).   
 Behavioral Interventions 
This study focuses exclusively on the state of the science of behavioral 
interventions.  Behavioral interventions have the strongest evidence base for reducing 
sexual risk behavior, but they have not shown evidence for reducing incidence 
(Sullivan et al., 2012).   However, it is logical to continue to support behavioral 
interventions because HIV transmission among MSM is driven primarily by the risk 
behavior of unprotected anal intercourse (UAI).  UAI with serodiscordant partners 
(known or unknown HIV-positive partners) and subsequent exposure to high HIV 
viral load increases risk of HIV acquisition (Coates, Richter, & Caceres, 2008; 
Sullivan et al., 2012).  Among US MSM, encounters of UAI increased nearly 20 
percent from 2005 to 2011 (Frieden, Foti, & Mermin, 2015; Paz-Bailey et al. 2013).  
Behavioral risk data highlight the importance of efficacious sexual risk reduction 
interventions that have specific prevention targets such as: 1) reduced UAI, 2) 
increased condom use, 3) partner selection based on HIV status, and 4) decreased viral 
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load for HIV-positive MSM.  Substance use prior to sex, unknown HIV status, 
incident STI, and poor treatment adherence among HIV-positive MSM are additional 
potential targets for comprehensive or “integrated” behavioral interventions (Coates et 
al., 2008; Grossman et al., 2011; Kurth et al., 2011; Mayer et al., 2014; Sullivan, 
2012).   
Efficacy of Behavioral Interventions 
 High-quality meta-analytic reviews conducted so far have provided reliable 
evidence that behavioral interventions are efficacious in reducing HIV risk among 
MSM either by increasing condom use (range: 61% - 81% increase) or decreasing 
incidence of UAI (range: 23% - 43% decrease) (Herbst, et al., 2005; Johnson et al., 
2002a; Johnson et al., 2005; Johnson et al., 2008; Sullivan et al, 2012).   Intervention 
research meta-analyses were further examined by Noar (2008) in a meta-review; the 
weighted mean effect sizes for UAI among MSM were consistent with previous 
reviews (OR range: 0.65-0.78).   
Reviews identified study moderators that produced more favorable effects in 
sexual risk reduction interventions.  Design variables were shown to most influence 
effects.  For example, Johnson (2002a, 2008) found count outcomes to be a more 
sensitive outcome than dichotomous outcomes because they identify smaller, and 
meaningful, reductions in risk behavior.  Johnson (2008) also found greater effects in 
group-level interventions were associated with shorter intervention spans, better 
retention in the intervention condition, and comparison groups with little to no HIV 
prevention intervention.  Johnson found community-level interventions that addressed 
personal skill development were associated with the greatest reductions of UAI, and 
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that effects were associated with random assignment over convenience, shorter recall 
periods with longer follow-up periods, higher percentage of non-gay identified MSM, 
and higher percentages of white MSM.  Herbst et al (2007) found individual-level 
interventions based on multiple health behavior theories were associated with greater 
effects on sexual risk reduction.  Interpersonal skills, awareness, risk and loss 
perceptions, and self-efficacy were shown to be important moderators for group-level 
interventions, as well as for interventions with multiple sessions and mixed 
components (Herbst et al., 2005, 2007; Johnson et al., 2002a, 2007).  Theory-based 
interventions were more effective than non-theory based interventions (Herbst et al., 
2005; Noar, 2008).   
Behavioral interventions are currently supported by the Centers for Disease 
Control and Prevention, and evidence-based interventions (EBIs) are published in the 
Compendium of Effective Behavioral Interventions (CDC, 2014b).  CDC relies on 
standardized evaluation of all published interventions using CDC-designed efficacy 
criteria (CDC, 2014c).  Additionally, CDC routinely publishes research syntheses of 
behavioral interventions (Johnson et al., 2002; Johnson et al., 2008; Higa et al., 2013).  
All reviews published to date were conducted before recommendations for 
combination approaches.  Recommendations for combination agendas are driven by 
increased evidence pointing to the limitations of behavioral interventions.  No review 
has examined behavioral interventions in the context of a combination prevention 
agenda, and no review has examined how effect sizes may have changed over the past 
decade as HIV prevention research has evolved to focus more exclusively on higher-
risk MSM subpopulations. 
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Integrated Behavioral Interventions 
This study acknowledges that behavioral interventions are necessary, but not 
sufficient for HIV prevention.  Behavioral interventions can better contribute to 
combination prevention agendas if their most effective components are well-
understood and applied most effectively to the highest risk populations.  Higher risk 
populations include MSM subgroups identified to have higher burden of HIV and 
complex risk factors (e.g. young MSM, black MSM, substance-using MSM).  Further, 
behavioral interventions may have more impact if they strategically target additional 
behavioral outcomes other than sexual risk, otherwise known as syndemic risk factors. 
A new area of research is exploring the prevention effects of “integrated 
interventions” that address multiple problem behaviors simultaneously (i.e. substance 
use, infrequent HIV testing) (Collins, 2015; Crepaz et al., 2014).  For example, a 
meta-analysis of integrated interventions for HIV-positive persons demonstrated 
positive effects for sexual risk reduction, and promising effects for medication 
adherence, lending strong evidence for further research into behavioral interventions 
that can influence more than one problem behavior at a time (Crepaz et al., 2014).    
HIV-negative MSM may also benefit from this approach.  The majority of 
evidence to date supports only single-behavior sexual risk behavior trials.  
Measurement of multiple outcome indicators is not new to the field, and many trials 
already include two to three indicators of sexual risk (i.e. UAI, condom use, number of 
partners).  However, very few trials in the past 25 years have measured convergent 
behaviors.  Recently, intervention research for HIV-negative MSM has tested 
interventions that aim to concurrently reduce sexual and drug risk behaviors for 
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substance users.  A recent behavioral intervention using a randomized controlled trial 
(RCT) design for young substance-using MSM showed positive effects for substance 
use and sexual risk and was classified as an evidence-based intervention by the 
Centers for Disease Control (Parsons et al., 2014).  Research compiled from other 
trials suggests motivational interviewing, cognitive behavioral counseling (CBC), 
personalized cognitive counseling (PCC), and empowerment theory influence 
intervention effectiveness for substance-using MSM (Kurtz, Stall, Buttram, Surratt, & 
Chen, 2013; Morgenstern et al., 2012; Santos et al., 2014; Velasquez et al., 2009).  
However, other RCTs found no effect for PCC or CBC (Mansergh et al., 2010; 
Schwarcz et al., 2013), and highlight the need for updated research syntheses to clarify 
what works best for substance-using MSM (Melendez-Torres & Bonell, 2013).  
Increasing HIV testing among high-risk populations, particularly for MSM of 
color, is another outcome directly related to improved prevention and care outcomes.   
There is less meta-analytic and experimental research specific to increasing HIV 
testing.  Most studies lack rigor and use observational designs, or have insufficient 
sample sizes of MSM (Johnson et al., 2002a).  It is known that MSM do not test for 
HIV as frequently as recommended, and this observation has stimulated new and 
stronger research in this area (Maulsby et al., 2013; Paz-Bailey et al., 2013; Wejnert et 
al., 2013).  HIV testing is recommended for all MSM at least once per year, but only 
67 percent of US MSM reported receipt of an HIV test in the past 12 months (Paz-
Bailey et al., 2013).   Meta-analytic research demonstrates that knowledge of HIV 
status is a robust predictor of reduced risk behavior and increased disclosure to sexual 
partners (Marks, Crepaz, & Janssen, 2006).  Individuals who test frequently are more 
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likely to identify acute HIV infection earlier, reduce transmission to others, and 
expedite linkage to care (van den Berg, Larson, Zimet & Lally, 2014).  Social 
network-based strategies have been evaluated in primary studies among black MSM, 
but findings and designs have varied (Baytop et al., 2014; Ellen et al., 2013;  Fuqua et 
al., 2011; Halkitis et al., 2011; McCree et al., 2013).  Additionally, internet-based 
interventions show some evidence for increasing HIV testing among MSM, yet the 
research body is too small to be rigorously evaluated (Rhodes et al., 2011; Schnall, 
Travers, Rojas & Carballo-Diequez, 2014).   Increasing access to convenient, free HIV 
testing is a current CDC priority for structural interventions and required through CDC 
cooperative agreements with state health departments (CDC, 2015a), but behavioral 
interventions will be required to increase individual motivation and receipt of HIV 
testing among MSM. 
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CHAPTER 2: STUDY JUSTIFICATION  
 
Study Objectives 
 
Behavioral HIV prevention interventions for MSM are efficacious in reducing 
sexual risk behaviors and should continue to be supported and developed.  However, 
behavioral interventions alone are not expected to reduce HIV incidence.  Research 
suggests that combination approaches that maximize prevention impact of all available 
components to prevent HIV are most promising for disrupting transmission dynamics 
in MSM epidemics.  New behavioral interventions used in combination approaches 
need to be based on the most current evidence, relevant to today’s mature epidemic, 
and effective with high-risk MSM.   This study aims to identify the most promising 
and relevant features of behavioral interventions for MSM to inform the development 
of new behavioral interventions. 
Objectives of this study are to: 
1. Locate and describe experimental outcome studies evaluating effects of 
behavioral HIV interventions for US MSM.  
2. Summarize effectiveness of interventions to reduce sexual risk behavior using 
meta-analysis. 
3. Identify study moderators associated with effectiveness. 
4. Display cumulative effect sizes over time. 
5. Identify experimental trials that examine multiple problem behaviors in 
addition to sexual risk reduction such as increased HIV testing and decreased 
substance use. 
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Study Justification 
HIV prevention for US MSM is a persistent public health challenge and new 
approaches are urgently needed.  Trials testing new combination prevention 
approaches are currently underway (e.g. HIV Prevention Trials Network 080 and 073).  
To support the role of behavioral interventions in new combination agendas, updated 
research syntheses are needed to re-evaluate the current overall effect size, examine 
shifts in effect size over time, and identify other behavioral outcomes feasible for 
“integrated interventions.”   
The last research synthesis was conducted by the Prevention Research 
Synthesis Team at the Centers for Disease Control (CDC).  Their team published the 
last meta-analysis of findings in 2008 (including trials up to 2007) by Johnson et al.  
This review included all known RCT designs testing any behavioral intervention that 
included some proportion of MSM participants.  This review included trials inside and 
outside of the US and did not require trials to be specifically designed for MSM (e.g. 
trials designed for HIV-positive clinic populations generally have higher proportions 
of MSM, but MSM were not the trial focus).  In 2013, the team performed a (mostly) 
qualitative synthesis of interventions previously evaluated by CDC to meet criteria for 
being specifically designed for US MSM (Higa et al., 2013).  This systematic review 
revealed trends in HIV prevention research and helped explain reasons for failed 
efficacy.  However, it did not quantitatively summarize findings to produce an updated 
effect size.  While systematic reviews are essential to research synthesis, they are 
limited if they do not calculate updated effect sizes.  Quantitative analyses, or meta-
analytic results, are required to justify the rationale for ongoing behavioral research in 
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MSM, focus research questions based on reliable data, set benchmarks to validate 
future research, and examine moderators of effect (Cook et al., 1992; Marsh, Johnson, 
& Carey, 2001; Johnson et al., 2008).  
Study Hypotheses 
This study used systematic review and meta-analysis to synthesize sexual risk 
reduction behavioral interventions specifically designed for adult US MSM from 
1988-2014.   Eligible trials that include integrated interventions such as HIV testing 
and substance use were summarized to evaluate the prevalence of integrated 
interventions.  Hypotheses for this study were: 
1. Behavioral interventions are effective to reduce sexual risk behavior 
among US MSM. 
2. Effects of behavioral interventions are moderated by design variables 
(i.e. outcome measure, comparison condition, differential retention, and 
intervention time span). 
3. An updated meta-analysis will validate effect sizes observed in 
previous reviews. 
4.  Integrated interventions, or trials with multiple behavioral outcomes, 
have increased since the last review.  
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CHAPTER 3: Methodology 
Systematic Review 
A systematic review of the HIV prevention literature was conducted to locate 
and retrieve trials evaluating behavioral interventions for US MSM and published 
between 1988 and 2014.  The systematic review procedure was informed by 
guidelines from The Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins & Green, 2008) and Preferred Reporting Guidelines for Systematic Review 
and Meta-Analysis (Moher, Liberati, Tetzlaff, Altman & PRISMA Group, 2009).    
The review was influenced by previous high-quality meta-analyses that have 
been used to inform evidence-based recommendations for HIV prevention (Herbst et 
al., 2007; Johnson et al., 2008; Higa et al 2013).  The present review differs from other 
reviews because it excludes interventions designed exclusively for HIV-positive 
MSM, and it only includes trials specifically designed for MSM.  Trials specific to 
HIV-positive MSM did not fall under this study’s classification as HIV prevention to 
prevent HIV acquisition.  Following Higa et al.’s approach, only trials designed for 
MSM were included to understand intervention effects and past research specific to 
this population.   This review updates the qualitative synthesis of Higa et al. (2013) by 
adding randomized controlled trials from 2011-2014, and also providing a meta-
analytic synthesis of trials published from 1988-2014. 
Inclusion Criteria 
 
Trials were reviewed for relevance based on four major criteria: 1) types of 
participants (i.e., MSM), 2) types of outcome measures (i.e., HIV risk behaviors), 3) 
types of interventions (i.e., behavioral interventions), and 4) types of trials (i.e., RCT 
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design). Trials were considered in scope if they examined any behavioral intervention 
aimed at reducing sexual risk behaviors for HIV transmission among US MSM. Trials 
were eligible for inclusion if they were: 1) behavioral interventions to prevent 
acquisition of HIV, 2) specifically designed for adult MSM, 3) conducted in the 
United States, 4) tested using a randomized controlled trial, 5) measured at least one 
behavioral or biological outcome variable of relevance (e.g., HIV or STI incidence, 
anal sex without a condom, number of sexual partners, condom use for anal sex), and 
6) published in a peer-reviewed journal between 1988 and 2014. 
Exclusion Criteria 
Review was restricted to interventions focused on the primary prevention of 
HIV infection among adult MSM.  This restriction assumes there may be important 
differences between HIV-negative MSM and HIV-positive MSM, as well as 
differences between adult MSM and adolescent MSM, in the underlying processes of 
behavior change (Herbst et al., 2007).  Inclusion of such trials may have increased 
statistical heterogeneity or obscured effects of prevention interventions on the 
population of interest: HIV-negative adult MSM.  Trials were excluded if they: 1) 
focused on HIV-positive MSM (i.e., 100 percent HIV-positive sample) and secondary 
prevention of HIV transmission to sexual partners, 2) included some proportion of 
MSM participants, but were not specifically designed for adult MSM (i.e., less than 95 
percent MSM), and 3) focused on adolescent MSM (i.e., mean sample age of <18 
years).   Trials that did not report enough statistical information to calculate an effect 
size were excluded after attempts to contact study authors failed to produce necessary 
data. 
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Types of Participants 
 Trials were included if participants were adult men over 18 years old who 
reported sex with other men and lived in the United States.  MSM were included 
regardless of race/ethnicity, sexual identity (e.g., gay, bisexual, homosexual, 
heterosexual, etc.), or other demographic characteristics. Trials that included some 
proportion of HIV-positive MSM in the sample were included except when the trial 
exclusively focused on HIV-positive MSM.    
Types of Interventions 
 Trials were included if they were behavioral interventions designed to prevent 
the acquisition of HIV infection by changing individual sexual risk behaviors through  
modeling, demonstration, role-playing, risk reduction planning, group or individual 
counseling, or other behavioral intervention method.  Individual-level, group-level, 
couples-level, and community-level interventions were included.  Behavioral 
interventions were defined to be different than provision-of-information-only 
interventions that aim to change knowledge, attitudes, or norms only (e.g., increasing 
HIV knowledge), and different than environmental or structural interventions that aim 
to change the physical or social environment to promote health and prevent disease 
(e.g., mass media campaigns, policy change) (The Community Guide, 2008).  Trials 
that focused only on psychological moderators of risk behavior, cognitive outcomes, 
or affective outcomes (e.g., distress, depression) were considered out of scope.   
Types of Outcome Measures 
 Review was restricted to trials that measured intervention effects on behaviors 
known to influence risk of HIV acquisition among MSM (e.g., anal sex without a 
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condom, number of male sexual partners, frequency of condom use for anal sex), or 
trials with biological outcomes such as HIV or STI incidence.  Operational definitions 
of primary outcome variables are not standardized among HIV prevention trials 
(Johnson et al., 2002b).  The most frequently reported measures used for sexual risk 
behavior in most at-risk populations are frequency of unprotected sex, condom use, 
and number of sex partners (Johnson et al., 2002b).  Unprotected sex is often reported 
using dichotomous (i.e., proportion of participants reporting any unprotected sex 
within the recall period) and count measures (i.e., number of partners, or number of 
episodes for unprotected sex within the recall period).    Trials were eligible for review 
if they reported at least one measure of sexual risk behavior that was specific to male-
to-male sexual contact.    
Types of Trials 
 Trials were eligible if they included a relevant outcome variable and 
methodological rigor as demonstrated by study design.  Only trials that used a 
randomized controlled trial (RCT) with independent comparison group were included 
for review.  No exclusions were made by type of comparison group.  All other study 
designs, including rigorous quasi-experimental, were excluded.  This restriction was 
intended to ensure that the evidence under review had a high level of methodological 
rigor (Guyatt et al., 1995; Stephenson & Irmie, 1998).  RCT designs are experimental 
studies where subjects are randomly allocated to intervention (i.e., treatment) or 
comparison (i.e., control) group, and then followed under controlled conditions 
(CEBR, 2015).  When implemented with high quality, RCTs are better able than other 
designs to attribute observed effects to the intervention condition while also 
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minimizing potential sources of bias (Higa et al., 2013; CEBR, 2015).  Most 
interventions classified as Evidence-Based Interventions (EBI) by CDC are tested 
using RCT design to ensure internal validity before disseminating evidence-based 
interventions into real-world settings.   
Search Strategy 
 The peer-reviewed published HIV prevention literature was systematically 
searched from April 2015 to June 2015 to locate trials that met eligibility criteria.  
Five electronic databases were searched from January 1988 to April 2015: 1) PubMed, 
2) EMBASE, 3) CENTRAL, 4) PsycInfo, and 5) CINAHL.  The year of 1988 was 
chosen as the start date to capture the earliest known intervention trials and is 
consistent with previous reviews (Johnson et al., 2008).   Search sensitivity was 
prioritized over precision; no restrictions by country, geography, outcomes, or 
language were applied.  After electronic searches, hand searches of five key journals 
(AIDS & Behavior, American Journal of Public Health, AIDS Education & 
Prevention, Journal of the Association of Nurses in AIDS Care, and AIDS Care) were 
conducted to locate articles published between January 2014 to December 2014 that 
may have been missed by electronic searches due to indexing lags. References from 
prior systematic reviews and meta-analyses were reviewed until no new references 
were identified.    
Keywords, search strings, and search strategies varied by electronic database.  
Three search strings were developed to systematically search the literature: 1) MSM 
string (the population filter), 2) HIV/AIDS prevention string (the disease filter), and 3) 
RCT string (design filter).  The population filter and disease filter were specified using 
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controlled vocabulary (e.g., MeSH terms for PubMed or EMTREE terms for 
EMBASE) to retrieve articles that may be indexed by different words.  Controlled 
vocabulary terms were identified through a comprehensive approach.   Search 
strategies from previous reviews and consultations with experts trained in Cochrane 
Systematic Reviews helped to inform the first draft of each string.  Strings were then 
refined by identifying trials known to fit eligibility criteria and looking up their index 
terms, common text words, and subject words.   Other terms were identified using 
search tools in each database (e.g., MeSH database in PubMed) to customize the 
search to each database.  Once key terms were identified, terms were exploded to 
generate more specific terms or synonyms to include in each search string.   Boolean 
operators joined together controlled vocabulary terms, free-text terms, and identified 
synonyms for the final string.  The published “Cochrane Highly Sensitive Search 
Strategy for Identifying Randomized Trials in Medline” (Higgins & Green, 2008) was 
used in its exact form to filter trials by RCT design in PubMed.  This string was 
adapted for use in other databases.   A detailed Search Strategy document (Appendix 
A) details the search strategy, final strings, date and time of search, results, and final 
number of trials located for each database searched.   Citations and abstracts for 
located trials were downloaded from each database and exported into an EndNote X7 
file for reference management.  Duplicates were deleted.  Titles and abstracts were 
scanned by the primary author to validate they met inclusion criteria.  Trials that did 
not meet inclusion criteria were discarded into an Excluded folder.  Full manuscripts 
that met inclusion criteria were downloaded for data extraction.  
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Data Extraction 
 A study protocol was developed to guide data extraction (Appendix B) and 
was informed by The Community Guide’s Data Abstraction Form (2008).  Data 
extraction forms collected a wide range of information on study descriptors (e.g., 
participant characteristics, study characteristics, design characteristics), study results 
(e.g., primary and secondary outcomes, significance, study retention), statistical 
information (e.g., descriptive data to calculate effect sizes), and methodological 
quality (e.g., CDC’s Prevention Research Synthesis criteria).  Two independent coders 
extracted trial data using standardized forms; one coder completed 50 percent of 
records.  Disagreements were resolved by discussion until consensus was reached; a 
methodological expert was consulted as needed.   
Data to Test Study Hypotheses 
 Moderating variables specified a priori were extracted to test study 
hypotheses.  Based on Johnson et al. (2008), four variables were selected and coded 
for moderator analyses: 1) effect measure type, 2) intervention time span, 3) 
differential retention by group, and 4) control condition.  A second hypothesis 
specified that studies with multiple behavioral outcomes have increased since 2007.  
To test this hypothesis, a dichotomous variable was created to indicate (yes/no) if the 
study reported multiple behavioral outcomes (e.g., substance use and sexual risk, or 
HIV testing and sexual risk).  If multiple outcomes were found, study coders described 
them in a free-text field. 
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Assessment of Methodological Quality 
 Methodological quality was assessed according to CDC’s Prevention Research 
Synthesis (PRS) criteria for evidence-based interventions (CDC, 2014c).  The PRS 
team was created in 1996 to systematically review and summarize HIV behavioral 
intervention research.  PRS aims to translate scientific evidence into evidence-based 
recommendations for HIV prevention (Higa et al., 2013; Lyles, Crepaz, Herbst, & 
Hay, 2006).   PRS efficacy criteria were informed by efficacy criteria used in other 
projects such as the Community Guide and Grades of Recommendation, Assessment, 
Development, and Evaluation (GRADE).  PRS prioritizes assessing the internal 
validity of trials “to ensure a reasonable level of confidence that the observed changes 
can be attributed to the intervention” (Higa et al., 2013; Lyles et al., 2006).  Efficacy 
criteria can be applied to individual, group, couples, or community-level behavioral 
interventions and are comprised of five major domains: Intervention Description (e.g., 
clarity), Quality of Study Design (e.g., comparison arm, allocation), Quality of Study 
Implementation and Analysis (e.g., follow-up time, retention rate, alpha level, sample 
size), Strength of Evidence (e.g., statistically significant result [p<.05], relevant 
outcome, no harmful effects), and Additional Limitations to Evaluate (e.g., fatal flaws 
such as differential retention or substantial missing data).  Studies that meet all criteria 
are classified as Evidence-Based Interventions either at the Good Evidence level or 
Best Evidence level.  In 2013, Higa et al. of the PRS team reviewed MSM-specific 
interventions previously reviewed in the PRS database to better understand 
methodological challenges to demonstrating efficacy of HIV behavioral interventions 
for MSM.  Higa et al. classified each trial into one of four mutually exclusive 
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categories: Evidence-Based Interventions (EBIs: trials that meet all efficacy criteria); 
Rigorous Non-EBIs (trials that meet all efficacy criteria except for a significant 
positive finding); Positive Non-EBIs (trials that reported a significant positive finding, 
but did not meet at least one other criterion); and Other Non-EBIs (trials that did not 
report significant positive finding and did not meet at least one other PRS criterion).  
This review uses original PRS criteria and Higa’s additional four-level categorization 
system (Appendix C).   Higa et al.’s ratings were entered into the data extraction form 
for trials prior to 2011.  For trials not already rated by Higa, coders applied PRS 
criteria and resolved any disagreement by discussion.    
Protocol Modifications 
 The original study protocol was modified during data extraction to make three 
important changes.  The original scope of the review included any behavioral 
intervention trial with a comparison arm that targeted MSM with enough information 
to calculate an effect size.  Upon reviewing the literature, three changes were made to 
the scope: 1) include only trials designed specifically for MSM (e.g., MSM 
representing at least 95 percent of the sample instead of trials that included >50 
percent MSM), 2) exclude trials designed specifically for HIV-positive MSM (e.g. 
HIV-positive MSM comprising 100 percent of the sample), and 3) exclude any study 
that was not RCT (e.g., exclude quasi-experimental designs, even those with 
comparison groups).  Changes were based on narrowing the scope of the review to 
best understand the effects of diverse interventions on MSM while minimizing threats 
to validity.  Statistical challenges were found when attempting to isolate effects of the 
intervention on MSM if trials included non-MSM (e.g., reducing study weight to only 
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reflect the MSM subset), concerns emerged about increasing statistical and clinical 
heterogeneity if HIV-positive MSM were included, and concerns emerged about 
decreased methodological quality if non-RCT designs were included.    
Statistical and Other Software 
 Microsoft Excel (2007), EndNote (X7), Biostat Comprehensive Meta-Analysis 
(Version 3), and SPSS (Version 22.0) were used to enter, manage, and analyze data 
for the systematic review, meta-analysis, and other data analyses.  The data extraction 
protocol and standardized forms were created in Microsoft Excel.  Descriptive 
statistics were calculated in Microsoft Excel and SPSS.  Reference management was 
conducted exclusively in EndNote.   Meta-analyses, moderator analyses, cumulative 
analyses, outlier analyses, and publication bias analyses were conducted in Biostat 
Comprehensive Meta-Analysis (Borenstein, Hedges, Higgins, & Rothstein, 2015).   
Statistical Analyses  
Meta-Analysis 
Meta-analysis was used as the primary analysis to synthesize results across 
trials and calculate a standardized effect size.  One overall meta-analysis was 
conducted using the primary outcome from each study.  Meta-regressions and 
subgroup analyses examined potential moderators of the overall effect size.  
Additional analyses included cumulative meta-analysis to calculate the cumulative 
effect size by year, homogeneity tests of the effect size distribution, analyses of 
publication bias, and sensitivity analysis for outlier analysis.   
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Outcome Measures 
Outcomes used in this meta-analysis included: 1) mean number of episodes of 
UAI (k=14), 2) proportion of MSM reporting any UAI (k=18), 3) or mean number of 
male sexual partners for any anal intercourse (k=2).  This study focused on 
unprotected anal intercourse (UAI) as the outcome of interest.  UAI is the most 
epidemiologically important HIV risk behavior for MSM, and UAI data were 
available for most trials.  Number of male sexual partners for anal intercourse was 
used only when the authors specified it as a primary outcome, and there was no 
available secondary outcome about UAI (k=2).  This outcome is imperfect as it may 
measure partners for unprotected sex or protected sex, and may not be a reliable 
indicator of true HIV risk.  Despite this limitation as an outcome measure, these 
studies were included because they contributed some meaningful measure of sexual 
risk.       
Meta-analysis requires an assumption of independence between trials; only one 
outcome per trial is appropriate for calculating an overall effect size (Borenstein,  
Hedges, Higgins, & Rothstein., 2009).  The primary outcome specified by trial authors 
was used to calculate one effect size for each trial. Fifteen studies reported multiple 
outcomes related to the same sexual risk construct, but did not specify a primary 
outcome.  For these studies, the most precise outcome associated with highest risk of 
HIV acquisition was used.  UAI confers the greatest risk for HIV and previous reviews 
have revealed count outcomes to be more sensitive than dichotomous outcomes 
(Johnson et al., 2008).  Based on this rationale, mean number of UAI episodes was 
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specified as primary outcome.  If count-level UAI data were not available, the 
proportion of any UAI was used.   
Outcome variables used for meta-analysis did not discriminate between 
insertive or receptive anal intercourse (i.e., sexual position), primary or non-primary 
partners, or partner’s HIV status (i.e., serodiscordant or seroconcordant partners).  
Specific results about behaviors with certain partners, or specific results about 
behaviors by sexual position (i.e., insertive vs. receptive anal intercourse) were used 
when more general results were unavailable.  When UAI results were only presented 
by sexual position (e.g., insertive UAI vs. receptive UAI), results describing receptive 
anal intercourse were used because it is a higher risk behavior than insertive anal 
intercourse (k=2).  When UAI results were only presented by primary vs. non-primary 
partner, non-primary partner results were used (k=1) under the assumption this 
situation conferred greater risk.  Risk behavior outcomes specific to vaginal sex, oral 
sex, or sex with female partners were excluded from analysis.  For trials that reported 
sexual behavior with both male and female partners as primary outcomes, secondary 
outcomes specific to anal intercourse with male partners were used (k=2).   
Three trials tested more than two experimental conditions against one control 
group (Dilley et al., 2007; Hirschfield et al., 2012; Shoptaw et al., 2005).   One 
approach to multiple comparisons is to split the comparison group into equal parts to 
compare each intervention to a control group.  While this can preserve the assumption 
of independence, it can also create a bias towards homogeneity, especially if the study 
is large (Borenstein et al., 2009).  While only one of the three studies was large, an 
alternative protocol was used.  For the three studies, the most relevant intervention 
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condition was selected to compare to the control.  Descriptive data for the excluded 
condition/s were not used in the meta-analysis and overall sample size for the study 
was adjusted.   
For studies that reported outcomes at multiple time points, the last follow-up 
assessment was used to calculate effect sizes.  Last follow-up was selected to examine 
sustained intervention effects.  Most trials used a 3, 6, or 12 month follow up.  Follow-
up period was included as a moderator variable to statistically examine its relationship 
to the overall effect size. 
Calculation of Effect Sizes 
Effect sizes for each trial were calculated using the odds ratio (OR) for 
dichotomous measures and standardized mean difference (SMD) for count-level 
measures.   Estimates of effect size were calculated based on descriptive data (e.g., 
means, standard deviations, frequencies, or proportions).  When descriptive data were 
not available in any published report, requests for additional trial data were sent to trial 
authors.  If data were not obtained from trial authors, the trial was excluded from 
analysis (k=4). 
One measure of effect size is required to estimate the overall pooled effect 
size. To be consistent with previous meta-analyses using RCT designs, the OR was 
chosen as the common metric. SMDs were converted to the OR for the main meta-
analysis.  Disadvantages to using the OR for meta-analysis are that odds are less 
intuitive than risk, ORs are centered around 1, and ORs are problematic when cell size 
equals zero (Lipsey & Wilson, 2001).  Advantages are that ORs have favorable 
mathematical properties, standard errors are easy to calculate, and they are commonly 
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reported in epidemiological research (Lipsey & Wilson, 2001; Borenstein et al., 2009; 
Higgins & Green, 2008).   Calculations for odds ratios were conducted using the 
natural logarithm scale (lnOR). The lnOR, standard error (SE) of the lnOR, and 
confidence limits were calculated to generate values that are used in each step of the 
meta-analysis (Borenstein et al., 2009).  Each lnOR was multiplied by its inverse 
variance weight, weighted lnORs across trials were summed, and then divided by the 
sum of the weights (Lipsey & Wilson, 2001).  After meta-analysis, the results were 
converted back into OR units for display purposes.    
Odds Ratios 
For trials reporting dichotomous outcomes (e.g. frequencies or proportions), 
the odds ratio (OR) was calculated to estimate intervention effect.  The OR was 
calculated for each cross-product ratio from 2x2 tables representing the frequency of 
UAI in the intervention group as compared to the control group at last follow-up 
(Herbst et al., 2007; Haddock, Rindskopf, & Shadish, 1988).   
 The computational formula for an odds ratio is (Borenstein et al., 2009): 
OR =
𝐴𝐷
𝐵𝐶
 
Each OR was then transformed to the log scale using the natural logarithm 
(lnOR) to obtain the log odds ratio (Johnson, 2002b; Bornstein et al., 2009): 
𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 = ln⁡(𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜) 
with approximate variance: 
𝑉𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 =
1
𝐴
+
1
𝐵
+
1
𝐶
+
1
𝐷
 
and approximate standard error: 
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𝑆𝐸𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜⁡⁡⁡⁡ = √𝑉𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 
  As specified previously, the log odds ratio and its variance were used to 
generate the summary effect, confidence limits (LL=lower limits; UL=upper limits), 
and other measures in log units.  Each value was then converted back to the odds ratio.  
Log odds ratios, variances, and 95% confidence intervals were transformed back to 
ORs by using the formula (Borenstein et al, 2009): 
𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 = exp(𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜), 
𝐿𝐿𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 = exp(𝐿𝐿𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜), 
𝑈𝐿𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 = exp(𝑈𝐿𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜). 
Standardized Mean Differences 
For trials with count-level outcomes (e.g., mean number of UAI events), 
standardized mean differences (SMD) and variances were calculated to estimate 
intervention effects (Johnson et al., 2002b; Bornstein et al., 2009).  SMDs are the more 
appropriate option (as opposed to raw mean differences) when studies use different 
instruments to measure the outcome.  Unadjusted, descriptive data (e.g., means, 
standard deviations, standard errors, frequencies, proportions) were used to calculate 
effect sizes.  If measures of variance (i.e., standard deviation or standard error) were 
not reported, standard deviation was obtained by using sample sizes for intervention 
and control groups and the independent groups exact p-value.  From these values, a t-
value can be computed to obtain standard error which can be converted to standard 
deviation (Higgins & Green, 2008).  The SMD (or Cohen’s d) was the mean 
difference of intervention and control at follow-up divided by the within-group pooled 
standard deviation.  Cohen’s d is calculated by the formula: (Borenstein et al., 2009): 
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𝑑 =
𝑀1 −𝑀2
𝑆𝑤𝑖𝑡ℎ𝑖𝑛
 
The numerator values represent the sample means in each group and the 
denominator represents the pooled within-groups standard deviation calculated as: 
𝑆𝑤𝑖𝑡ℎ𝑖𝑛 = √
(𝑛1 − 1)𝑆1⁡
2 + (𝑛2 − 1)𝑆2
2
𝑛1 + 𝑛2 − 2
 
The variance of d is approximated by: 
𝑉𝑑⁡ =
𝑛1+𝑛2
𝑛1
+
𝑑2
2⁡(𝑛1+𝑛2)
 . 
The standard error of d is the square root of 𝑉𝑑⁡ given as: 
𝑆𝐸𝑑 = √𝑉𝑑. 
SMD was converted to the OR to achieve a common metric, but has been 
shown to be upwardly biased when applied to small samples (Hedges, 1981).  Hedges’ 
g corrects for this bias (Lipsey & Wilson, 2001) with a correction factor (J), and 
provides an alternative effect size to Cohen’s d.  Hedges’ g was additionally calculated 
by the following formula: 
𝐽 = 1 −
3
4𝑑𝑓−1
⁡ , 
𝑔 = 𝐽 × 𝑑, 
𝑉𝑔 = 𝐽
2 × 𝑉𝑑, 
and 
𝑆𝐸𝑔 = √𝑉𝑔. 
To transform data, Cohen’s d was converted to the logs odds ratio by 
standardized formulas (Johnson, 2002b): 
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SMD=√3 × [ln(𝑎) + ln(𝑑) − ln(𝑏) − ln(𝑐)] ÷ 𝜋, 
 
Var(SMD)≈3/𝜋2 × [
1
𝑎
+
1
𝑏
+
1
𝑐
+
1
𝑑
], 
 
ln OR=
𝜋
√3
× 𝑆𝑀𝐷, 
 
𝑉𝑎𝑟(𝑙𝑛𝑂𝑅) =
𝜋2
3
× 𝑉𝑎𝑟(𝑆𝑀𝐷). 
 
Intraclass Correlation Coefficient 
 For trials that used the community as the unit of assignment (i.e. community-
level interventions, k=3), an estimate of the intraclass correlation coefficient (ICC) 
was applied to adjust study weights when cluster data was available.  The ICC 
estimates the relative variability within and between clusters (Donner & Koval, 1980; 
Higgins & Greene, 2008).   If the ICC is not accounted for, the variance of the 
intervention effect may be underestimated and the weight will be overestimated 
(Johnson et al., 2008).   ICCs are not frequently available in study reports and it is 
common to use ICCs from other studies (Higgins & Green, 2008). To reduce each trial 
to the “effective sample size,” an ICC of .005 was assumed because this value was 
cited in one community-level intervention report (Kelly et al., 1997; Johnson et al., 
2002).  To calculate the effective sample size, the original sample size is divided by 
the design effect: 
𝐷𝑒𝑠𝑖𝑔𝑛⁡𝐸𝑓𝑓𝑒𝑐𝑡 = 1 + (𝑀 − 1)𝐼𝐶𝐶, 
where M is the average cluster size.  Calculation of average cluster size was not 
possible for two of three trials due to missing cluster data and unadjusted results were 
used in the meta-analysis. 
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Model of Analysis 
 Variance was modeled using fixed and random effects models.  Both models 
were specified a priori for comparison.  Previous HIV prevention reviews have 
revealed highly homogeneous distributions so it was assumed that random and fixed 
models would yield identical results for the primary meta-analysis (Johnson et al., 
2008.).  Fixed effects models assume the variance is subject-level sampling error only 
(not study level variance) and are generally used for homogenous distributions.  
Random effects models are more conservative and assume that the variance has 
random study-level variance in addition to random subject-level sampling error.  An 
additional random effects model was specified due to possible heterogeneity of trial 
subgroups, outcome measures, intervention content, and design variables (Hedges & 
Olkin, 1985).  To fit a random effects model, non-iterative methods of the moment 
were used (Lipsey & Wilson, 2001).  Biostat’s Comprehensive Meta-Analysis was 
used to provide fixed and random effects mean effect sizes.  
Calculations for the Mean Effect Size 
A mean effect size, or summary effect size across studies, was calculated to 
obtain the most precise estimate of the mean using both fixed and random models.  
Before calculating the mean effect size, each effect size (lnOR) was weighted by the 
inverse of its variance to correct sample size bias.   Effect sizes based on larger 
samples provide more precise estimates because the sampling error is smaller.  
Optimal weights are achieved by using the standard error (Hedges & Olkin, 1985).  
Individual studies were weighted by their respective sample sizes after all study effect 
sizes had been transformed to the lnOR.  Each study was assigned a weight that was 
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the inverse of its variance, or the “inverse variance weight” (Lipsey & Wilson, 2001).  
The study weight is computed by this formula where VYi  is the within-study variance 
for the study (i) Borenstein et al., 2009): 
𝑊𝑖 =
1
𝑉𝑌𝑖
 
For random effects analyses, study weights included within-study variance and 
an estimate of the between-studies variance (T2). 
 The weighted mean effect size (M) was then calculated by multiplying each 
effect size by its weight, summing the products (WiYi), and then dividing by the sum of 
the weights (Borenstein et al., 2009): 
𝑀 =
∑ 𝑊𝑖
𝑘
𝑖=1 𝑌𝑖
∑ 𝑤𝑖
𝑘
𝑖=1
 
     The variance of the mean effect size was calculated as the reciprocal of the 
sum of the weights (Borenstein et al., 2009): 
𝑉𝑀 =
1
∑ 𝑊𝑖
𝑘
𝑖=1
 , 
 and the standard error of the mean effect size was calculated by taking the 
square root of the variance (Borenstein et al., 2009): 
𝑆𝐸𝑀 = √𝑉𝑀. 
 Confidence intervals (CIs) were set at 95% to examine the precision of the 
mean effect size and individual study effect size estimates. CIs demonstrate precision 
by providing the range of possible values for the effect size; a 95% confidence interval 
implies that the population mean effect size has a 95% probability of being in between 
the lower and upper bound of the CI.  CIs were calculated by multiplying the standard 
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error by a critical z value to represent the proposed confidence level, adding the 
product to the point estimate for the upper limit, and subtracting the product from the 
point estimate for the lower limit.   Upper (UL) and lower limits (LL) were given by 
these formulas (Borenstein et al., 2009): 
⁡𝐿𝐿𝑀 = 𝑀 − 1.96⁡ × 𝑆𝐸𝑀⁡ , 
⁡𝑈𝐿𝑀 = 𝑀 + 1.96⁡ × 𝑆𝐸𝑀⁡ . 
 To test the null hypothesis that the mean effect size is zero, a Z-value was 
calculated (Borenstein et al., 2009): 
𝑍 =
𝑀
𝑆𝐸𝑀
, 
and a p-value was given for the two-tailed test by (Borenstein et al., 2009): 
𝑝 = 2[1 − (Φ(|𝑍|))], 
where Ф(Z) represents the normal cumulative distribution. 
Interpretation of Effect Sizes 
 Effect sizes are the primary result reported.  After all calculations were 
conducted using the lnOR, values were converted back to the OR for display purposes.  
ORs are centered around 1 instead of zero with 1 indicating no relationship, or a null 
effect (Lipsey & Wilson, 2001).  For behavioral trials in this study, ORs between 0 
and 1 favor the intervention condition and indicate a positive effect.  ORs greater than 
1 favor the comparison group.  ORs of 1 indicate no difference between intervention 
and comparison group.  ORs are interpreted with their corresponding 95% CI to 
indicate the precision of the estimate.  Wider confidence intervals indicate a less 
reliable estimate.  Wider confidence intervals are associated with higher relative 
standard error and smaller samples.  Confidence intervals that include the null value of 
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1 indicate there is insufficient evidence to detect a significant difference between 
groups.  P-values were considered significant at the p<.05 level.  
Cumulative Meta-Analysis by Year 
 Cumulative meta-analysis was performed to display how the weight of 
evidence has shifted over time.  Cumulative meta-analyses are conducted by running a 
meta-analysis with one study, then repeating it with a second study added, and 
repeating again until all studies are included.  Studies were sorted chronologically by 
year from oldest to newest, and overall percent change from earliest to latest year was 
calculated.  Effect size change was also calculated from the earliest statistically 
significant cumulative effect size to the latest effect size. Forest plots were produced 
for visual examination of effect size with each new study added, and shifts in effect 
size over time.  Cumulative meta-analysis is primarily a method for displaying results 
of a series of separate meta-analyses in one forest plot (Borenstein et al., 2009).  To 
better understand how the evidence has accumulated over time, study year was also 
coded as a moderator and used in meta-regression to statistically evaluate the 
relationship between effect size and year.      
Heterogeneity of Variance 
Heterogeneity of variance implies that the effect size is not consistent across 
studies.  Observed heterogeneity can occur because of random error (e.g. spurious or 
excess variation) or systematic differences (e.g. true variation) that require further 
analysis such as in the case of moderator variables.  Variation between effect sizes was 
first examined by visually analyzing the forest plot to detect large differences between 
point estimates (OR) and the extent of the CI overlap.  Large differences between ORs 
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or non-overlapping CIs suggest that random error is an unlikely explanation for the 
observed variation (Murad et al., 2014).  Measures of Q and I2 were used to 
statistically evaluate the true variance and proportion of real dispersion (Borenstein et 
al., 2009). 
 The Q statistic tests the homogeneity of the overall effect size with a null 
hypothesis that the underlying effect is the same across studies.  Q is an approximate 
chi-square distribution with degrees of freedom equal to the number of studies minus 
one.   Rejection of the null hypothesis (p<.05) suggests that the effect size distribution 
is heterogeneous and the variability is larger than what would be expected from 
random error; variability and most likely attributable to study characteristics or 
moderating variables.  If the Q statistic is less than critical it suggests that the observed 
variance does not exceed what would be expected from sampling error alone.   
However, there are limitations to the Q statistic.   Power can be low with small 
samples and may miss the effects of study-level error (Lipsey & Wilson, 2001); in 
consideration of Q’s limitations, P-values <.10 were considered significant to justify 
moderator analyses.  Q is a standardized measure and was computed as (Borenstein et 
al., 2009): 
𝑄 = ∑ 𝑊𝑖(𝑌𝑖 −𝑀)
2𝑘
𝑖−𝐼 , 
where Wi  is the study weight, Yi is the study effect size, and M is the overall effect 
size.  
The second statistical test used I2 where: 
𝐼2 = (
𝑄 − 𝑑𝑓
𝑄
) × 100%. 
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  I2 is a measure of the magnitude of variability as opposed to a measure of statistical 
significance like the Q statistic (Murad et al., 2014).  I2 is a measure of the real 
dispersion due to heterogeneity over random error alone (Higgins & Green, 2008), or 
the ratio of excess dispersion to total dispersion (Borenstein et al., 2009). When I2 is 
close to 0%, it is likely that observed variability between point estimates is due to 
random error.   The further I2 moves from 0, the more likely that variability is 
explained by systematic differences requiring subgroup or moderator analyses.  
Interpretation of I2 needs to consider not only magnitude and direction of effects, but 
also the Q statistic and CIs for I2. Guidelines to interpret I2 vary, but rough guidelines 
were used (Higgins et al., 2003): 
1. 25%=low heterogeneity 
2. 50%= moderate heterogeneity 
3. 75% =high heterogeneity. 
Statistical Tests of Moderators 
Four design variables were specified as moderators a priori based on previous 
work from Johnson et al., 2008: 1) outcome measure (count-level vs. dichotomous), 2) 
comparison condition (non HIV-related vs. HIV-related vs. waitlist), 3) and 
intervention time span (≤1 month vs. >1 month) and retention rate (better in 
comparison vs. equal or intervention).  Hypotheses specified that count-level 
measures, non-HIV-related controls, interventions with shorter time spans, and 
interventions with better retention in the treatment group would yield stronger effects 
across all studies.  In addition to a priori variables, participant characteristics and 
study characteristics were analyzed as potential moderators for exploratory purposes.      
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 Variables tested for moderator analysis were categorical and continuous 
variables and required different statistical tests.  Categorical variables were tested 
using the analog to analysis of variance (ANOVA).  Continuous variables were tested 
using weighted meta-regression analysis.  Subgroup analyses used mixed-effects 
models which use a fixed effect model across subgroups and a random effects model 
within subgroup (Borenstein et al., 2009).  The analog to ANOVA separates the total 
homogeneity (Q) into between-group variance and within-group variance.  Subgroup 
analyses were computed by the general analog ANOVA given by: 
𝑄𝑤 =∑𝑤𝑖(𝐸𝑆𝑖 −𝑀𝑗)
2
𝑘
𝑖=1
 
 where Qw is the pooled group (within) variance and QB is the between groups 
variance: 
𝑄𝐵 = ∑ 𝑤𝑗𝑀𝑗
2𝑘
𝑖=1 −
(Σ𝑗𝑀𝑗)
2
Σ𝑤𝑗
. 
  𝑤𝑗 is equal to the sum of weights for each subgroup, 𝑀𝑗 refers to the weighted 
mean effect size for each subgroup, 𝑤𝑖 is equal to the study weight (
1
𝑆𝐸2
), 𝐸𝑆𝑖 refers to 
the study effect size, M is the summary effect, k is the number of studies (effect sizes) 
and j refers to the number of groups (Borenstein et al., 2009; Lipsey & Wilson, 2001).  
 Continuous moderators were tested using the method of moments for meta-
regression analyses.   Meta-regression assesses heterogeneity by developing regression 
models with independent variables that represent individual study characteristics and 
the dependent variable is the effect size (Borenstein et al., 2009; Murad et al., 2014).  
Comparable to the analog ANOVA, variables were first assessed by a Q test; Q was 
separated into variability accounted for by the: 1) regression equation (QR), and 2) the 
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residual variance (QB) (Borenstein, 2009).  True variance was explained by R
2 given 
by: 
𝑅2 = 1 −⁡(
𝑇𝑢𝑛𝑒𝑥𝑝𝑙𝑎𝑖𝑛𝑒𝑑
2
𝑇𝑡𝑜𝑡𝑎𝑙
2 ) 
where R2 is the variance of true effect sizes across studies and T2 is Tau-squared.  
(Borenstein et al., 2009).   
Outliers and Sensitivity Analysis 
Outlier analysis was performed to identify any study effect sizes that were extreme 
and could distort the mean effect size or variance.   The forest plot was visually 
analyzed to identify extreme observations or very large sample sizes.   Potential 
outliers were then checked for data entry errors by performing a secondary review of 
the manuscript and a second data extraction.  Outliers found to be three standard 
deviations from the mean (z=>3.0) were tested using sensitivity analysis where the 
meta-analysis was run with outliers removed and compared to the original meta-
analysis.  Sensitivity analysis was also performed using a “one study removed” 
analysis where the meta-analysis was run with all studies except the first, then all 
studies except the second, and then the third, until all studies were run (Borenstein et 
al., 2009).  Forest plots were produced to plot effect sizes as each study was added and 
their 95% CIs.  Plots were visually examined to detect any shift in the effect sizes.  
Studies found to be problematic were excluded and the meta-analysis was re-run to 
compare results.   
Publication Bias 
Publication bias addresses the larger research issue that not all completed trials 
are published.  Trials accepted for publications are more likely to report large 
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treatment effects than studies reporting modest or null effects (Dickersin & Min, 1993; 
Borenstein et al., 2009).   This publication bias can overestimate the treatment effect.  
Every meta-analysis is vulnerable to publication bias and requires a combination of 
methods to detect the impact of bias on the overall effect size.   This review included 
only peer-reviewed published articles as a method of quality control to ensure review 
of the highest quality evidence.   Therefore, this review may have a high risk of the 
“file drawer” problem (Rosenthal, 1979) where the effect size is overestimated due to 
studies with lower effect sizes being excluded.  However, publication bias is thought 
to be less likely in fields of public health importance such as HIV prevention because 
results with small samples, small effects, or insignificant results are often published 
(Marsh et al., 2001).   
To test for publication bias and study its impact, six tests were conducted: 1) 
the funnel plot, 2) Egger’s regression index, 3) Duval and Tweedie’s trim and fill test, 
4) Rosenthal’s fail-safe N, 5) Orwin’s adapted version of Rosenthal’s fail-safe N, and 
6) cumulative meta-analysis based on trial standard error.  Additionally, trials were 
coded as yes/no to indicate statistically significant positive effects. 
Funnel Plot 
The funnel plot was examined first.  The funnel plot is a scatterplot that plots 
the intervention effect size against the standard error or other measure of study 
precision (i.e. sample size).  Funnel plots allow for a quick visual display of 
symmetry.  Effect sizes were plotted on the X-axis and standard errors were plotted on 
a reverse scale on the Y-axis.  In the absence of publication bias, the scatter plot looks 
like an inverted, symmetrical funnel.  Typically, large studies (or studies with smaller 
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standard errors) cluster towards the top of the graph and around the mean effect size 
(Borenstein et al., 2009; Higgins & Green, 2008).  Smaller studies appear towards the 
bottom part of the graph and are often widely dispersed and fall to the right and left of 
the mean.  When an asymmetrical pattern appears with gaps on the left or right of the 
mean, it suggests the presence of publication bias.  The asymmetrical shape can 
suggest that smaller studies were more likely to be included if they have larger than 
average effects.  These studies most likely met criterion for statistical significance and 
were favored in publication over smaller studies with moderate results.  
 Visual interpretation of symmetry can help detect a relationship between 
sample size and effect size, but it does not explain the relationship (Gleser & Olkin, 
1996; Duval & Tweedie, 2000; Pham et al., 2000).  For example, the studies may 
represent a biased sample of smaller studies, or it is possible that the observed larger 
effect size is truly larger in these studies due to study quality.  Additional tests were 
conducted to study “small study effects” and examine if small-study effects are caused 
by methodological quality, true heterogeneity, study artifacts, or chance (Higgins & 
Green, 2008; Egger 1997a). 
Egger’s Test of the Intercept 
Egger’s test of the intercept was conducted to yield a quantitative estimate of 
the amount of bias observed in the funnel plot.  Egger’s test is calculated by regressing 
the standardized effect (i.e., the effect size divided by standard error) on the inverse of 
the standard error (i.e., precision estimate).  For this equation, the size of the treatment 
effect is captured by the slope of the regression line (B1) and bias is captured by the 
intercept (B0) (Borenstein et al., 2009).  Studies with higher standard errors produce 
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precision estimates closer to zero whereas studies with lower estimates of standard 
error produce precision estimates further from zero, suggesting studies with more 
robust sample sizes.  Bias is detected by a regression line that does not approach the 
intercept of origin.   
Duval and Tweedie's Trim and Fill 
 Duval and Tweedie’s Trim and Fill method was used to impute studies that 
were indicated as missing from the funnel plot (Duval & Tweedie, 2000).  This 
analysis was used to determine where the studies were missing on the plot, impute 
their estimated values to the analysis, and then re-compute the combined effect 
(Borenstein et al, 2009).  The trim and fill method is an iterative procedure to remove, 
or trim, extremely small studies from the right side of the plot while re-computing the 
overall effect size with each iteration.  Iterations continue until a symmetric funnel 
plot is achieved for the revised effect size.  Trimming reduces variance of effects and 
shrinks confidence intervals.  To compensate, the original studies are added (i.e., 
filled) back into the analysis, imputing a mirror image for each.  A funnel plot was 
produced that included both the original and imputed studies to visually examine any 
effect size shift when imputed studies are included.  The Trim and Fill method is very 
sensitive to outlier studies, and has strong assumptions about reasons for the missing 
data. 
Rosenthal’s fail-safe N and Orwin’s adapted version of the fail-safe N 
 Rosenthal’s fail-safe N and Orwin’s adapted version of the fail-safe N were 
conducted to assess the magnitude of the effect of publication bias and account for the 
file-drawer problem (Rosenthal, 1979; Begg & Mazumdar, 1994).  Rosenthal’s 
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method computes the number of studies required to nullify the effect.  When this 
number is relatively small, publication bias is a potential threat.  If this number if 
large, it suggests the intervention effect is not nil.  Rosenthal’s method needs to be 
interpreted with caution because it assumes that the effect in the missing studies is nil, 
as opposed to the effect of these studies being in the opposite direction, therefore the 
true number of studies required to nullify the effect may be smaller than the calculated 
fail-safe N.  Additionally, the fail-safe N is a test based on statistical significance and 
does not account for clinical significance.  This study calculated the fail-safe N using 
the modern practice of computing a summary effect, combining the effect sizes, and 
then computing a p-value for the combined effect sizes.  To address limitations of the 
fail-safe N, Orwin’s fail-safe N was calculated and treated as a more reliable measure 
of the number of studies needed to nullify the effect (Orwin, 1983).  Orwin’s fail-safe 
N differs from Rosenthal’s because it determines the number of studies using a 
predetermined effect size set by the researcher, rather than an arbitrary p-value.  This 
allows the researcher to estimate how many missing studies are needed to bring the 
overall effect size down before the overall effect would be trivial.  In this study, the 
criterion odds ratio that defined a trivial effect was set as 1.0 and the missing study 
mean odds ratio was assumed to be 1.5.    
Cumulative Meta-Analysis by Standard Error 
 Publication bias is assumed to be related to smaller studies or small-study 
effects.  The effect of study size was also examined using a cumulative meta-analysis. 
This procedure is generally used to display shifts in the cumulative weight of the 
evidence over time, but may also be used to further investigate impact of 
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publication bias or small-study effects (Borenstein, Higgins, Rothstein, & Hedges, 
2015).  To use this procedure for publication bias, trials are sorted by precision, or 
their standard error, in order of the most precise to least precise (i.e. smallest standard 
errors to largest standard errors).  Larger standard errors roughly correspond to smaller 
sample size and less precision, so if the odds ratio does not shift with the addition of 
the smaller studies, then there is no evidence to suggest publication bias related to 
small-study effects.   After trials were added from smallest to largest standard error, 
cumulative meta-analysis was performed as each new study was added.  Forest plots 
were produced to display cumulative effect sizes with each new study.  Visual 
examination was performed to detect any shift in overall effect size when the smaller 
trials (i.e. larger standard errors or less precise) were added.  There is valid concern for 
bias if the point estimate shifts with the addition of smaller trials, or trials with less 
precision.   
Missing data 
 For this study, missing data was related to reporting bias and refers to data 
needed to calculate effect sizes for positive or negative effects in studies otherwise 
eligible for review.  Missing data can also refer missing values specific to covariates 
used for subgroup analyses or meta-regressions.   Effect sizes were calculated from 
descriptive statistics when possible (e.g. sample size for intervention and comparison 
groups, means, standard deviations, proportions).  When descriptive statistics were not 
available, values were converted from standard errors, t, F, exact p-values, or 95% 
confidence intervals as appropriate (Higgins & Green, 2008).   When data were not 
available for effect size calculation, requests for descriptive data were sent to study 
 46 
 
authors.  When study authors did not respond, requests were sent to authors of 
previous meta-analyses who may have previously retrieved missing data from study 
authors (e.g. CDC’s Prevention Research Synthesis Team).  If study authors did not 
respond, and effect sizes could not be accurately calculated, studies were excluded 
from meta-analysis rather than performing imputation.   Case analysis was used for 
moderator data.  Data were not imputed for moderator analyses, and studies with 
missing data were excluded. 
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CHAPTER 5: RESULTS 
Search Results 
The search process is summarized in Figure 1. The search retrieved 4,147 
records from electronic databases as potentially relevant citations: PubMed (1,208), 
PsycINFO (1,807), EMBASE (766), CINAHL (245), and CENTRAL (121).   De-
duplication resulted in 3,059 records.  Seven additional records were found through 
hand searches resulting in 3,066 records for review.  Manual review of record titles 
resulted in 233 records deemed to be potentially relevant.  Manual review of record 
abstracts resulted in 108 records potentially eligible for inclusion and these 
manuscripts were retrieved.  After manual review of full text, 40 records were 
excluded because they did not meet eligibility criteria.  Sixty-eight manuscripts were 
retained for full review by two coders.   
During coding, the protocol was revised to add additional exclusions to 
eligibility.  Full review with new protocol exclusions resulted in thirty manuscripts 
excluded due to having 100% HIV-positive MSM (k=16), not reporting a behavioral 
outcome (k=5), not being specifically designed for MSM (k=2), or not having an 
independent comparison group (k=7).    A total of 38 records were selected for 
inclusion and effect size data were examined.  Eight records were identified as eligible 
for inclusion, but missing essential data.   All eight authors were contacted and 
missing data were requested.  Three authors responded and provided data to calculate 
an effect size for the specified primary outcome, and a previous meta-analysis 
supplied effect size data for one trial.  Four trials were excluded due to missing data 
resulting in a final sample size of 34 trials (Table 1) 
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Figure 1 
Search and Retrieval Process Results 
 
 
Description of Trials 
An overview of trials are summarized in Table 1.  Descriptive characteristics 
are summarized in Table 2.  A total of 17,872 participants were enrolled at baseline 
across 34 trials (median sample size=328, range=50-4,295).  Across all trials, a 
median of 66 percent of participants were white (M=50.8, SD=35.8).  A median of 
nine percent of participants were black (M=29.5, SD=39.0), and 11 percent were 
Latino (M=17.0, SD=25.3).  Mean age was 33.3 (SD=5.4, median=34) years with a 
mean range of 21.3-42.8 years.  A median of 31 percent were high school graduates or 
less, and a median of 15 percent were HIV-positive.   Across 34 trials, only nine (26.4 
percent) focused specifically on minority racial or ethnic groups (6=black, 
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2=Hispanic/Latino, 1=Asian), four (11.8 percent) focused specifically on young adult 
MSM, and 6 (17.6 percent) focused specifically on substance-using MSM.  No studies 
specifically focused on male sex workers, and only one study focused on men who 
have sex with men and women (MSMW).  A median of 74 percent of participants 
reported any substance use and 42 percent reported mental health distress or history of 
victimization.  Most participants self-identified as gay or bisexual (median=98 
percent).  The majority of trials were conducted in the Western region of the U.S. 
(k=16), 11 trials were conducted in the Northeast, five trials were conducted in the 
Midwest, five were conducted in the South, and four recruited national samples using 
the internet or telephone.  Four trials had multiple trial sites in more than one U.S. 
region.  The most frequently reported trial sites were in cities with higher proportions 
of MSM such as New York City, San Francisco, Los Angeles, and Seattle.      
 Eighteen trials (52.9 percent) contributed count-level primary outcomes and 16 
(47.0 percent) contributed dichotomous outcomes as primary outcomes.  Most trials 
were either group-level interventions (k=17) or individual-level interventions (k=14).  
Three interventions were community-level interventions.  Median intervention time 
span was 3 weeks (range 1-288 weeks) with a median of 4 sessions (range:1-48) and 
median of 8 hours (range: 1-96).   The majority of trials used an HIV-related 
comparison group (k=17), seven used a non-HIV related comparison group, and 10 
used a wait-list comparison group.  More trials reported ≥80 percent overall retention 
rates (k=19) than <80 percent retention (k=14).  One study did not clearly report 
retention rates and was excluded from retention analysis.  Of trials that reported 
retention rates by experimental condition (k=30), most trials (k=19 or 55.8 percent) 
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reported equal or about equal retention rates, 10 trials reported better retention in the 
comparison group, and no trials reported better retention in the intervention group.         
Intervention content varied across trials.  The majority of trials reported 
intervention content that included the development of individualized risk reduction 
plans (k=27).  About 68 percent of trials (k=23) reported intervention content that 
focused on increasing sexual communication, 58.8 percent (k=20) reported content 
focused on increasing skills, and 41.1 percent (k=14) reported intervention content 
focused on the impact of stigma or discrimination.  Nine trials reported having 
multiple behavioral outcomes of interest other than sexual risk reduction.  Six focused 
on additional outcomes of substance use reduction and three focused on increasing 
HIV testing.  Of these trials, six or 66.6 percent were conducted after the last review in 
2007.    
About half of trials (k=21, 62 percent) reported statistically significantly 
different findings (P<.05) between experimental conditions on at least one relevant 
outcome at last follow-up assessment.  Eleven of 34 trials were found to be previously 
classified as Evidence-Based Interventions (EBI) by CDC PRS and listed in the 
Compendium (CDC, 2014b).  Of the remaining 23 trials, 10 were classified as Positive 
Non-EBIs, seven were Rigorous Non-EBIs, and six were Other Non-EBIs. 
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Table 1 
Overview of Included Trials 
Publication Year 
Participants at 
Baseline 
Intervention 
Description 
Level 
Effect 
Measure* 
Control 
Group 
Follow-Up 
Quality 
Rating 
Carballo-
Dieguez et al. 
2005 
180 Latino MSM 
in 
New York City 
8 weekly two-
hour sessions  
 
GLI 
No. UAI 
events*, % 
UAI  
 Wait-list 12 months 
Other Non-
EBI 
Carpenter et 
al. 
2010 
112 MSM aged 
18-39 recruited 
online 
Web-based skills 
training, 1 two-
hour session 
 
ILI 
No. UAI 
events 
Non-HIV 
related 
3 months 
Positive 
Non-EBI 
Choi et al. 1995 
329 Asian Pacific 
Islander MSM in 
San Francisco 
 1 three-hour safer 
sex skills training 
group 
GLI 
% UAI*, 
No. male 
partners 
Wait-list 3 months EBI 
Coffin et al. 2014 
326 substance-
using MSM in 
San Francisco 
1 one-hour 
session of PCC 
ILI 
No. UAI 
events*, No. 
male 
partners 
HIV-related 6 months 
Rigorous 
Non-EBI 
Dilley et al. 2002 
305 HIV-negative 
MSM in San 
Francisco 
1 one-hour 
session of PCC 
with 
paraprofessional 
counselor 
ILI 
No. UAI 
events 
HIV-related 12 months EBI 
Dilley et al. 2007 
248 HIV-negative 
MSM in San 
Francisco 
1 one-hour 
session of PCC, 
sexual diary   
ILI % UAI HIV-related 12 months 
Rigorous 
Non-EBI 
Eaton et al. 2011 
149 HIV-negative 
MSM in Atlanta 
1 one-hour 
session with peer 
counselors to 
address 
serosorting risks  
ILI 
No. male 
partners 
HIV-related 3 months EBI 
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Publication Year 
Participants at 
Baseline 
Intervention 
Description 
Level 
Effect 
Measure 
Control 
Group 
Follow-Up 
Quality  
Rating 
Harawa et al. 2013 
437 black MSMW 
in Los Angeles 
MAALES 6 two-
hour small group 
sessions   
GLI 
No. UAI 
events 
HIV-related 6 months EBI 
Hightow-
Weidman et 
al. 
2012 
50 young black 
MSM in North 
Carolina 
Four 30-minute 
weekly sessions 
by website  
ILI 
No. male 
partners*, % 
UAI 
HIV-related 3 months 
Other Non-
EBI 
Hirshfield et 
al. 
2012 
3092 MSM 
recruited online 
brief HIV 
prevention video 
or webpage 
ILI 
% UAI 
events 
HIV-related 2 months 
Positive 
Non-EBI 
Kegeles et al. 1996 
300 young MSM 
in Oregon 
Peer-led outreach, 
small groups, and 
media campaign 
CLI 
% UAI 
events 
Wait-list 12 months EBI 
Kelly et al. 1989 
104 HIV-negative 
MSM in mid-
sized city 
Twelve 90-minute 
weekly CBT 
group sessions 
GLI 
No. UAI 
events*, % 
condom use, 
No. partners 
Wait-list 4 months 
Positive 
Non-EBI 
Kelly et al. 1991 
659 MSM in 
Mississippi and 
Louisiana 
POL peer-led 
community 
intervention 
CLI 
% UAI 
events*, % 
condom use, 
No. male 
partners 
Non-HIV 
related 
12 months EBI 
Kelly et al.  1997 
442 MSM in 8 US 
cities 
POL peer-led 
community 
intervention 
CLI 
No. UAI 
events*, % 
UAI; No. 
male 
partners 
HIV-related 12 months EBI 
Koblin et al. 2012 
283 black MSM 
in New York City 
5 two-hour risk 
reduction sessions 
with meal prep  
GLI 
% UAI 
events 
Non HIV-
related 
3 months 
Rigorous 
Non-EBI 
  
 
 
5
3
 
 
Publication Year 
Participants at 
Baseline 
Intervention 
Description 
Level 
Effect 
Measure 
Control 
Group 
Follow-Up 
Quality  
Rating 
EXPLORE 2004 
4295 MSM in six 
US cities 
10 counseling 
sessions with 3- 
month booster 
session for 4 years 
ILI 
% UAI 
events 
HIV-related 48 months EBI 
Kurtz et al. 2013 
515 substance-
using MSM in  
South Florida 
4 two-hour small 
group weekly 
sessions about 
substance use and 
sexual risk  
GLI 
No. UAI 
events*, No. 
male 
partners 
HIV-related 12 months 
Rigorous 
Non-EBI 
Lui et al. 2013 
400 HIV-negative  
MSM in San 
Francisco, 
Atlanta, and 
Boston 
PrEP, HIV 
testing, risk 
reduction 
counseling every 
3 months  
ILI 
% UAI 
events 
Wait-list 24 months 
Other Non-
EBI 
Mansergh et 
al. 
2010 
1686 substance 
using MSM in 4 
US cities 
6 two-hour CBT 
group sessions 
focused on 
substance use and 
sexual risk  
GLI 
% UAI 
events 
Non HIV-
related 
12 months 
Rigorous 
Non-EBI 
Menza et al. 2010 
127 MSM who 
use 
methamphetamine 
in Seattle  
12 weeks of bi-
weekly 
contingency  
management  
ILI 
% UAI 
events*, No. 
male 
partners 
Non HIV-
related 
6 months 
Rigorous 
Non-EBI 
Mustanski et 
al. 
2013 
102 young MSM 
in Chicago 
3 two-hour 
sessions of KIU! 
online program 
focused on HIV 
testing and sexual 
risk  
ILI 
No. UAI 
events 
HIV-related 3 months 
Positive 
Non-EBI 
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Publication Year 
Participants at 
Baseline 
Intervention 
Description 
Level 
Effect 
Measure 
Control 
Group 
Follow-Up 
Quality  
Rating 
O’Donnell et 
al. 
2014 
370 Latino MSM 
in New York City 
Adaptation of 
VOICES/VOCES 
(1 hour video) 
into No 
Excuses/Sin 
Buscar Excuses 
GLI 
No. UAI 
events*, % 
condom use 
HIV-related 3 months EBI 
Parsons et al. 2014 
143 substance 
using young 
MSM in New 
York City 
4 sessions of MI 
delivered over 12 
weeks focused on 
substance use and 
sexual risk 
reduction 
LI 
No. UAI 
events 
HIV-related 12 months EBI 
Peterson et al. 1996 
318 HIV-negative 
African-American 
MSM in San 
Francisco 
1 group or 3 
three-hour weekly 
small groups 
using CBT self-
management 
training 
GLI 
% UAI 
events 
Wait-list 18 months 
Positive 
Non-EBI 
Picciano et al. 2001 
89 MSM in 
Seattle 
Single session 90-
minute telephone-
based brief 
counseling using 
MI 
ILI 
No. UAI 
events*, No. 
male 
partners 
Wait-list 2 months 
Rigorous 
Non-EBI 
Picciano et al. 2007 
319 MSM in 
Seattle and 
Portland 
Three 90-minute 
sessions of MET 
delivered by 
telephone over 6 
weeks 
ILI 
No. male 
sex partners 
HIV-related 10 months 
Other Non-
EBI 
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Publication Year 
Participants at 
Baseline 
Intervention 
Description 
Level 
Effect 
Measure 
Control 
Group 
Follow-Up 
Quality  
Rating 
Roffman et 
al. 
1997 
548 MSM 
recruited by 
telephone 
14 weekly 90-
minute group 
CBT focused on 
relapse prevention  
by telephone   
GLI 
% UAI 
events*, No. 
UAI events, 
No. male 
partners 
Wait-list 3 months 
Positive 
Non-EBI 
Roffman et 
al. 
1998 
159 MSM in 
Seattle 
17weekly sessions 
of group CBT 
counseling 
focused on relapse 
prevention 
GLI 
No. UAI 
events*, No. 
male 
partners 
Wait-list 1 months 
Positive 
Non-EBI 
Simon Rosser 
et al. 
2002 
422 MSM in a 
Midwestern city 
2-day 
comprehensive 
human sexuality 
seminar 
GLI 
% UAI 
events 
HIV-related 12 months 
Positive 
Non-EBI 
Shoptaw et 
al. 
2005 
162 
methamphetamine 
dependent MSM 
in Los Angeles 
16 weeks of tri-
weekly 90-minute 
culturally tailored 
group CBT 
GLI 
No. UAI 
events*, % 
UAI 
Non HIV-
related 
12 months 
Other Non-
EBI 
Stall et al. 1998 
456 MSM in 
substance use 
treatment in San 
Francisco 
16 unstructured 
weekly 3-hour  
treatment groups 
focused on coping 
skills  
GLI 
% UAI 
events 
Non HIV-
related 
15 months 
Other Non-
EBI 
Tobin et al. 2013 
188 African-
American  MSM 
in Baltimore 
6 bi-weekly 2-
hour culturally 
tailored group 
modules plus one 
individual session  
GLI 
% UAI 
events 
HIV-related 3 months 
Positive 
Non-EBI 
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Publication Year 
Participants at 
Baseline 
Intervention 
Description 
Level 
Effect 
Measure 
Control 
Group 
Follow-Up 
Quality  
Rating 
Valdiserri et 
al. 
1989 
584 MSM in 
Pittsburgh 
Small group 
lecture plus skills 
training for safer 
sex negotiation  
GLI 
No. male 
sex partners 
HIV-related 12 months 
Positive 
Non-EBI 
Wilton et al. 2009 
338 HIV-negative 
black MSM in 
New York City 
3MV 6 three-hour 
sessions delivered 
over 3 days as a 
weekend retreat 
GLI 
No. UAI 
events*, No. 
male 
partners 
Wait-list 6 months EBI 
 Notes: *effect measure extracted for meta-analysis based on primary outcome or meta-analysis protocol  
No.=number 
%=percent 
UAI=unprotected anal intercourse 
MSM=men who have sex with men 
MSMW=men who have sex with men and women 
 ILI=individual-level intervention 
GLI=group-level intervention 
CLI=community level intervention 
EBI=evidence-based intervention 
PCC=personalized cognitive counseling 
MAALES=Men of African American Legacy Empowering Self 
CBT=cognitive behavioral therapy 
POL=Popular Opinion Leader 
PrEP=pre-exposure prophylaxis 
KIU!=Keep It Up! 
MI=motivational interviewing 
MET=motivational enhancement therapy 
3MV=Many Men Many Voices. 
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Table 2 
General Characteristics of Trials 
  k (34) Percent Mean SD 
Conducted Pre or Post ART     
 Pre-ART 11 32.3   
 Post-ART 23 67.6   
MSM Subgroup     
 Young MSM 4 11.8   
 Racial/ethnic minority MSM 9 26.5   
 Substance-using MSM 6 17.6   
 Other or none specified 15 44.1   
Region     
 Northeast 11 32.3   
 South 5 14.7   
 Midwest 5 14.7   
 West 16 47.0   
 National 4 6.8   
Sample Characteristics     
 Median % black 29 9 29.5 39.0 
 Median % Latino 29 11 17.0 25.3 
 Median % white 34 66 50.8 35.8 
 Median % gay or bisexual                      20 98 94.5 7.6 
 Median % HIV-positive 30 15 19.5 22.0 
                 Median % high school or less 25                     31 35.4 19.6  
                 Median % mental health 5 42 56.5 25.8  
                 Median age 34 34 33.3 5.4  
Intervention Level     
 Individual 14 41.1   
 Group 17 50.0   
 Community 3 8.8   
Comparison Group     
  Wait-list 10 29.4   
  HIV-related 17 50.0   
  Non HIV-related 7 20.6   
Outcomes     
 Count-level* 18 52.9   
 Dichotomous* 16 47.0   
 Multiple outcomes reported 9 26.5   
 P<.05 result reported 21 61.7   
Retention     
 >80% overall retention 19 55.9   
 Better in comparison condition 11 32.3   
 Better in intervention condition 0 0   
 About equal 19 55.9   
Follow-Up Assessment     
 <3 months 12 35.2   
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Table 2 
General Characteristics of Trials 
  k (34) Percent Mean SD 
 ≥3 months 22 64.7   
Intervention Dose     
 Median time span in weeks 33 3 14.9 49.6 
 Median total time in hours 28 8 12.9 21.3 
 Median # of sessions  33 4 7.3 10.1 
Intervention Characteristics 
 Pilot tested 19 55.8   
 Conducted in MSM setting 6 17.6   
 Delivered by peers 6 17.6   
 Focus on sexual communication 23 67.6   
 Focus on skills building 18 52.9   
                 Focus on individual plans 27 79.4    
                 Focus on stigma 13 38.2    
                 Use of technology 8 23.5    
Evidence Level     
 Evidence-Based Intervention 11 32.3   
 Positive Non-EBI 10 29.4   
 Rigorous Non-EBI 7 20.6   
 Other Non-EBI 6 17.6   
Notes: * outcome used in meta-analysis as primary outcome 
 
Overall Meta-Analysis 
Meta-analysis was conducted using data extracted from all 34 studies.  Count-
level outcomes were used in 18 (52.9 percent) trials and dichotomous outcomes were 
used in 16 (47.1 percent) trials.  Effect sizes resulted from a total of 13,272 
participants. Figure 2 displays the descriptive data, ORs, confidence intervals, and 
outcome measures from each trial. Trials were sorted in descending order by year.  
Effect sizes ranged from OR=0.431 to OR=1.343. Under the random effects model the 
mean effect size was OR =0.859 (95% CI [0.790, 0.933]).  This result was 
significantly different than zero (p<.001). The fixed effects model yielded a 
statistically significant result consistent with random effects (OR=.865, 95% CI 
[0.815, 0.919], p<.001).  Test of the Q statistic indicated little heterogeneity and was 
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not significant (Q[33]=39.35, p =.207).  I2 was low indicating relatively little 
heterogeneity (I2=16.14). 
Cumulative Meta-Analysis 
Cumulative meta-analysis was conducted on all 34 studies sorting by 
publication year from earliest to latest (Figure 3).   Effect size shrinkage was 
determined by calculating the percent change from the first cumulative effect size that 
became significant (third row: Kelly, 1991) to the last row.  A gradual effect size 
shrinkage of 19.5 percent was observed from 1991 (OR=.719) to 2014 (OR=.859).  
The forest plot reveals the largest effect size shift to occur after the inclusion of 
EXPLORE in 2004 from .720 (95% CI [0.619, 0.838]) to .777 (95% CI [0.688, 
0.878]) resulting in a relative change over 1.0.  After EXPLORE, the cumulative effect 
size stabilized and confidence intervals narrowed.  The effect size moved closer to the 
null value of 1.0 with the addition of each new trial.  Results warrant statistical 
analysis of year as a covariate in meta-regression analyses.
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Figure 2  
Overall Meta-Analysis Results 
 
Study name Outcome Statistics for each study Odds ratio and 95%  CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Parsons, 2014 % UAI events 0.473 0.219 1.021 -1.908 0.056
Coffin, 2014 # UAI events 0.978 0.659 1.449 -0.113 0.910
Odonnell, 2014 # UAI events 1.000 0.682 1.466 0.000 1.000
Mutanski, 2013 # UAI events 0.624 0.308 1.265 -1.307 0.191
Tobin, 2013 % UAI events 0.738 0.328 1.660 -0.734 0.463
Kurtz, 2013 # UAI events 0.817 0.585 1.141 -1.186 0.236
Harawa, 2012 # UAI events 0.946 0.623 1.435 -0.262 0.794
Lui, 2013 % UAI events 1.212 0.789 1.861 0.880 0.379
Hightow-Weidman, 2012 # sex partners 0.688 0.219 2.161 -0.641 0.521
Hirshfield, 2012 % UAI events 1.082 0.825 1.418 0.570 0.569
Koblin, 2012 % UAI events 1.343 0.806 2.239 1.131 0.258
Eaton, 2011 # sex partners 0.477 0.246 0.924 -2.195 0.028
Carpenter, 2010 # UAI events 0.717 0.365 1.408 -0.966 0.334
Menza, 2010 % UAI events 0.933 0.266 3.269 -0.108 0.914
Mansergh, 2010 % UAI events 1.089 0.853 1.391 0.683 0.494
Wilton, 2009 # UAI events 0.634 0.407 0.987 -2.019 0.043
Dilley, 2007 # UAI events 0.937 0.624 1.409 -0.311 0.756
Picciano, 2007 # sex partners 0.938 0.630 1.397 -0.313 0.754
Shoptaw, 2005 # sex partners 1.016 0.382 2.702 0.031 0.975
Carballo-Dieguez, 2005 # UAI events 1.223 0.628 2.382 0.592 0.554
EXPLORE, 2004 % UAI events 0.860 0.788 0.938 -3.401 0.001
Dilley, 2002 % UAI events 0.431 0.187 0.993 -1.975 0.048
Simon Rosser, 2002 % UAI events 0.523 0.236 1.158 -1.597 0.110
Picciano, 2001 # UAI events 0.740 0.348 1.576 -0.780 0.435
Roffman, 1998 # UAI events 1.089 0.578 2.052 0.265 0.791
Stall, 1998 % UAI events 1.327 0.593 2.973 0.688 0.491
Roffman, 1997 % UAI events 0.563 0.325 0.976 -2.045 0.041
Kelly, 1997 # UAI events 0.630 0.406 0.979 -2.056 0.040
Kegeles, 1996 % UAI events 0.649 0.355 1.188 -1.402 0.161
Choi, 1996 % UAI events 0.777 0.449 1.347 -0.899 0.369
Peterson, 1996 % UAI events 1.119 0.442 2.832 0.237 0.813
Kelly, 1991 % UAI events 0.625 0.443 0.883 -2.668 0.008
Kelly, 1989 # UAI events 0.528 0.243 1.149 -1.610 0.108
Valdiserri, 1989 # sex partners 0.900 0.641 1.263 -0.610 0.542
0.859 0.790 0.933 -3.580 0.000
0.1 0.2 0.5 1 2 5 10
Fav ours interv ention Fav ours control
Effect Sizes of Behavioral Interventions for US MSM, 1988-2014
k=34, random effects model
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Figure 3  
Cumulative Meta-Analysis Results 
Study name Outcome Cumulativ e statistics Cumulativ e odds ratio (95%  CI)
Lower Upper 
Point limit limit Z-Value p-Value
Kelly, 1989 # UAI events 0.528 0.243 1.149 -1.610 0.108
Valdiserri, 1989 # sex partners 0.777 0.487 1.239 -1.059 0.289
Kelly, 1991 % UAI events 0.719 0.534 0.966 -2.188 0.029
Kegeles, 1996 % UAI events 0.718 0.578 0.893 -2.981 0.003
Choi, 1996 % UAI events 0.726 0.594 0.888 -3.123 0.002
Peterson, 1996 % UAI events 0.740 0.608 0.901 -3.002 0.003
Roffman, 1997 % UAI events 0.718 0.597 0.864 -3.514 0.000
Kelly, 1997 # UAI events 0.704 0.594 0.835 -4.036 0.000
Roffman, 1998 # UAI events 0.725 0.615 0.855 -3.829 0.000
Stall, 1998 % UAI events 0.743 0.632 0.873 -3.614 0.000
Picciano, 2001 # UAI events 0.743 0.634 0.870 -3.697 0.000
Dilley, 2002 % UAI events 0.729 0.624 0.851 -3.999 0.000
Simon Rosser, 2002 % UAI events 0.720 0.619 0.838 -4.231 0.000
EXPLORE, 2004 % UAI events 0.777 0.688 0.878 -4.062 0.000
Shoptaw, 2005 # sex partners 0.793 0.711 0.883 -4.218 0.000
Carballo-Dieguez, 2005 # UAI events 0.797 0.714 0.891 -3.998 0.000
Dilley, 2007 # UAI events 0.815 0.741 0.897 -4.207 0.000
Picciano, 2007 # sex partners 0.832 0.770 0.899 -4.679 0.000
Wilton, 2009 # UAI events 0.817 0.750 0.890 -4.635 0.000
Carpenter, 2010 # UAI events 0.828 0.771 0.889 -5.222 0.000
Menza, 2010 % UAI events 0.828 0.771 0.889 -5.219 0.000
Mansergh, 2010 % UAI events 0.831 0.757 0.913 -3.884 0.000
Eaton, 2011 # sex partners 0.815 0.737 0.902 -3.960 0.000
Hightow-Weidman, 2012 # sex partners 0.818 0.742 0.901 -4.077 0.000
Hirshfield, 2012 % UAI events 0.833 0.755 0.919 -3.635 0.000
Koblin, 2012 % UAI events 0.843 0.761 0.933 -3.307 0.001
Mutanski, 2013 # UAI events 0.838 0.759 0.926 -3.460 0.001
Tobin, 2013 % UAI events 0.839 0.761 0.924 -3.558 0.000
Kurtz, 2013 # UAI events 0.840 0.767 0.920 -3.768 0.000
Harawa, 2012 # UAI events 0.846 0.776 0.922 -3.803 0.000
Lui, 2013 % UAI events 0.855 0.783 0.933 -3.508 0.000
Parsons, 2014 % UAI events 0.846 0.774 0.926 -3.637 0.000
Coffin, 2014 # UAI events 0.853 0.782 0.929 -3.621 0.000
Odonnell, 2014 # UAI events 0.859 0.790 0.933 -3.580 0.000
0.859 0.790 0.933 -3.580 0.000
0.5 1 2
Fav ours interv ention Fav ours control
Cumulative Effect Sizes by Trial Year of Publication, 1988-2014
k=34, random effects model
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Publication Bias Analysis 
Analysis of publication bias indicated a small amount of risk based on 
observed asymmetry in the funnel plot (Figure 4).  More studies are observed towards 
the top of the graph, and less towards the bottom.  Slightly more trials were observed 
to the left of the mean effect size indicating there were a few trials that may be missing 
from the right side of the mean effect size (OR>1.0) due to reporting bias.  Statistical 
analyses of potential publication bias suggests a small amount of bias.   
Figure 4 
Funnel Plot for Publication Bias 
 
Rosenthal’s fail-safe N test required the addition of 143 missing trials to nullify 
the effect, or 4.2 studies per every observed trial. Orwin’s N was more conservative, 
but indicated that 101 missing studies would be needed to bring the effect size over a 
mean odds ratio of 1.0.   Both of these tests indicate minimal potential for publication 
bias. Trim and fill analysis suggested the imputation of five studies which aligns 
closely with our missing data procedures that resulted in 4 excluded studies.  The 
filled circles in Figure 4 represent imputed values on the right side.   Trim and fill 
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estimated the real effect size to be consistent with the observed effect size with OR = 
.858 (95% CI [0.790, 0.933]) under the random effects model, and OR=.865 under the 
fixed effects model (95% CI [0.814, 0.919]).  Egger’s regression was not significant 
(B = -0.35, t(32) = 1.19, 95% CI [-0.949, 0.247], p =0.120), indicating lack of 
publication bias.  Finally, a cumulative meta-analysis of precision was conducted 
where trials were sorted by precision, and added in order of smallest to largest 
standard error.   Visual examination did not detect a shift in overall effect size when 
the trials with larger standard errors (i.e. trials with smaller samples) were added, 
indicating minimal publication bias or minimal small-study effects.  Results are 
presented in Figure 5.  Synthesis of all publication bias analyses suggests this study 
was subject to minimal publication bias, though there may be some trials missing.  
Minimal bias results are consistent with literature cited previously that suggests 
statistically insignificant, and small studies, are likely to published in the HIV 
prevention literature.  
  
6
4
 
 
 
Figure 5 
Cumulative Effect Sizes by Precision 
Study name Outcome Cumulativ e statistics Cumulativ e odds ratio (95%  CI)
Lower Upper 
Point limit limit Z-Value p-Value
EXPLORE, 2004 % UAI events 0.860 0.788 0.938 -3.401 0.001
Mansergh, 2010 % UAI events 0.940 0.751 1.177 -0.538 0.591
Hirshfield, 2012 % UAI events 0.970 0.810 1.163 -0.326 0.744
Kurtz, 2013 # UAI events 0.937 0.812 1.082 -0.887 0.375
Valdiserri, 1989 # sex partners 0.923 0.824 1.034 -1.389 0.165
Kelly, 1991 % UAI events 0.895 0.781 1.025 -1.604 0.109
Odonnell, 2014 # UAI events 0.903 0.799 1.020 -1.637 0.102
Coffin, 2014 # UAI events 0.906 0.812 1.012 -1.745 0.081
Picciano, 2007 # sex partners 0.905 0.821 0.999 -1.980 0.048
Dilley, 2007 # UAI events 0.902 0.827 0.983 -2.338 0.019
Harawa, 2012 # UAI events 0.895 0.832 0.962 -2.995 0.003
Lui, 2013 % UAI events 0.912 0.841 0.990 -2.192 0.028
Kelly, 1997 # UAI events 0.906 0.829 0.991 -2.147 0.032
Wilton, 2009 # UAI events 0.896 0.816 0.983 -2.323 0.020
Koblin, 2012 % UAI events 0.908 0.824 1.000 -1.969 0.049
Choi, 1996 % UAI events 0.903 0.824 0.991 -2.159 0.031
Roffman, 1997 % UAI events 0.893 0.812 0.982 -2.333 0.020
Kegeles, 1996 % UAI events 0.887 0.807 0.974 -2.514 0.012
Roffman, 1998 # UAI events 0.890 0.813 0.975 -2.498 0.012
Eaton, 2011 # sex partners 0.879 0.799 0.967 -2.638 0.008
Carballo-Dieguez, 2005 # UAI events 0.885 0.805 0.972 -2.546 0.011
Carpenter, 2010 # UAI events 0.882 0.805 0.967 -2.682 0.007
Mutanski, 2013 # UAI events 0.877 0.801 0.961 -2.828 0.005
Picciano, 2001 # UAI events 0.876 0.802 0.957 -2.942 0.003
Parsons, 2014 % UAI events 0.868 0.793 0.950 -3.066 0.002
Kelly, 1989 # UAI events 0.862 0.787 0.944 -3.202 0.001
Simon Rosser, 2002 % UAI events 0.856 0.782 0.938 -3.337 0.001
Stall, 1998 % UAI events 0.861 0.787 0.942 -3.246 0.001
Tobin, 2013 % UAI events 0.860 0.788 0.940 -3.336 0.001
Dilley, 2002 % UAI events 0.852 0.779 0.933 -3.464 0.001
Peterson, 1996 % UAI events 0.855 0.782 0.935 -3.450 0.001
Shoptaw, 2005 # sex partners 0.857 0.786 0.935 -3.466 0.001
Hightow-Weidman, 2012 # sex partners 0.857 0.787 0.934 -3.537 0.000
Menza, 2010 % UAI events 0.859 0.790 0.933 -3.580 0.000
0.859 0.790 0.933 -3.580 0.000
0.5 1 2
Fav ours interv ention Fav ours control
Cumulative Effect Sizes by Precision, 1988-2014
k=34, random effects model
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Outlier Examination 
Only one trial produced a z-score higher than 3.0 and was subject to outlier 
examination.  EXPLORE (Koblin et al., 2004) was the largest trial (N=4,295) with the 
smallest standard error (0.04) and z-score of -3.401 (OR=.860, 95% CI [0.788, 
0.938]).  Meta-analysis was repeated without EXPLORE and results were compared.  
Table 3 displays the mean effect sizes with all trials and then with EXPLORE 
removed.  EXPLORE was retained in the overall analysis because its exclusion did not 
contribute to change in the overall result.  EXPLORE was also retained due to its 
important contribution to HIV prevention as a landmark trial enrolling the largest 
group of MSM with the longest follow-up period.  Sensitivity analysis using a “one 
study removed” analysis was performed to confirm that no single study (including 
EXPLORE) contributed to an observed shift in effect sizes.   Forest plots produced 
from a one-study-removed analysis showed little shift in effect sizes (Figure 6). 
Table 3 
Sensitivity Analysis 
Analysis k Model OR 
95% CI 
P Q (df) 
LCL UCL 
All studies 34 
Fixed 0.865 0.815 0.919 <.001 39.35 (33)* 
Random 0.859 0.790 0.933 <.001  
EXPLORE  
removed 
33 
Fixed 0.870 0.800 0.946 <.001 39.32 (32)* 
Random 0.853 0.773 0.940 <.001  
Notes: *not significant 
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Figure 6 
One Study Removed Outlier Analysis 
Outcome Study name Statistics with study remov ed Odds ratio (95%  CI) with study remov ed
Lower Upper 
Point limit limit Z-Value p-Value
# UAI events Odonnell, 2014 0.853 0.782 0.929 -3.621 0.000
# UAI events Coffin, 2014 0.853 0.783 0.931 -3.590 0.000
% UAI events Parsons, 2014 0.866 0.798 0.939 -3.478 0.001
# UAI events Kurtz, 2013 0.859 0.787 0.938 -3.381 0.001
# UAI events Harawa, 2012 0.855 0.784 0.932 -3.551 0.000
% UAI events Lui, 2013 0.851 0.784 0.924 -3.855 0.000
# UAI events Mutanski, 2013 0.862 0.792 0.938 -3.445 0.001
% UAI events Tobin, 2013 0.859 0.789 0.936 -3.485 0.000
% UAI events Hirshfield, 2012 0.846 0.779 0.920 -3.915 0.000
% UAI events Koblin, 2012 0.852 0.786 0.924 -3.888 0.000
# sex partners Hightow-Weidman, 2012 0.859 0.789 0.935 -3.505 0.000
# sex partners Eaton, 2011 0.868 0.802 0.940 -3.478 0.001
% UAI events Mansergh, 2010 0.845 0.778 0.917 -4.039 0.000
# UAI events Carpenter, 2010 0.860 0.790 0.937 -3.458 0.001
% UAI events Menza, 2010 0.857 0.787 0.934 -3.537 0.000
# UAI events Wilton, 2009 0.868 0.799 0.943 -3.341 0.001
# sex partners Picciano, 2007 0.855 0.783 0.932 -3.544 0.000
# UAI events Dilley, 2007 0.855 0.784 0.932 -3.543 0.000
# UAI events Carballo-Dieguez, 2005 0.854 0.785 0.929 -3.674 0.000
# sex partners Shoptaw, 2005 0.857 0.787 0.933 -3.555 0.000
% UAI events EXPLORE, 2004 0.853 0.773 0.940 -3.201 0.001
% UAI events Simon Rosser, 2002 0.864 0.795 0.938 -3.464 0.001
% UAI events Dilley, 2002 0.866 0.799 0.939 -3.505 0.000
# UAI events Picciano, 2001 0.859 0.789 0.936 -3.478 0.001
# UAI events Roffman, 1998 0.855 0.785 0.931 -3.616 0.000
% UAI events Stall, 1998 0.855 0.786 0.930 -3.668 0.000
# UAI events Kelly, 1997 0.868 0.799 0.943 -3.339 0.001
% UAI events Roffman, 1997 0.868 0.800 0.942 -3.404 0.001
% UAI events Choi, 1996 0.859 0.789 0.937 -3.449 0.001
% UAI events Kegeles, 1996 0.863 0.793 0.939 -3.421 0.001
% UAI events Peterson, 1996 0.856 0.786 0.932 -3.582 0.000
% UAI events Kelly, 1991 0.875 0.807 0.948 -3.274 0.001
# sex partners Valdiserri, 1989 0.855 0.783 0.934 -3.492 0.000
# UAI events Kelly, 1989 0.864 0.795 0.939 -3.460 0.001
0.859 0.790 0.933 -3.580 0.000
0.5 1 2
Fav ours interv ention Fav ours control
One Study Removed, 1988-2014
k=34, random effects model
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Moderator Analysis 
 The presence of moderating effects was not indicated by a significant Q 
statistic or an I2 statistic that suggested heterogeneity.  However, both Q and I2 have 
limitations in interpreting heterogeneity, and due to the relatively small number of 
trials included, moderator analyses were conducted as planned.   Effect sizes and 
moderator analyses identified a priori are displayed first in Table 4, followed by other 
moderator analyses using analog to ANOVA, and then meta-regressions.  No variables 
hypothesized a priori as moderators were found to be significant (i.e. effect size 
measure, differential retention, intervention time span, and comparison group).   
 Two variables tested post-hoc were statistically significant at the p<.05 level in 
analog to ANOVA tests.  Peer-led interventions were found to be more effective than 
non Peer-Led interventions (OR=0.676, 95% CI [0.569, 0.803], Q(1)=9.148, p=.002), 
Larger effect sizes were found for community-level interventions [OR=0.631, 95% CI 
[0.492, 0.808], Q(2)=6.879, p=.032), than individual or group-level interventions.  
Post-hoc meta-regressions of continuous variables revealed four statistically 
significant moderators (p<.05).  The overall effect size decreased with year of 
publication (QR=5.80(1), B=.012, 95% CI [0.002, 0.022], p=.016), (Figure 7) 
supporting previous results from cumulative meta-analyses that showed declines in 
effect size over time.  Effect sizes were larger when trials had a higher proportion of 
MSM under 30 or younger MSM (QR=16.02(1), B=.034, 95% CI [0.015, 0.055],  
p<.001), (Figure 8) and when trials had lower representation of MSM with a high 
school education or less (QR=4.49(1), B=.005, 95% CI [0.006, 0.009], p=.023) (Figure 
9).  Of trials that did not exclude HIV-positive persons, effect sizes were smaller 
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among trials with more HIV-positive participants (QR=5.50(1), B=.005, 95% CI 
[0.001, 0.008], p=.019) (Figure 10).  HIV-status was further analyzed by creating a 
dichotomous variable to indicate when trials had more than 20 percent HIV-positive 
participants.  Based on this analysis, trials with less HIV-positive participants were 
observed to have larger effects (OR=.809, 95% CI [0.726, 0.902], Q(1)=4.58, p=.032).  
Finally, 11 trials excluded HIV-positive participants in their eligibility criteria.  In 
subgroup analyses, trials that excluded HIV-positive MSM had larger effects 
(OR=.765, 95% CI [0.640, 0.916], Q(2)=9.742, p=.008).    
  ANOVA analog also indicated trend level (p <.10) differences between 
Evidence-Level [Q=6.869(3), p=.076].  Trials classified as highest-level evidence, 
Evidence-Based Interventions (EBI), showed larger effect sizes (OR=.776, 95% CI 
[0.682, 0.883]) than lower levels of evidence.  Trials focusing on specific MSM 
subpopulations suggested varying effects based on subpopulation [Q=6.271(3), 
p=.099).  Trials focused on young MSM (OR=.616, 95% CI [0.418, 0.907]) and trials 
with no specific population (OR=.825, 95% CI [0.793, 0.913]) appeared to be more 
effective than trials focusing on substance users or MSM of color.  Finally, trials with 
<80 percent overall retention appeared to be slightly more effective than trials with 
higher retention (OR=.775, 95% CI [0.667, 0.901], Q(1)=2.809, p=.094).    
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Table 4 
Moderator Analyses 
Variable K OR SE 
95% CI 
P 
LCL UCL 
Mean Effect Size  
 
 
    
Fixed 34 0.865 0.026 0.815 0.919 .<001 
Random 34 0.859 0.036 0.790 0.933 <.001 
Homogeneity Q [33] = 39.350,  p =.207    
Comparison 
Condition* 
      
HIV-related 17 0.857 0.012 0.787 0.932 .666 
Non HIV-related 7 0.947 0.068 0.728 1.232  
Wait-list 10 0.813 0.052 0.661 0.998  
Effect Measure*       
Count-level 16 0.859 0.028 0.742 0.993 .835 
Dichotomous 18 0.842 0.051 0.167 0.369  
Retention Better*       
Control 10 0.857 0.017 0.794 0.926 .861 
Equal  24 0.846 0.114 0.745 0.961  
Time Span*        
≤1 month 20 0.847 0.022 0.754 0.952 .792 
>1 month 14 0.868 0.022 0.758 0.993  
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Table 4 
Moderator Analyses 
Variable K OR SE 
95% CI 
P 
LCL UCL 
 
Pre or Post ART 
Pre 11 0.866 0.004 0.812 0.968 .273 
Post 23 0.792 0.022 0.661 0.949  
MSM Subpopulation       
Young MSM 4 0.616 0.133 0.418 0.907 .099 
MSM of color 9 0.881 0.718 0.742 1.056  
Substance Users 6 0.996 0.842 0.842 1.179  
None 15 0.825 0.729 0.793 0.913  
Region       
Northeast 7 0.887 0.056 0.703 1.118 .523 
West 13 0.859 0.039 0.729 1.013  
South 4 0.749 0.041 0.605 0.927  
Midwest 2 0.577 0.208 0.340 0.979  
National 4 0.809 0.118 0.560 1.170  
Multi-site 4 0.924 0.037 0.751 1.137  
Intervention Level       
Individual 14 0.872 0.019 0.795 0.981 .032 
Group 17 0.909 0.023 0.806 1.025  
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Table 4 
Moderator Analyses 
Variable K OR SE 
95% CI 
P 
LCL UCL 
Community 3 0.631 0.053 0.492 0.808  
Multiple Outcomes       
Yes 9 0.915 0.030 0.785 1.066 .372 
No 25 0.842 0.017 0.760 0.933  
Significant Result       
Yes 21 0.826 0.016 0.744 0.916 .217 
No 13 0.921 0.026   0.801 1.059  
≥80% Retention       
      Yes 19 0.898 0.013 0.826 0.975 .094 
No 15 0.775 0.032 0.667 0.901  
Follow-Up 
Assessment 
      
≤3 Months 11 0.841 0.038 0.709 0.998 .796 
>3 Months 23 0.864 0.015 0.782 0.955  
Peer Delivery       
Yes 7 0.676 0.033 0.569 0.803 .002 
No 27 0.901 0.012 0.840 0.968  
Sexual 
Communication 
      
Yes 23 0.838 0.013 0.764 0.919 .228 
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Table 4 
Moderator Analyses 
Variable K OR SE 
95% CI 
P 
LCL UCL 
No 11 0.954 0.047 0.789 1.154  
Skills Building       
Yes 18 0.876 0.011 0.819 0.937 .433 
No 16 0.813 0.043 0.684 0.967  
Individual Plans      .118 
Yes 27 0.829 0.017 0.749 0.917  
No 7 0.965 0.030 0.821 1.133  
Stigma      .997 
Yes 13 0.854 0.019 0.791 0.922  
No 21 0.854 0.025 0.754 0.967  
Technology      .704 
Yes 8 0.826 0.048 0.673 1.014  
No 26 0.863 0.015 0.785 0.949  
Evidence Level      .076 
EBI 11 0.776 0.020 0.682 0.883  
Positive 10 0.839 0.041 0.846 1.368  
Rigorous 7 0.952 0.040 0.700 1.007  
Other 6 1.076 0.064 0.784 1.157  
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Variable K QR B SE 
B 95% CI 
P 
LCL UCL 
Study Year 34 5.08 0.012 0.005 0.002 0.022 .016 
Demographics        
Age 34 16.02  0.034 0.010 0.015 0.055 <.001 
%  Black 29 0.03 -0.000 0.001 -0.003 0.003 .864 
% White 29 0.03 -0.000 0.001 -0.003 0.002 .854 
% Latino 29 0.75 0.002 0.002 -0.002 0.005 .387 
% Gay or 
Bisexual 
20 0.93 0.008 0.009 -0.009 0.025 .335 
% HIV-positive 23 5.50 0.005 0.002 0.001 0.008 .019 
% High school 
or less 
25 4.49 0.005 0.002 0.006 0.009 .034 
Number of 
Sessions 
20 0.01 0.001 0.010 -0.018 0.021 .910 
Number of Hours 18 0.01 0.001 0.007 -0.013 0.014 .934 
*=moderators hypothesized a priori 
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Figure 7  
Scatter Plot of Log Odds Ratio by Year Published 
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Figure 8 
Scatter Plot of Log Odds Ratio by Age 
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Figure 9 
Scatter Plot of Log Odds Ratio by Education Level 
 
 
Regression of Log odds ratio on Education Level (% High School or Less)
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Figure 10 
Scatter Plot of Log Odds Ratio by HIV Status 
Regression of Log odds ratio on HIV Status (% HIV-Positive)
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CHAPTER 5: DISCUSSION 
Summary of Findings 
 This study evaluated effects of 34 randomized controlled trials of HIV 
behavioral interventions for 17,872 MSM conducted between 1989 and 2014.  
Overall, behavioral interventions reduced the odds of sexual risk behavior by 14 
percent (OR=.859, 95% CI [0.790, 0.933], p<.001).  These findings show that 
behavioral interventions are still somewhat effective to prevent HIV transmission 
among MSM.  However, the updated effect size was considerably smaller than the 
magnitude of effects observed in earlier meta-analyses. 
This study also examined effect size moderators, integrated interventions, and 
cumulative effect sizes over time.  Intervention effects were highly statistically 
homogenous, and all moderators hypothesized a priori were insignificant.  Post-hoc 
analyses found eight variables (subpopulation, retention, peer delivery, evidence-level, 
intervention-level, age, HIV status, education) to be statistically related to 
effectiveness, but findings need to be interpreted with caution due to their exploratory 
nature.  Qualitative review identified nine trials as integrated interventions; six trials 
included a primary outcome related to substance use and three included outcomes 
related to HIV testing.  Consistent with study hypotheses, most of these trials were 
conducted after the last review in 2007. 
Most notably, this study revealed an unexpected finding related to the 
cumulative effect size over time.  Cumulative meta-analysis revealed that intervention 
effects gradually weakened over time.  From 1991 to 2014, the magnitude of the effect 
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size decreased by 19.5 percent (OR=.719-.859).   Follow-up meta-regression analysis 
using publication year as a moderator variable added statistical evidence for effect size 
shrinkage over time.  Reasons for effect size decline were not able to be explained due 
to statistical homogeneity.  However, several factors such as HIV prevention fatigue, 
inclusion criteria, comparison condition, and underpowered trials may contribute to 
effect size shrinkage. 
Overall Meta-Analysis and Effect Size 
This meta-analysis provides updated evidence that HIV behavioral 
interventions still show significant overall effects to reduce sexual risk behavior 
among US MSM.  However, the current evidence is weaker than hypothesized.  
Findings support current thinking that behavioral interventions are necessary, but no 
longer sufficient for HIV prevention (Coates, 2013).  To our knowledge, this meta-
analysis is the most recent quantitative synthesis of behavioral interventions designed 
for US MSM, and includes trials conducted up to the end of calendar year 2014.  
Multiple tests were conducted to support the validity of its overall finding.  
Publication bias analyses indicated little to no publication bias, and small study effects 
were not shown to inject bias when effect sizes were plotted by precision.  Iterative 
sensitivity analyses did not reveal any significant outliers.  These results combined 
with previous meta-analyses provide good support for the continued funding of 
behavioral intervention trials, especially when implemented as part of combination 
prevention agendas. 
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 The observed 14 percent decrease in sexual risk behavior is modest, and 
considerably smaller than the last meta-analysis.  While a 14 percent decrease may 
still confer some protection on an individual level, significant changes in HIV 
epidemics require larger effect sizes maintained over time, and among more people 
(Coates et al., 2008).  More successful interventions have decreased the odds of risk 
behavior by about 25 percent (Johnson et al., 2002).  Even if HIV behavioral 
interventions were to demonstrate greater reductions in risk behavior, it is unlikely that 
they can avert large numbers of infections (IOM, 2001).    
This study hypothesized that the updated effect size would be comparable to 
previous meta-analyses, despite variations in study protocols.  Previous meta-analyses 
found behavioral interventions to decrease sexual risk behavior by about twice as 
much (Herbst, et al., 2005; Johnson et al., 2002a; Johnson et al 2005; Johnson et al., 
2008).  In the last meta-analysis, Johnson (2008) found interventions to decrease UAI 
by 27 percent when compared to non-HIV related controls, and by 17 percent when 
compared with HIV-related controls.   While it is possible that this study’s scope was 
too different to merit meaningful comparisons to other meta-analyses, it is clear that 
effects have changed over time.   Observed effect size shrinkage warrants additional 
research including replication studies to examine if earlier trials (especially pre-ART) 
are no longer comparably effective among current MSM populations (Higa et al., 
2013).    
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Gradual Effect Size Shrinkage  
 Contrary to the hypothesis, this study found that the effect size was only about 
half as large as expected.  Further, cumulative meta-analysis showed that the effect 
size gradually weakened over time, and has slowly moved closer to the null value of 1.  
Visual results were supported by meta-regression results that revealed a linear 
relationship between publication year and effect size; the overall effect size declined 
with each new publication year (Figure 7).  Reasons for effect size decline are not 
known, but may be related to multiple factors including MSM subpopulation, HIV 
prevention fatigue, comparison condition, and underpowered trials.   
Cumulative meta-analysis (CMA) was used to accomplish the study objective 
of displaying effect sizes over time.  CMA addresses the impact of each new trial on 
prior pooled results and assesses how robust meta-analytic results remain over time 
(Trikalinos et al., 2004; Ioannidis, Contopoulous-Ioannidis & Lau, 1999).  A 
systematic review of over 1,500 CMAs conducted on healthcare interventions 
discovered three main patterns of effect size change: early positive results became null 
or negative over time; null or negative results became positive over time; or results 
stabilized, but intervention research continued (Clarke, Brice, & Chalmers, 2014).   
Studies demonstrating effect size shrinkage over time with CMA are not 
uncommon, and CMA may be particularly important in fields where small trials 
dominate the RCT literature (Bollen, Utterwaal, & Vaught, 2003; Hanson & Broom, 
2005; Klein, Jacobs, & Reinecke, 2007; Zhang et al., 2010; Trikalinos et al., 2004).  
Trikalonas et al. conducted a review of 100 meta-analyses of mental health 
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randomized trials (N=99,303) to test how effect sizes changed over time.  The authors 
calculated the size and direction of the relative change in the cumulative effect size at 
each calendar year.  Relative changes were calculated by the formula: ORsubsequent 
step/ORcurrent step.  Relative changes over 1 indicated shift favoring the comparison over 
intervention group.   They found that the magnitude of the effect size shifted 
considerably from early positive results to null results, raising questions about how 
effect size shrinkage in the mental health field may impact declining clinical 
importance. 
In this study, the most noticeable shift in effect size occurred with the inclusion 
of EXPLORE in 2004 when the cumulative ES shifts from .720 to .777.  Using 
Trikalinos’s calculations, this shift equates to a relative change over 1 and a shift 
unfavorable to the intervention group (Trikalonas et al., 2004).  After 2005, the effect 
size clearly stabilizes, showing gradual effect size shrinkage over time.  The impact of 
EXPLORE’s weight is the most likely explanation for the overall effect size shift;      
EXPLORE is the largest behavioral trial to date (N=4,295, OR=0.86) and accounts for 
the largest relative weight in this study (18.2).  Generally, HIV prevention research is 
dominated by smaller studies.  Median sample size for this study was 328 and only 
two trials in this study had samples over 1,000 participants.  In addition to its 
unusually large sample size, EXPLORE was also the only trial with a z-score >3.0.  
Since sensitivity analyses did not show that EXPLORE exerted influence on the 
overall effect size, it was included in the meta-analysis.  While the weight of 
EXPLORE may have contributed to some effect size shift, there are likely other 
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important reasons that contribute more to effect size decline.  In many cases of CMA, 
there are limited data to fully understand effect size shift over time (Iaonnidis et al., 
1999).  
  To our knowledge, CMA has not been conducted to assess the robustness of 
effect sizes for HIV behavioral interventions over time. Effect size shrinkage may 
reflect contextual or temporal factors that influence intervention effectiveness (e.g., 
HIV prevention fatigue or reduced fear of HIV post-ART), trends in experimental 
design (e.g. MSM subpopulation, choice of comparison group), or underpowered 
trials.   Potential limitations of current behavioral interventions have been cited in 
other studies and argue that behavioral interventions, when implemented alone, are 
outdated (Higa et al., 2013; Wolfeiler & Ellen, 2007; Kippax, 2007; Ross & Wight, 
2007; Coates et al., 2008; Coates, 2013; Sullivan et al., 2012).  This study aimed to 
identify the most effective components of behavioral interventions to inform next-
generation combination approaches.  Due to statistical limitations related to 
homogeneity, this study used qualitative review to examine potential limitations of 
interventions. 
Effect of Underpowered Trials 
A priori power analysis was not performed for this meta-analysis, and 
investigation of post-hoc power was not a study objective.  Additionally, assessing 
post-hoc power for the primary studies was out of scope for this review, but is a 
relevant question for future reviews.  Meta-analyses will often have higher power than 
the primary studies due how to precision changes in a meta-analysis (Borenstein et al., 
  84 
2009).   Trialists across various fields are encouraged to conduct a priori power 
analyses to ensure at least 80 percent power to detect an effect.  However, many trials 
do not report a priori power analysis for sample specification, or do not achieve 80 
percent power upon post-hoc analysis (Borenstein et al., 2009).  Underpowered trials 
are a particular problem for intervention research using small samples.  Reviews of the 
psychological literature have demonstrated improved overall power in trials over time, 
but trials examining small effects remain persistently underpowered (Rossi, 1990; 
Maddock & Rossi, 2001).  
 A recent review of 14,866 meta-analyses in 1,991 Cochrane reviews 
calculated power per study in each meta-analysis and found that 70 percent of 
Cochrane meta-analyses were underpowered (Turner, Bird, & Higgins, 2013).  Of the 
34 trials reviewed in this study, less than one third of trial manuscripts (k=10) reported 
an a priori power analysis at 80 percent for primary outcomes.  Lack of reporting of 
power analysis does not necessarily imply that one was not performed or that power 
was low, but highlights the need for more transparent reporting in RCTs.  Many 
studies did not specify the primary outcome, and results extracted for meta-analysis 
may have been for a secondary outcome that was not adequately powered, and thus 
not appropriate for meta-analysis (Turner et al., 2013).     
Finally, CDC efficacy criteria specify a minimum threshold of 40 subjects per 
intervention and comparison arm (CDC, 2014c) to be classified as an evidence-based 
intervention.   Most trials in this study met this criterion, and only four did not.  
Further review of RCTs for evidence-based behavioral interventions may benefit from 
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post-hoc analyses similar to Turner et al., 2013 and Rossi (1990) to determine if a 
general guideline of 40 participants per arm adequately assesses power for the primary 
study outcome.     
Post-ART and HIV Prevention Fatigue 
 This study found that most trials (k=23) were conducted after the introduction 
of antiretroviral therapy (HIV medications) in 1996 (post-ART).  Eleven trials were 
conducted pre-ART.  Trials conducted later in time are more likely to face contextual 
challenges related to HIV prevention fatigue or ART-optimism.  ART-optimism is 
when high-risk individuals become less concerned about HIV infection because of the 
disruptive success of ART; HIV prevention fatigue describes the attitude that HIV 
prevention has become tiresome and leads to fatigue in maintaining safer sex 
behaviors over time (Ostrow et al., 2002; Stockman et al., 2004).   
Distribution of pre- and post-ART trials in this study are different than in 
Johnson’s 2008 review.   This is mostly due to more MSM-specific trials conducted 
after 1996 (82 percent), and a high number conducted 2010 or later (44 percent).  
Johnson’s review protocol resulted in trials being about equally distributed between 
pre- and post-ART years (24 and 23 respectively).  While neither meta-analysis found 
pre- or post-ART to be a significant moderator of effect, early pre-ART interventions 
were associated with the most successful examples of behavior change resulting in 
dramatic decreases in HIV incidence (Coates et al., 2008; Wohlfeiler & Ellen, 2007).  
Within 10 years, this effect has decreased (Wohlfeiler & Ellen 2007).  It is not known 
if pre-ART trials, or even trials older than 5-10 years, would be effective among 
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current MSM.  This observation raises important questions about the need for 
replication studies of all trials deemed to be evidence-based, especially when these 
trials used small samples, but continue to be recommended in public health practice.       
Inclusion Criteria or MSM Subpopulation 
 Higa (2013) suggested that HIV prevention research is more now challenging 
than previously due to an increased focus on enrolling the highest risk MSM for 
behavioral interventions.  Current recommendations suggest targeting MSM at the 
highest risk of HIV acquisition and transmission.  As many other MSM of lower risk 
have benefited from behavioral interventions, the remaining at-risk MSM subgroups 
continue to challenge the limits of current interventions due to complex risk factors 
not easily addressed by short-term interventions.  Priority MSM subgroups include 
substance using MSM, black and Latino MSM, young MSM, HIV-positive MSM, and 
sexually high-risk MSM.  All priority MSM subgroups experience “syndemics.”  
Syndemics are defined by “a set of enmeshed and mutually enhancing health problems 
that working together in a context of deleterious social and physical conditions  
increase vulnerability, significantly affect the overall disease status of a population” 
(Singer, 2010).  Current behavioral interventions generally cannot address structural or 
other risk factors that contribute to syndemics such as poverty, stigma and 
discrimination, health care access, and mental health.  These unaddressed risk factors 
contribute to ongoing sexual risk, and interventions demonstrated to be effective in the 
research setting are unlikely to produce sustained effects due to social or economic 
inequities that persist beyond the intervention period. 
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Comparison Condition 
Johnson (2008) found interventions to decrease unprotected anal intercourse by 
27 percent when compared to non-HIV related controls, and by 17 percent when 
compared with HIV-related controls.  This study found that effect size did not 
statistically differ by control condition.  Interventions using non-HIV related controls 
decreased UAI by six percent, interventions using HIV-related controls decreased UAI 
by 14 percent, and interventions using wait list controls decreased UAI by 19 percent. 
Most trials used an HIV-related control (k=17) or a wait-list control (k=10), and only 
seven trials used non-HIV related control.    In Johnson’s review, 65 percent of trials 
used non-HIV related controls.  This discrepancy suggests that more recent trials 
designed exclusively for MSM are more likely to choose an HIV-related control.  This 
observation is supported by Higa et al., (2013) who found that wait-list controls 
decreased over time, and demand controls using an HIV-related comparison increased.   
While there are certain advantages to using a wait-list or non-HIV related 
controls for rigorous evaluation (Menza et al., 2010), others argue that use of wait-list 
or non-HIV related attention controls is unethical because it withholds potentially 
effective treatment conditions from high-risk individuals (Higa et al., 2013).  
However, use of better control conditions that essentially use a diluted version of the 
intervention may greatly reduce the trial’s ability to detect effects (Crepaz et al., 2015; 
Higa et al., 2013).  This study found that 21 trials did not find significant results 
between groups; however many of these trials did report statistically significant risk 
reduction changes in both intervention and comparison groups.  While this may be 
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attributed to assessment bias, it is also possible that the value of exposure to minimal 
or standard HIV-related intervention may be underestimated due to the lack of finding 
a “significant positive effect” between groups.  HIV prevention research may benefit 
from a standardized comparison condition to compare intervention effects across trials 
(Crepaz et al., 2015; Higa et al., 2013), as well as further examination into control 
group effects. 
Integrated Interventions  
Only nine trials were classified as “integrated interventions.”  Integrated 
interventions were defined as interventions that simultaneously address multiple 
problem behaviors that share a root cause (e.g. substance use, mental health, 
homelessness, stigma) (Crepaz et al., 2015).  This study found that integrated 
interventions were more common among trials designed for substance users (k=6); 
these trials included at least one outcome (other than sexual risk reduction) directly 
related to reducing substance use (Harawa et al., 2012; Menza et al., 2010; Parsons et 
al., 2014; Picciano et al., 2001; Picciano et al., 2007; Shoptaw et al., 2005).  The other 
three integrated interventions included additional outcomes related to the receipt of 
HIV tests at follow-up (Hirshfield et al., 2012; Odonnell et al., 2014; Wilton et al., 
2009).  Of trials with HIV testing outcomes, two were designed for black or Latino 
MSM.  Consistent with the study hypothesis, most integrated interventions (k=6) were 
conducted after the last review in 2007 and suggests an increased use of these 
approaches for MSM.  
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Integrated interventions are an emerging research priority in the development 
of combination prevention approaches for high-risk groups.  In 2015, CDC published 
a systematic review and meta-analysis that showed positive effects of integrated 
interventions for people living with HIV (Crepaz et al., 2015).  Their review found 
that integrated interventions were effective in reducing sex without condoms, and 
showed promise for increasing adherence to HIV medications.  At the 2015 National 
HIV Prevention Conference, CDC announced that at least two EBIs for MSM had 
been adapted to an integrated intervention approach (Collins, 2015).  For example, 
Many Men, Many Voices (3MV) integrated a new component specific to pre-exposure 
prophylaxis (PrEP) for black MSM, and Popular Opinion Leader has integrated 
multiple outcomes related to HIV care as well as PrEP initiation and adherence.  
However, trial results from these adaptations have not been shared or published. 
To our knowledge, there is no systematic review or research synthesis 
describing the effects of integrated interventions among high-risk HIV-negative MSM.  
This study aimed to understand research trends in using this approach, and 
hypothesized that more integrated interventions would be available for review than in 
the past review (pre-2008).   This study also examined integrated interventions as a 
moderator variable and found that integrated interventions were not a significant 
moderator of effect (p>.05).   However, five of nine trials reported statistically 
significant effects on at least one sexual risk behavior outcome (Harawa et al., 2012; 
Hirshfield et al., 2012; Odonnell et al., 2014; Parsons et al., 2014; Wilton et al., 2009), 
and four of the nine integrated interventions were also classified as EBIs (Harawa et 
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al., 2012; Odonnell et al, 2014; Parsons et al., 2014; Wilton et al., 2009).  
Demonstration of positive effects among hard-to-reach MSM subpopulations such as 
substance users and MSM shows promise for using integrated interventions in 
combination prevention approaches, but further research beyond this review is needed.    
While this study can offer some descriptive information from its narrative 
review, further research synthesis including data from recent EBI adaptations are 
required to determine if integrated interventions are effective in reducing sexual risk 
behavior among high-risk MSM.  As stated previously, most integrated interventions 
were conducted after 2008 and this area of research is relatively young.  Integrated 
interventions have intuitive appeal due to their logical approach in addressing 
syndemic factors of HIV risk (Parsons, Grov, & Golub, 2012; Starks, Miller, 
Eggleston, & Parsons, 2014).   Integrated interventions may also have implementation 
benefits since they would likely require fewer intervention sessions than single-target 
interventions that address one behavior at a time (Crepaz et al., 2015).  However, it is 
not yet known if integrated interventions are more effective than single-target 
interventions, and if there would be negative effects related to scaling up integrated 
interventions.  Single-target interventions provide clear evidence about what works 
when changing one behavior at a time, and it is not clear if integrated interventions 
may dilute any single outcome (Crepaz et al., 2015).  Updated reviews that examine 
the most recent examples of integrated interventions applied in the field are necessary 
to answer these questions.    
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Moderator Analyses 
Overall, trials seemed to have considerable clinical heterogeneity due to their 
diverse intervention components, control conditions, and design variables.  However, 
an insignificant Q statistic combined with an I2 value less than 25 percent suggested 
very little statistical heterogeneity.  Heterogeneity this low was not expected, but 
homogeneity was also observed in the previous meta-analysis (Johnson et al., 2008). 
Lack of observed heterogeneity was disappointing, and restricted this study’s overall 
goal to identify factors statistically associated with intervention effectiveness.  Lack of 
heterogeneity generally indicates that moderator analyses are not warranted, unless 
they are hypothesized a priori.  However, typical measures of heterogeneity have 
some level of uncertainty, or in other words, “lack of evidence of heterogeneity is not 
evidence for homogeneity” (Borenstein, Higgins, Rothstein, & Hedges, 2015; 
Ioannidis, Patsopoulous, & Evangelou, 2007).  Following Johnson et al (2008)’s 
example, this study pursued post-hoc analyses despite statistically homogeneous 
effects.  While results need to be interpreted with caution due to potentially spurious 
findings, these data can inform hypotheses for future reviews.    
 This study used subgroup analyses and meta-regressions to explore 
independent variables previously examined by CDC’s Prevention Research Synthesis 
reviews.  Twenty-two analyses were conducted in total, and four independent 
variables were specified a priori.  A priori moderators included comparison condition, 
retention, time span, and outcome measure.  All hypothesized moderators were 
insignificant at the p<.05 level (p-values ranged from p=.67 to p=.86).  This finding 
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was surprising.  Eighteen other variables were examined post-hoc.  Five were 
significant at the p<.05 level (e.g. age, HIV status, education, peer-led, and 
intervention-level) and three were significant at the trend level of p<.10 level (e.g. 
evidence-level, subpopulation, and retention).  All independent variables found to be 
significant are supported by context and previous research, and thus warrant further 
examination in future meta-analyses.  Moderators are presented in order of relevance 
to the study’s scope. 
Evidence Level 
Trials classified as evidence-based interventions (EBIs) as opposed to 
Rigorous Non-EBIs, Positive Non-EBIs, and Other Non-EBIs were shown to be most 
effective at the trend level (OR=.776, p=.076).  Currently, there are 20 EBIs listed for 
MSM out of 93 other EBIs in CDC’s Compendium for Evidence-Based Interventions 
(CDC, 2014b).  Eleven are for HIV-negative MSM, and nine are for HIV-positive 
MSM.  All 11 EBIs for HIV-negative MSM were included in this review and coded as 
EBIs.  Ten trials were classified as Positive-Non EBIs (i.e. significant finding, but did 
not meet criteria for methodological quality), seven trials were classified as Rigorous-
Non EBIs (i.e. met methodological criteria, but did not find a significant result), and 
six trials were classified as Other Non-EBIs.   
Consistent with findings from Higa et al. (2013), all Rigorous Non-EBIs were 
conducted post-ART, suggesting improved methodological quality over time.  When 
Rigorous Non-EBIs were compared to EBIs, they were more likely to include higher-
risk MSM with multiple vulnerabilities (e.g., substance users and low education).  
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Trials enrolling populations with higher baseline risk, and more barriers to behavior 
change have greater challenges to demonstrating efficacy compared to trials enrolling 
more compliant MSM of low to moderate risk.   
Of the 10 trials classified as Positive Non-EBIs, the most frequent reasons for 
not achieving EBI or Rigorous classification were: having analytic samples under 40 
participants per condition (k=2), having only one immediate follow-up session in both 
comparison groups (k=3), having less than 60 percent retention in either comparison 
(k=2), or having other methodological fatal flaws (k=3) such as contradictory findings, 
considerable missing data, or reassignment of participants.  Interestingly, five out of 
seven interventions using technology (i.e. internet, telephone) were classified as 
Positive Non-EBIs.  Technology-based interventions struggle with high loss to follow 
up rates, and most did not meet EBI criteria for retention.  Other Non-EBIs did not 
find a positive effect and they did not meet criteria for methodological quality.  
Similar to positive non-EBIs, methodological limitations included analytic samples 
with less than 40 participants per condition (k=2), only one immediate follow-up 
session (k=2), or having other fatal flaws (k=2).    
Age 
 Trials with higher proportions of younger participants were associated with 
greater intervention effects (p<.001).   Mean age of all trials was 33.3 (SD=5.4).  
Scatter plot of meta-regression result showed that intervention effects declined with 
increasing mean age (Figure 8).  The effect of age was supported by a separate 
subpopulation moderator analysis that examined trials designed for high-risk groups, 
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including young MSM.  Young MSM were defined as MSM under 30 years of age.  
Trend-level results were found for the overall group comparison (p=.09), and post-hoc 
analyses revealed that interventions for young MSM (OR=.616) were associated with 
larger effects than all other subgroups.   
While these findings are hopeful for future trials targeting young MSM, these 
findings highlight an important HIV prevention research gap.  Only four trials were 
designed for young MSM.   In the US, HIV infections have increased most among 
young MSM aged 13-24.  Further, young black MSM account for more new HIV 
infections than any other age or race group, and it is estimated that at least 50 percent 
of young black MSM will be HIV-positive by the time they turn 35 (CDC, 2014a; 
Stall et al., 2009).  These results show that younger MSM are willing to participate in 
behavioral interventions, and can be effectively recruited for HIV prevention research.  
Younger MSM who have had less exposure to behavioral interventions may be more 
amenable to sexual risk behavior change than older MSM who experience “HIV 
prevention fatigue” (Sullivan et al., 2012).  However, there may be other challenges 
associated with enrolling young MSM.  Trials for younger MSM had smaller sample 
sizes than the median sample size (range: 39-113) and retention was lower among this 
group compared to other MSM.  Only one of four trials for young MSM achieved an 
overall retention rate ≥80 percent; the three other trials had retention rates between 56 
percent and 79 percent.   
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Subpopulation 
 A four-level independent variable was created to examine the amount of 
research allocated to high-risk MSM subpopulations, and then to examine if effects 
varied by subpopulation.  Subpopulations included young MSM, substance users, 
MSM of color, and none.  As stated previously, overall results indicated trend-level 
significance (p=.09). Interventions designed for substance users (k=6) or MSM of 
color (k=9) were less effective than interventions for young MSM (k=4) or none 
(k=15). 
 Over the past ten years, there has been an increase in interventions designed 
specifically for black and Latino MSM in an effort to align research with the current 
epidemic.  Despite an increased research focus, there are few evidence-based 
interventions for MSM of color.  To date, there are only four EBIs for MSM of color 
in CDC’s Compendium; two are for black MSM, one is for Latino MSM, and one is 
for Asian/Pacific Islander MSM.  As the epidemic shifts to become increasingly 
concentrated among Black and Latino MSM, well-funded research agendas will be 
essential to develop and test behavioral interventions that work for MSM of color.  
Future research in this area should aim to develop interventions guided by a 
comprehensive approach to address the social, cultural, and structural factors (i.e. 
economic or social inequities) that may influence effectiveness (Sullivan et al., 2012), 
as well as factors related to research participation (Hatfield et al., 2010). 
 Trials focusing on substance-using MSM (SUMSM) have also increased in the 
past decade, yet there is only one EBI for SUMSM and it was added in 2015 (Parsons 
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et al., 2014).  Substance use is well-known to be an important driver of HIV infection 
among MSM (Coates et al., 2008; Sullivan et al., 2012).  This study found that 
interventions were less effective among substance-users than any other groups.  
Failure to find significant effects highlights the persistent HIV prevention research 
challenge of recruiting, retaining, and demonstrating effects among SUMSM.   
Challenges associated with SUMSM provide a clear example of when 
behavioral interventions are necessary, but not sufficient.  SUMSM are particularly 
difficult to engage due to factors directly associated with active substance use (i.e. 
homelessness, economic insecurity, sex work, psychological issues).  SUMSM 
generally have higher baseline risk and more complex risk situations that make 
demonstrating sexual behavior change an elusive goal for current interventions.  
Behavioral interventions designed for SUMSM may benefit more from focusing on 
directly reducing substance use (e.g. contingency management or personalized 
cognitive counseling) or decreasing sexual behavior during substance use (Higa et al, 
2013; Ostrow & Stall, 2008; Sullivan et al, 2012).  In a combination prevention 
approach, it is likely that very high-risk SUMSM will require resource-intensive, 
individual-level interventions that address syndemic factors (i.e. childhood sexual 
abuse, mental health, homelessness) combined with biomedical interventions of  pre 
and post-exposure prophylaxis (Chesney et al., 2003; Higa et al., 2013).    
Peer-Led Interventions 
 Peer-led interventions were found to be more effective than other interventions 
(OR=.676, p=.002).  This finding is consistent with Higa’s 2013 review of EBIs; they 
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found that six out of nine EBIs were delivered by a peer facilitator.  This study found 
seven out of 11 EBIs for HIV-negative MSM to be peer-led.  Peers may aid in 
recruitment and retention, especially for high-risk or socially marginalized MSM who 
may not otherwise present for HIV prevention services.  Peers may be perceived to be 
more credible and trustworthy than other professional facilitators, and can help 
increase retention by creating environments that feel non-judgmental, safe, and 
comfortable (Higa et al., 2013; Ye et al., 2014).  A meta-analysis (Ye et al., 2014) of 
15 peer-led interventions to reduce UAI among MSM showed that peer-led 
interventions decreased UAI overall, but effects varied by design type with the 
weakest effects being observed from RCTs.  The evidence supporting peer-led 
interventions is very promising, especially for young MSM and MSM of color.  More 
rigorous research is needed to understand factors related to effective peer-led 
interventions, and how peer-led components can best support combination approaches. 
HIV Status 
 Trials were less effective when they had more HIV-positive participants 
(p=.02).  The impact of HIV status was examined in three ways.  First, meta-
regression analysis of trials with any HIV-positive individuals showed that the effect 
size decreased with larger proportions of HIV-positive participants (Figure 10).  
Second, HIV status was dichotomized to indicate if the trial sample consisted of 20 
percent or more HIV-positive MSM.  These results were consistent with meta-
regression; trials with less than 20 percent had stronger effects (p=.032).  Finally, 11 
trials excluded HIV-positive participants in their eligibility criteria.  In subgroup 
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analyses, trials that excluded HIV-positive MSM had larger effects (OR=.765, 
Q(2)=9.742, p=.008).    
Interventions designed for HIV-positive persons are a key component of CDC 
PRS’s new prioritization agenda (CDC, 2015).  Eligibility criteria for this study 
excluded trials designed exclusively for HIV-positive individuals because those trials 
were considered out of scope.  However, most trials in this review allowed some 
proportion of HIV-positive individuals to enroll.  Inclusion of HIV-positive 
participants may obscure the intervention’s effect on HIV-negative MSM and 
contribute to challenges to demonstrate efficacy.   This study’s findings are consistent 
with Higa et al. (2013).  Their review found that EBIs were more likely to exclusively 
focus on HIV-negative MSM.  Currently, nine of 20 EBIs for MSM are recommended 
for HIV-positive MSM, yet not all were designed specifically for MSM.  Previous 
meta-analysis suggests that HIV-positive individuals may benefit more from 
individual-level interventions rather than group-based, as well as interventions 
delivered in a clinical setting where they access other services (Crepaz et al., 2006).  
Similar to SUMSM, HIV-positive MSM represent a risk group where behavioral 
interventions are necessary, but not sufficient.  Combination approaches that address 
medication adherence, biomedical options for sexual partners, and structural factors 
related to syndemics are necessary for HIV-positive MSM at high risk of transmitting 
to partners.   
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Education Level 
 Lower education level was found to be associated with effect size.  
Interventions with higher proportions of MSM with a high school education or less 
were shown to decrease overall effect size in meta-regression analyses (Figure 9) 
(p=.023).  Reasons for this finding are not totally clear, but as stated previously, Higa 
found that trials with high methodological quality, but non-significant findings (i.e., 
“rigorous non-EBIs), were more likely to include MSM with lower education levels, 
as well as more substance users.  Education is highly correlated with socioeconomic 
status and may indicate syndemics such as social or economic inequities (e.g. food 
insecurity, homelessness) that contribute to ongoing risk (van den Berg et al., 2015).  
Intervention Level 
 Community-level interventions (CLIs) were found to be associated with 
greater effects (OR=.631, p=.032).   Community-level interventions are different than 
individual or group-level interventions because they aim to change social norms and 
then measure behavior change at the community-level. CLIs are typically better-
resourced and able to provide longer-term, multi-level interventions.  This study’s 
finding is consistent previous reviews demonstrating stronger effects among CLIs 
(Herbst et al., 2007; Johnson et al., 2008).  It is possible that CLIs may be more 
effective than other interventions.  CLIs may have more potential to address syndemic 
risk, and they may also be able to reach more MSM.  Despite their potential reach, 
CLIs are usually a low dose intervention on a one-on-one level (i.e. brief encounters, 
handing out condoms) and unlikely to sustain individual behavior change.   More 
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research is needed to answer questions.  In this review, there were only three 
community-level trials (Kegeles et al., 2006; Kelly et al., 1991; Kelly et al., 1997), and 
one trial was a replication study (Kelly et al., 1997). 
There was little difference in effect between individual and group-level 
interventions.  In this study, more trials used group-level interventions (k=17) than 
individual-level (k=14).  There is some research that suggests group-level 
interventions may have unintended negative outcomes for higher-risk MSM 
subpopulations because high-risk behaviors can be reinforced by peers met in small-
group interventions (Johnson et al., 2005).  However, evidence describing this effect is 
mixed.  Crepaz (2006) and Herbst (2007) found individual-level interventions to offer 
the most benefit, especially for higher-risk populations requiring more intensive, 
tailored interventions such as substance users and HIV-positive MSM.   Ye (2014) 
found peer-based interventions to only be effective in group-based interventions.   
Retention 
 Trials with <80% retention showed slightly better effects (OR=.775, p=.09) 
than trials with better retention.  Small sample size and poor retention were common 
reasons that trials did not meet criteria for methodological quality.  High quality 
behavioral interventions targeting higher risk MSM such as substance-using MSM are 
likely to experience higher loss to follow up.  Additionally, 50 percent of trials in this 
study reported use of an intention-to-treat (ITT) design; ITT designs are more likely to 
underestimate the effect when attrition is high and may further challenge 
demonstrations of efficacy.  Finally, most trials used follow-up periods of more than 3 
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months (k=23), and 16 trials used follow-up periods of 12 months or more.  However, 
median intervention time span was only three weeks.  Follow-up periods that extend 
well beyond intervention termination are unlikely to demonstrate efficacy, especially 
among MSM subgroups that experience structural-level stressors, substance use, or 
mental health issues. 
Implications  
Despite a smaller than expected effect size, these results indicate that 
behavioral interventions continue to show some benefit for MSM.  It is generally 
accepted that behavioral interventions are too small to decrease HIV incidence, but 
they can effectively reduce sexual risk behaviors over the short-term.  Results from 
this study show that the effect size declined over time, challenging what is known 
about the relevance of behavioral interventions to reduce sexual risk behaviors.  Over 
time, the effect size has gradually decreased and suggests that these interventions may 
soon be outdated if they are not improved.   
To our knowledge, this is the first study that has examined effect size 
shrinkage of HIV behavioral interventions for MSM using cumulative meta-analysis.  
These summary findings lend strong support to arguments that behavioral 
interventions (and behavioral science) need to do better to improve effectiveness in the 
current social and political context.  Further research, and future funding, is required 
to explain the most important reasons for effect size shrinkage, conduct replication 
studies to retire outdated components, and identify the most relevant and promising 
intervention features to use in combination approaches.   
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Qualitative review of presumably high-quality RCTs revealed lower 
methodological quality than expected and highlights limitations of the current 
evidence base.  These findings are consistent with findings from CDC’s Prevention 
Research Synthesis team (Higa et al., 2013).  Despite 25 years of prevention research 
with MSM, there are only 11 out of 93 EBIs in the entire Compendium for HIV-
negative MSM (an additional nine are for HIV-positive MSM) even though MSM are 
the most epidemiologically important risk group.  Higa et al. (2013) described 
methodological challenges to demonstrating efficacy among MSM, but also pointed to 
misaligned funding priorities that result in the underfunding of high-quality research 
for MSM.  Trials published after 2010 were less likely to have reporting biases or fatal 
flaws, and trials published after 2010 make up about half of trials eligible for this 
review.  However, more than half of eligible trials were published prior to 2010 and 
influenced the overall effect size.  In addition to efforts to make interventions work 
better, the research community would benefit from HIV prevention research standards 
that require high methodological quality (e.g., a priori power analyses, minimal 
retention requirements in both arms, criteria for missing data, replication studies, and 
required trial registration), standardized comparison across studies (e.g., similar 
outcome measures, standard control groups), and transparent reporting of results to 
facilitate high-quality research syntheses (e.g., CONSORT requirements; raw means 
and values). 
This review found that trials using “integrated interventions” increased since 
2008.  Results suggest that intervening on and measuring diverse outcomes is feasible 
  103 
and relevant for HIV-negative MSM.   Future primary trials that use integrated 
approaches may be more efficient for HIV prevention because they can target multiple 
behavioral drivers of HIV risk among MSM.  Integrated behavioral interventions used 
in combination with the most relevant biomedical strategies (e.g., interventions that 
decrease substance use and sexual risk behaviors with the additive benefit of PrEP for 
substance-using MSM) have high potential to curb HIV infection among high-risk 
MSM subgroups.  Further research is needed to evaluate the effects of these 
approaches in real-world settings. 
 More research is needed to better understand how to use HIV behavioral 
interventions that support combination prevention approaches.  A primary aim of this 
study was to re-evaluate HIV behavioral interventions in the context of new 
recommendations for combination approaches and identify the most promising factors 
associated with effectiveness.  This was not possible due to unexpected statistical 
homogeneity.  Combination prevention approaches are expected to focus intensive 
efforts on HIV subpopulations most at risk for HIV.  Future research syntheses may 
benefit from narrowing the scope of reviews to focus on only these MSM 
subpopulations, and excluding MSM included in earlier trials that are no longer 
prioritized for HIV prevention interventions (i.e., white, older MSM of low to 
moderate HIV risk). 
 This review found that some priority MSM subpopulations were under-
represented in current HIV research.  Most notably, young MSM comprise the 
majority of new infections among MSM, but only accounted for 12 percent of eligible 
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trials.  Six trials, or only 18 percent, were designed for substance-using MSM; nine 
trials, or 26 percent, were designed for MSM of color; and only one trial was 
specifically designed for MSM who are behaviorally bisexual (also have sex with 
women).   There were no interventions specifically designed for emerging MSM 
subpopulations such as male sex workers or transgender women (who are sometimes 
classified under MSM).  There were no RCTs designed for couple-level interventions. 
These findings highlight important research gaps.  The research base is limited in its 
ability to examine how behavioral interventions would benefit emerging and priority 
subpopulations.  Future primary trials need to prioritize the highest risk MSM.  
Research standards that set minimum risk requirements for inclusion should be 
established to ensure only high-risk MSM are enrolled in prevention trials.   
Limitations 
Findings must be interpreted within the context of this study’s limitations.  
First, this study used a protocol that was very narrow in scope, and findings may not 
be perfectly comparable to other meta-analyses that included HIV-positive MSM, 
adolescent MSM, or MSM outside of the United States.  Variation in study protocols 
and subjective decision-making throughout the research synthesis process can weaken 
the validity of comparisons between reviews and lead to spurious results (Ekkekakis, 
2015).  Future reviews in HIV prevention research should be guided by a standardized 
protocol so that the evidence for behavioral interventions can be regularly updated and 
compared to past reviews.     
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Second, a systematic review and meta-analysis cannot compensate for trials of 
low methodological quality.  Trials published after 2010 showed higher quality than 
earlier trials, most likely resulting from trends in the research field such as the 
CONSORT statement (CONSORT, 2010).  Earlier trials had more methodological 
flaws and higher reporting bias.  Most early trials had some level of missing data or 
did not clearly report outcomes, statistical analyses, basic statistical information to 
calculate effect sizes (e.g., sample sizes by study arm; standard deviations), ITT, 
demographic information,  or study procedures.  This study excluded trials with 
missing data after attempts were made to contact study authors, resulting in a reduced 
set of trials for review.  Additionally, many trials did not report a priori power 
analyses, and it is possible that many primary trials were underpowered.  Future trials 
should aim to improve transparency in reporting to facilitate future evaluations of 
prevention research. 
Third, sexual risk reduction outcomes are assessed through self-report and may 
be vulnerable to social desirability bias or recall bias.  Many trials employed methods 
to reduce reporting bias such as using computer-assisted assessments or validated 
measures such as the Timeline Follow-Back.  However, some trials did not clearly 
report how the outcome was measured or what procedures were used to increase 
confidentiality so as to reduce self-report bias.      
Fourth, this study does not represent all MSM in the US.  Important MSM 
subgroups were under-represented or missing from this review.  For example, there 
were a surprisingly limited number of studies for young MSM or few studies specific 
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to MSM who also have sex with women.  There were no studies specific to male sex 
workers, and very few trials that even reported the prevalence of male sex work.  
Further research on priority subgroups is essential to target behavioral interventions to 
the groups at highest epidemiological risk.   
 Fifth, the independent coder was only able to complete 50 percent of trial 
records.  While there were few discrepancies, and all were able to be resolved through 
consensus, this still suggests threats to validity.  Prior to publication, 100 percent of 
records will need to be reviewed by at least two coders. 
Finally, this study’s largest limitation was its high homogeneity.  Lack of 
heterogeneity restricted this study from accomplishing its main goal of identifying the 
most promising and relevant intervention features of behavioral interventions for next 
generation combination approaches.  While this study can offer an updated effect size 
and estimate of heterogeneity, findings from post-hoc moderator analyses must be 
interpreted with caution.  
Conclusion 
This study found evidence that the overall effect size for MSM-specific HIV 
behavioral interventions is still statistically significant.  However, the magnitude of the 
effect size is considerably smaller than previous reviews, and if this trend continues, 
will slowly approach the null value as new trials are added.  Gradual effect size 
decline over time suggests that behavioral interventions are becoming less effective, 
and must evolve to meaningfully contribute to HIV prevention in the current epidemic.   
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This study did not find evidence to suggest reliable moderators of 
effectiveness.  Several variables were found to be potential moderators of effect, but 
will require additional research due to their post-hoc nature.  Future research would 
benefit from further exploring if behavioral interventions are more effective when they 
are peer-led or when they have higher proportions of younger MSM.   This study 
found promising results for the use of integrated behavioral interventions that address 
more than one problem behavior.  Results suggest that integrated interventions have 
become more common in HIV prevention research, especially for high-risk MSM 
subgroups (i.e. substance-using MSM), although further research is needed to better 
understand how to improve effectiveness. 
In conclusion, behavioral interventions remain necessary for HIV prevention 
among MSM, but are no longer sufficient.  Behavioral interventions do not produce 
substantial effects to reduce HIV incidence among MSM, and effect size shrinkage 
raises questions about their continued ability to effectively reduce sexual risk 
behavior.  Behavioral interventions may perform better when used in the context of 
new combination approaches, yet further research beyond this study is needed.   
To improve behavioral interventions, future research (primary trials and 
systematic evaluations) should focus limited research resources on MSM 
subpopulations at highest risk of acquiring HIV (i.e., substance users, young MSM, 
MSM of color), and aim to identify the most relevant intervention components for the 
current epidemic.  Replication studies of trials previously identified as effective 
interventions are needed to identify intervention components that are outdated and 
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need to be retired.   Frequent, ongoing systematic reviews and meta-analyses are 
required to monitor the effectiveness of new approaches.  Future research syntheses in 
this field should adopt routine cumulative meta-analysis to better monitor changes in 
the effect size as new evidence is accumulated. 
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APPENDIX A 
 
EFFECTS OF HIV BEHAVIORAL INTERVENTIONS FOR MEN WHO HAVE SEX WITH 
MEN - UNITED STATES, 1988-2014 
 
Systematic Review Search Strategy 
 
Inclusion Criteria 
Participants: Adult (<18) US men who have sex with men 
Interventions: Any intervention with at least one behavioral sexual risk reduction component that 
states HIV prevention as a goal 
Comparison: Any control (no treatment, usual care, attention control, another treatment) 
Outcomes: Behavioral and biological outcomes.  
Study design: Randomized controlled trials in which participants were prospectively assigned to study 
groups and in which control group outcomes were measured concurrently with intervention group 
outcomes.   
 
Exclusion Criteria 
Participants: Individuals who live outside the US, adolescents <18, 100% HIV-positive samples 
Study design: Any study without a contemporaneous control group 
 
Filter:  No filters except date (January 1, 1988 – current date) 
 
Search String 1. MSM terms (population filter): MSM, men who have sex with men, gay, homosexual, 
bisexual, transgender 
 
Search String 2. HIV terms (disease filter):  HIV, AIDS, STD (MeSH subheading prevention & control 
when available) 
 
Search String 3. Cochrane published RCT filter (study design filter): (randomized controlled trial [pt] 
OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR 
randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])  
 
Databases 
1. PubMed 
2. EMBASE  
3. CENTRAL 
4. PsycINFO 
5.    CINAHL 
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PUBMED 
Searched 04/26/15 
Limits: Publication Date 1988-2015 
Notes: Export by batch to Endnote (50 at a time); Delete “search” and post-script, filters, sort by, etc. 
when re-running.  Sort by Pub Date.  Export 500 per time to EndNote. 
 
Search Query Items found 
#10 Search ((#1) AND #3) AND #7 1208 
#9 
Search ((#1) AND #3) AND #7 Filters: Publication date from 1988/01/01 to 
2015/12/31 Sort by: PublicationDate 1208 
#8 
Search (((randomized controlled trial [pt] OR controlled clinical trial [pt] OR 
randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly 
[tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans 
[mh]))) 3064779 
#7 
Search (((randomized controlled trial [pt] OR controlled clinical trial [pt] OR 
randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly 
[tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans 
[mh]))) Filters: Publication date from 1988/01/01 to 2015/12/31 Sort by: 
PublicationDate 2554293 
#6 Search (#1) AND #3 4361 
#5 
Search (#1) AND #3 Filters: Publication date from 1988/01/01 to 
2015/12/31 Sort by: PublicationDate 4361 
#4 
Search ((((((((((("HIV Infections/prevention and control"[Mesh] OR 
"Acquired Immunodeficiency Syndrome/prevention and control"[MeSH 
Terms] OR "Sexually Transmitted Diseases/prevention and control"[MeSH 
Terms])))))))) 50184 
#3 
Search ((((((((((("HIV Infections/prevention and control"[Mesh] OR 
"Acquired Immunodeficiency Syndrome/prevention and control"[MeSH 
Terms] OR "Sexually Transmitted Diseases/prevention and control"[MeSH 
Terms])))))))) Filters: Publication date from 1988/01/01 to 2015/12/31 Sort 
by: PublicationDate 46377 
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#2 
Search ((((((((("men"[MeSH Terms] OR "men"[All Fields]) AND who[All 
Fields] AND ("sex"[MeSH Terms] OR "sex"[All Fields]) AND 
("men"[MeSH Terms] OR "men"[All Fields])) OR "msm"[All Fields])) OR 
"men who have sex with men"[All Fields]) OR ("homosexuality, 
male"[MeSH Terms] OR ("homosexuality"[All Fields] AND "male"[All 
Fields]) OR "male homosexuality"[All Fields] OR "gay"[All Fields])) OR 
("bisexuality"[MeSH Terms] OR "bisexuality"[All Fields] OR 
"bisexual"[All Fields])) OR ("homosexuality"[MeSH Terms] OR 
"homosexuality"[All Fields] OR "homosexual"[All Fields])) OR 
("transgendered persons"[MeSH Terms] OR ("transgendered"[All Fields] 
AND "persons"[All Fields]) OR "transgendered persons"[All Fields] OR 
"transgender"[All Fields]))) 61967 
#1 
 Search ((((((((("men"[MeSH Terms] OR "men"[All Fields]) AND who[All 
Fields] AND ("sex"[MeSH Terms] OR "sex"[All Fields]) AND 
("men"[MeSH Terms] OR "men"[All Fields])) OR "msm"[All Fields])) OR 
"men who have sex with men"[All Fields]) OR ("homosexuality, 
male"[MeSH Terms] OR ("homosexuality"[All Fields] AND "male"[All 
Fields]) OR "male homosexuality"[All Fields] OR "gay"[All Fields])) OR 
("bisexuality"[MeSH Terms] OR "bisexuality"[All Fields] OR 
"bisexual"[All Fields])) OR ("homosexuality"[MeSH Terms] OR 
"homosexuality"[All Fields] OR "homosexual"[All Fields])) OR 
("transgendered persons"[MeSH Terms] OR ("transgendered"[All Fields] 
AND "persons"[All Fields]) OR "transgendered persons"[All Fields] OR 
"transgender"[All Fields]))) Filters: Publication date from 1988/01/01 to 
2015/12/31 Sort by: PublicationDate 52369 
 
 
 
 
 
 
 
 
 
 
 
 
  112 
 
EMBASE 
Searched 04/26/15 
Limits: Publication Date 1988-2015 
Notes: Sorts by Pub Year by default; export records to CSV and RIS (EndNote); provides detailed 
queries upon export that specify contents of combined searches (i.e. #1 AND #3; #6 is complete final 
string) 
 
No. Query EMBASE 04/26/15 Results 
#6 
'men who have sex with men'/exp OR 'men who have sex with men' OR 
'homosexual male'/exp OR 'homosexual male' OR 'homosexuality'/exp OR 
'homosexuality' OR 'male homosexuality'/exp OR 'male homosexuality' OR 
'bisexual male'/exp OR 'bisexual male' OR 'bisexuality'/exp OR 'bisexuality' OR 
'transgender'/exp OR 'transgender' OR 'msm' OR 'gay' AND ('sexually transmitted 
diseases'/exp/dm_pc OR 'acquired immunodeficiency syndrome'/exp/dm_pc OR 
'human immunodeficiency virus infection'/exp/dm_pc) AND ('randomized 
controlled trial'/exp OR 'randomized controlled trial' OR 'controlled clinical 
trial'/exp OR 'controlled clinical trial' OR randomized:ti OR randomized:ab OR 
placebo:it OR placebo:ab OR randomly:it OR randomly:ab OR groups:it OR 
groups:ab OR trial:it OR trial:ab OR 'drug therapy'/de OR 'intervention study'/de) 
NOT ('animals'/exp OR animals NOT ('humans'/exp OR humans)) AND (1988:py 
OR 1989:py OR 1990:py OR 1991:py OR 1992:py OR 1993:py OR 1994:py OR 
1995:py OR 1996:py OR 1997:py OR 1998:py OR 1999:py OR 2000:py OR 
2001:py OR 2002:py OR 2003:py OR 2004:py OR 2005:py OR 2006:py OR 
2007:py OR 2008:py OR 2009:py OR 2010:py OR 2011:py OR 2012:py OR 
2013:py OR 2014:py OR 2015:py) 766 
#5 
'men who have sex with men'/exp OR 'men who have sex with men' OR 
'homosexual male'/exp OR 'homosexual male' OR 'homosexuality'/exp OR 
'homosexuality' OR 'male homosexuality'/exp OR 'male homosexuality' OR 
'bisexual male'/exp OR 'bisexual male' OR 'bisexuality'/exp OR 'bisexuality' OR 
'transgender'/exp OR 'transgender' OR 'msm' OR 'gay' AND ('sexually transmitted 
diseases'/exp/dm_pc OR 'acquired immunodeficiency syndrome'/exp/dm_pc OR 
'human immunodeficiency virus infection'/exp/dm_pc) AND ('randomized 
controlled trial'/exp OR 'randomized controlled trial' OR 'controlled clinical 
trial'/exp OR 'controlled clinical trial' OR randomized:ti OR randomized:ab OR 
placebo:it OR placebo:ab OR randomly:it OR randomly:ab OR groups:it OR 
groups:ab OR trial:it OR trial:ab OR 'drug therapy'/de OR 'intervention study'/de) 
NOT ('animals'/exp OR animals NOT ('humans'/exp OR humans)) 773 
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#4 
'randomized controlled trial'/exp OR 'randomized controlled trial' OR 'controlled 
clinical trial'/exp OR 'controlled clinical trial' OR randomized:ti OR 
randomized:ab OR placebo:it OR placebo:ab OR randomly:it OR randomly:ab 
OR groups:it OR groups:ab OR trial:it OR trial:ab OR 'drug therapy'/de OR 
'intervention study'/de NOT ('animals'/exp OR animals NOT ('humans'/exp OR 
humans)) 2734764 
#3 
'men who have sex with men'/exp OR 'men who have sex with men' OR 
'homosexual male'/exp OR 'homosexual male' OR 'homosexuality'/exp OR 
'homosexuality' OR 'male homosexuality'/exp OR 'male homosexuality' OR 
'bisexual male'/exp OR 'bisexual male' OR 'bisexuality'/exp OR 'bisexuality' OR 
'transgender'/exp OR 'transgender' OR 'msm' OR 'gay' AND ('sexually transmitted 
diseases'/exp/dm_pc OR 'acquired immunodeficiency syndrome'/exp/dm_pc OR 
'human immunodeficiency virus infection'/exp/dm_pc) 3648 
#2 
'sexually transmitted diseases'/exp/dm_pc OR 'acquired immunodeficiency 
syndrome'/exp/dm_pc OR 'human immunodeficiency virus infection'/exp/dm_pc 47878 
#1 
'men who have sex with men'/exp OR 'men who have sex with men' OR 
'homosexual male'/exp OR 'homosexual male' OR 'homosexuality'/exp OR 
'homosexuality' OR 'male homosexuality'/exp OR 'male homosexuality' OR 
'bisexual male'/exp OR 'bisexual male' OR 'bisexuality'/exp OR 'bisexuality' OR 
'transgender'/exp OR 'transgender' OR 'msm' OR 'gay' 49275 
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CENTRAL 
Searched 04/26/15 
Limits: Publication Year 1988-2015, Clinical Trials 
Notes: Do not use RCT filter; use MeSH terms when possible; Export to txt file with title and abstract 
 
1 MeSH descriptor: [HIV Infections] explode all trees and with qualifier(s): [Prevention 
& control - PC] 
1944 
2 MeSH descriptor: [Acquired Immunodeficiency Syndrome] explode all trees and with 
qualifier(s): [Prevention & control - PC] 
228 
3 MeSH descriptor: [Sexually Transmitted Diseases] explode all trees and with 
qualifier(s): [Prevention & control - PC] 
2172 
4 #1 or #2 or #3 Publication Year from 1988 to 2015, in Trials 1875 
5 "MEN WHO HAVE SEX WITH MEN" or "MSM"   447 
6 MeSH descriptor: [Homosexuality, Male] explode all trees 233 
7 HOMOSEXUALITY and MALE   373 
8 "MALE HOMOSEXUALITY"   18 
9 MeSH descriptor: [Homosexuality] explode all trees  338 
10 HOMOSEXUALITY or HOMOSEXUAL   543 
11 MeSH descriptor: [Bisexuality] explode all trees  43 
12 BISEXUALITY or BISEXUAL   133 
13 MeSH descriptor: [Transgendered Persons] explode all trees  2 
14 "TRANSGENDERED" and "PERSONS" or "TRANSGENDERED PERSONS" or 
TRANSGENDER   
36 
15 GAY   469 
16 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 Publication Year 
from 1988 to 2015, in Trials  
827 
17 #4 and #16 Publication Year from 1988 to 2015, in Trials  
 
116 
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PSYCINFO 
Searched 04/26/15 
Limits: 1988-2015 
Notes: Unable to use MeSH terms specific to DISEASE prevention & control resulting in a more 
sensitive string with more hits; view all in abstract view, 50 per page, and then save to folder 50 at a 
time.  Export entire folder to EndNote.  Save hyperlink with search string. 
 
S1 "men who have sex with men" OR "msm" OR "homosexual" OR "male 
homosexuality" OR "homosexuality" OR ("homosexual” AND “male") OR "gay" 
OR “gay men” OR (“gay” AND “men”) OR “bisexual” OR ("bisexual” AND 
“men") OR "bisexuality" OR "transgender persons" OR ("transgender" AND 
"persons") OR "transgender" OR (((ZU "homosexuality")) or ((ZU "bisexuality"))) 
or ((ZU "transgender")) 
 
27,805 
S2 (((ZU "hiv")) or ((ZU "aids") or (ZU "aids prevention"))) or ((ZU "sexually 
transmitted diseases")) 
38,015 
S3 ( PT randomized controlled trials OR PT controlled clinical trials OR TI randomized 
OR AB randomized OR TI placebo OR AB placebo OR AB trial OR TI randomly 
OR AB randomly OR TI groups OR AB groups OR TI trial ) OR DE drug therapy 
NOT ( (animals NOT humans)) 
877,947 
S4 #S1 AND #S2 5,794 
S5 #S4 AND #S3 1,803 
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CINAHL 
Searched 04/27/15 
Limits: 1988-2015 
Notes: Unable to use MeSH terms specific to DISEASE prevention & control resulting in a more 
sensitive string with more hits; view all in abstract view, 50 per page, and then save to folder 50 at a 
time.  Export entire folder to EndNote.   Same platform as psycINFO. 
 
 
S1 ( "men who have sex with men" OR "msm" OR "homosexual" OR "male homosexuality" 
OR "homosexuality" OR ("homosexual” AND “male") OR "gay" OR “gay men” OR 
(“gay” AND “men”) OR “bisexual” OR ("bisexual” AND “men") OR "bisexuality" OR 
"transgender persons" OR ("transgender" AND "persons") OR "transgender" ) OR ( (MH 
"Homosexuality+") OR (MH "Homosexuals+") OR (MH "Homosexuals, Male+") ) OR ( 
(MH "Bisexuality+") OR (MH "Bisexuals+ ") ) OR (MH "Transgendered Persons+") 
9,247 
S2 (MH "Human Immunodeficiency Virus+") OR (MH "Acquired Immunodeficiency 
Syndrome/PC") OR (MH "Sexually Transmitted Diseases+/PC") 
19,371 
S3 #S1 AND# S2 1,523 
S4  (MH "Clinical Trials") OR (MH "Community Trials") OR (MH "Randomized Controlled 
Trials") OR (MH "Preventive Trials") OR (MH "Intervention Trials") OR TI randomized 
OR AB randomized OR TI placebo OR AB placebo OR AB trial OR TI randomly OR AB 
randomly OR TI groups OR AB groups OR TI trial OR DE drug therapy NOT ( (animals 
NOT humans))  
292,348 
S5 #S3 AND #S4 245 
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APPENDIX B: STUDY PROTOCOL 
 
Study ID#  
(add report ID# if more than 1 
report from same study) 
Use pre-specified study ID# from coding assignment 
tab (example: 01).  If a study is identified as having 
multiple reports, use a report ID# (Example 01-A; use 
a letter). 
 Date of Review The date you conducted the review (e.g. 08/07/15) 
Coder Initials Your initials (e.g. EL - Elsa Larson) 
Author Last Name Author's last name for reference 
Year  Year of publication 
Key Words 
Provide 3-5 key words that you think are important 
to describe this article (i.e. bisexual men, 
methampethamine-users, internet-based 
intervention, young black MSM, etc). 
Notes (if any) Notes/concerns/questions for this article 
ELIGIBILITY REVIEW.  IF NO TO 
ANY QUESTION=NOT ELIGIBLE.  
STOP REVIEW. 
The following questions are the eligibility criteria for 
the review.  If NO to any question, STOP review.  
Note reason why. 
Is this study published in a 
peer-reviewed journal? 
(yes/no) 
Identify journal name and confirm it uses a peer-
review process 
Was this study specifically 
designed for MSM (y/n) 
Did the authors describe they designed this for MSM, 
and tested it on MSM? 
Are adult US MSM the primary 
study population? (y/n) 
Are U.S. MSM over 18 the primary study population, 
>95%?  MSM may be of any race/ethnicity, sexual 
identity, or HIV-status, etc.  Exclude studies that 
focus on non-US MSM, adolescents (<18).  If mean 
age is 18 or older, include. 
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Is this study a behavioral 
intervention? (y/n) 
Scan article to identify if the study is categorized as a 
Behavioral intervention.  Behavioral Interventions try 
to change individual risk behaviors by providing 
necessary skills or materials.  Intervention methods 
might involve modeling or demonstration, role-
playing, or participatory skill development (i.e. 
increasing condom use).  Behavioral interventions 
are different than provision-of-information-only 
interventions that try to change knowledge, 
attitudes, or norms only (e.g. increasing HIV 
knowledge), or environmental interventions that aim 
to change the physical or social environment to 
promote health and prevent disease (e.g.  reducing 
stigma).  Exclude information-only, environmental, 
and pharmaceutical interventions (i.e. PreP) 
Was this study tested in RCT 
with an independent 
comparison group? (y/n) 
Include only randomized controlled trials with an 
independent comparison group. (i.e. treatment and 
control, pre and post measurements for each group). 
Did this study measure HIV 
behavioral or biological 
outcomes? (y/n) 
Include studies that describe HIV prevention, or 
behavioral risk reduction, as the primary or 
secondary study outcome.  HIV prevention outcomes 
may be behavioral (e.g. increasing condom use, 
decreasing # of sexual partners, etc) or biological 
(e.g. HIV/STI incidence or prevalence).  Include 
studies that may have had a different primary 
outcome (e.g. alcohol or substance use behaviors), 
but included HIV prevention or behavioral risk 
reduction as a secondary outcome. 
100% HIV positive sample? 
If 100% of participants were HIV-positive, exclude. 
Include or exclude? Decision 
If excluded, why? If you excluded, indicate why the study was not 
eligible 
NOTES Any notes 
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Participant Characteristics If any variable is unclear or not reported, mark 
UNCLEAR or NOT REPORTED 
Sample size at baseline 
(enrollment) 
Report N at baseline (enrollment).  This may be what 
they report in the abstract 
Age Range Report the age range of participants included in the 
study (entire sample) 
Age (mean)   Report the mean age for the entire sample at 
baseline 
Age, SD Report the age standard deviation 
age (median) Report the age median, if available 
(%) race/ethnicity - (Black, 
Latino/Hispanic, white, other) 
Report the % of white, black, Asian, Hispanic, etc, for 
the entire study sample.  Studies will vary in how 
they report race and ethnicity.  Report Black, 
Latino/Hispanic, White, and Other. 
% racial/ethnic minority MSM  
Calculate the sum of Hispanic and non-white MSM in 
the sample and report as  % of minority 
race/ethnicity msm represented in the study 
 % HIV-Positive  Report % of sample that was HIV-positive 
How was HIV-status assessed? How did the authors measure HIV status (i.e. self-
report, testing at baseline?) 
(%) HS education or less Report percent that graduated HS or less than HS. 
Would you say this is a very 
high-risk MSM sample? (y/n) 
In your opinion, do you think this is a high-risk 
sample as defined by high numbers of baseline 
sexual partners, risky sex and drug activity, high-risk 
sexual networks, etc.  You do not need to qualify. 
% substance users Report % of study sample who were substance users 
(any) 
%  sex workers/trade sex Report % of study sample who were sex 
workers/traded sex 
% MSMW (not identified as 
bisexual) 
Report % of study sample who had sex with both 
men and women, but did not identify as bisexual 
% gay-identified Report % of study sample who identified as gay 
% bisexual-identified 
Report % of study sample who identified as bisexual 
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% mental health or 
vicitimization history 
Report % of study sample who had mental health 
issues, including but not limited to depression, 
childhood sexual abuse, lifetime victimization, 
mental distress other. 
Intervention Characteristics   
Any biological outcomes? Report if the study used biological outcomes as 
endpoints 
Intervention level (individual-
level, group-level, community-
level) 
Report if the study was an individual-level 
intervention (ILI), group-level intervention (GLI), or 
community-level intervention (CLI) - as stated in 
article - if unclear, mark unclear 
Randomized?   
Were participants randomized to study groups?  
(yes, no).  If not, report how they were assigned to 
arms.   
N randomized? Report N they randomized 
Method of 
randomization/allocation 
How did the authors operationalize the 
randomization procedure? 
Unit of randomization individual, group, community? 
Unit of analysis individual, group, community? 
If unit  of randomization does 
not match unit of analysis, did 
authors control for this? E.g. 
report intra-class correlation 
coefficient? 
Report only if unit of randomization and unit of 
assignment are different.  If they are different, did 
authors report that they controlled for it (e.g. intra-
class correlation coefficient)?   
More than 1 experimental 
condition? 
Note yes/no if study used more than 1 experimental 
condition (e.g. two group randomized trial with 
control) 
comparison/control condition 
(description of control) Describe the control group in 1-2 words (information 
only, usual treatment, general health education, etc)  
Classification of control (wait 
list control, HIV-related 
comparison group, non-HIV 
comparison group) 
categorize as wait-list, HIV-related comparison (any 
HIV information, etc), non-HIV related (i.e. nutrition 
workshop) 
Intervention setting 
(Community, clinic, MSM 
setting, other) Where did the intervention take place? 
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Who facilitated the 
intervention? (MSM, 
professional, paraprofessional)  
Who facilitated/delivered the intervention?  Was it 
another MSM, professional (e.g. mental health 
counselor), para-professional (e.g. HIV test 
counselor, community outreach worker)? 
Peer-led intervention? 
Indicate if it was a peer-led intervention.  It may not 
be explicit, so examine if the known facilitator 
matches the participants, if so, then classify as peer-
led. 
Group size? (if GLI) 
If GLI - about how many participants in each group? 
Intervention time span (# of 
weeks from start to finish) 
How many weeks did the intervention last from start 
to finish? (e.g. 6 weeks, 12 weeks, etc) 
Number of sessions How many total sessions were in the intervention 
(e.g. 2, 6, 12)  
Number of hours (total time of 
intervention) 
How many hours (or total time) was the 
intervention? (e.g. 3 sessions X 2 hours each = 6 
hours total dose) 
Last recall period for primary 
outcome 
What the recall period participants were asked to 
use for the last follow-up session? (e.g. ppts asked to 
report on last 30 days of sexual behavior=30 days) 
Incentives for participation? Did participants receive incentives for participation? 
(yes/no) 
Method of outcome 
assessment (interview, paper 
survey, ACASI, internet survey) 
How were the outcomes assessed? Use categories: 
interview, paper survey, ACASI/CASI, internet survey) 
Years conducted When was the study started and finished? (e.g. 1997-
1998) 
Multi-site or single site? 
 If interventions were conducted at one site, list as 
single-site.  If interventions were conducted across 
multiple sites, list as multi-site. 
US region Report US region if known 
Intervention Name/Title 
What did the authors call the intervention?  (i.e. 
Project RESPECT, Many Men Many Voices - 3MV, 
Living Well, etc…).  If there is no name, report NR. 
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Theory 
Did the authors report a theoretic principle (e.g. 
Transtheoretical Model/Stages of Change, 
Information-Motivation-Behavior, Social Cognitive 
Theory, Motivational Interviewing, etc)? If so, list. 
Did the authors report it was 
pilot tested? Did the authors describe any pilot testing or 
exploratory research prior to intervention launch? 
Include more than 1 behavioral 
outcome? 
Does the study measure outcomes on at least 1 
other behavior (other than sexual risk reduction; i.e. 
substance use, HIV testing)? 
Focus on racial/ethnic minority 
MSM? 
Did the authors describe any known psychometric 
properties of the scale (i.e. previously tested, 
cronbach's alpha/reliability coefficients, etc).   
Focus on MSM substance 
users? yes/no 
Other specified subgroup? 
Was this intervention designed, tailored to, or 
otherwise focused on MSM of color? (yes/no)  If yes, 
list specific group 
Focus on technology? (if yes, 
describe) 
Did this intervention focus on using technology such 
as the Internet, telephones, text messaging, or other 
communication channels? 
Focus on sexual 
communication? (yes/no) 
Did this intervention focus on improving or 
increasing any kind of sexual communication 
between partners (e.g. HIV status disclosure, 
condoms, safer sex, etc? 
Focus on individualized risk 
reduction plans? (yes/no) 
Did the intervention components include 
development of individualized risk reduction plans 
tailored to the individual? 
Focus on stigma and 
discrimination? (yes/no) 
Did the intervention focus on stigma and 
discrimination (related to being gay, or being MSM of 
color) in intervention components? 
Inclusion Criteria (HIV status, 
substance use, UAI, 
serodiscordant partner…) 
list inclusion criteria as described exactly by the 
authors 
Study Results 
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Primary outcome (s) 
What is the study's intended outcome? (e.g. increase 
condom use).  If multiple outcomes, list all; separate 
with comma/semi-colon 
Any significant positive effects 
on outcome/s? (difference 
between treatment and 
control) 
Were the statistical results significant between 
groups and in the right direction?  Yes/no (e.g. 
yes=study showed 26% decrease in UAI that was 
statistically significant) 
If other interesting results, 
describe here (i.e. within 
groups differences, etc). 
Use this spot to report on other significant or 
interesting results including within groups (pre-post 
change scores by group), subgroup analyses, etc. 
Significance testing based on 
α=.05 (or less) and 2-sided 
test? 
Were significance tests based on .05 alpha level (or 
more stringent such as .01) and a two-tailed test? 
Aim: reductions in UAI? (list 
sig/ns) 
If UAI (unprotected anal intercourse) was the 
outcome, were outcomes significant (sig) or not 
significant (ns)? 
Aim: increased condom use? 
(sig/ns) 
If condom use was the outcome, were outcomes 
significant or not significant? 
Aim: reduce number of sexual 
partners? 
if # of partners was an outcome, were outcomes 
significant or not significant? 
Aim reduced substance use? 
(sig/ns) 
If substance use was the outcome, were outcomes 
significant or not significant? 
Aim: reduce serodiscordant 
sex? (sig/ns) 
If serodiscordant sex was the outcome, were 
outcomes significant or not significant? 
Aim: reduce receptive sex? 
(sig/ns) 
If receptive sex was the outcome, were outcomes 
significant or not significant? 
Other outcomes (testing, 
disclosure, substance use, list 
sig/ns) 
If other outcomes were studies such as HIV testing, 
disclosure to partners, or substance use, describe 
and report if results were sig or ns. 
A priori power analysis 
conducted? 
Did the authors report that they conducted an a 
priori power analysis to specify sample size?  If so, 
did they specify >80% power? 
Follow-up time used for 
analyses (# months after T1) 
How many months between T1 and last follow up 
(T2)? 
Analytic sample >40 per 
group? 
Did the treatment and control groups have at least 
40 ppts in each at the time of analysis? 
n treatment group at T1 
(baseline) How many ppts in the tx group at T1 (at baseline)? 
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n control group at T1 
How many ppts in the control group at T1 (at 
baseline)? 
n tx group T2 (follow-up) How many ppts in the tx group at T2 (at follow-up)? 
n control group T2 
How many ppts in the control group at T2 (at follow-
up)? 
% and n - retention at last f/u 
At the last follow-up, what percent of ppts overall 
were retained in the study?  (compare overall 
baseline to overall f/u and calculate %) 
% retention tx group (at last 
f/u) 
At the last follow-up, what percent of ppts in the tx 
group were retained? 
% retention in control group 
(at last f/u) 
At the last follow-up, what percent of ppts in the 
control group were retained? 
Differential Retention? Is there differential retention between tx and control 
groups? 
Baseline differences between 
study groups? 
Were there baseline differences between the tx and 
control groups? Yes/no 
If yes, what?   
(ITT) Intent-to-treat analysis 
(ppts analyzed in original 
groups and data replacement 
for dropouts)? Did the authors specify they used an ITT analysis?   
Did study provide a CONSORT 
statement? 
Did the article have an attachment or reference to a 
CONSORT statement?  (standardized reporting for 
RCTs) 
Was study a registered trial? Did the study indicate a trial registration # in the 
article or abstract? 
Statistical Information   
For continuous data analyses 
(T1=baseline; T2=final f/u) 
Only for interval-level data  - skip to categorical 
if needed - retrieve baseline (T1) and final 
follow/up (T2).  Retrieve n for each of the four 
groups (baseline tx, baseline control, f/u tx, f/u 
control), the group means, and their SD or SE to 
calculate effect sizes later.  If there are multiple 
outcomes (e.g. reduced UAI, reduced substance 
use), use multiple rows and list study ID# each 
time 
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Study ID (use multiple lines for 
multiple outcomes) ID 
Specific outcome variable 
definition 
Describe the outcome as specifically as possible, 
matching the authors description 
N analyzed for results Total N for analytic sample 
N analyzed in tx group n for tx group 
N analyzed in control group n for control group 
Means transformed or 
adjusted? If so indicate with 
red type 
Indicate if any means were transformed or adjusted 
with yes/no and then mark the reported adjusted 
means with a (*). 
N analyzed at T1 - tx group n for how many in tx group at time 1 
Mean at T1 
(tx group) group mean for the tx group at T1 
SD at T1 (tx group) If reported, list standard deviation 
SE at T1 (tx group) if reported, list standard error 
N analyzed at T1 - control 
group 
n for how many in control group at time 1 
(baseline) 
Mean at T1 
(control group) group mean for the tx group at T2 
SD at T1 (control group) If reported, list standard deviation 
SE at T1 (control group) if reported, list standard error 
N analyzed at T2 - tx group 
n for how many in tx group at time 2 (last follow-
up) 
Mean at T2 
(tx group) 
What was the follow-up mean for the tx group? (e.g. 
mean number of UAI occasions at T1).   Use last 
possible follow-up. 
SD at T2 (tx group) If reported, list standard deviation 
SE at T2 (tx group) if reported, list standard error 
N analyzed at T2 - control 
group 
n for how many in control group at time 2 (f/u) 
Mean at T2 
(control group) 
What was the follow-up mean for the control group? 
(e.g. mean number of UAI occasions at T1).   Use last 
possible follow-up. 
SD at T2 (control group) list standard deviation 
SE at T2 (control group) list standard error 
Mean Difference Tx group (T1-
T2) calculate mean differences; use excel formula 
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Mean difference control group 
(T1-T2) calculate mean differences; use excel formula 
Mean Difference (T - C at T2) calculate mean differences; use excel formula 
correlation pre-post scores if reported, otherwise leave blank 
statistical method used Report test used 
t-value t-value if reported 
F statistic F-stat if reported 
p-value p-value if reported 
Df df if reported 
RR 
RR if reported (e.g. ratio of mean # of events  in Tx 
group to mean # of events in control, see Johnson's 
2008 Cochrane review) 
Beta betas for any regression models 
SMD 
Standardized mean difference if reported.  If unclear, 
consult Cochrane definition at: 
http://handbook.cochrane.org/chapter_9/9_2_3_2_t
he_standardized_mean_difference.htm 
95% CI If the authors reported 95% CI for ES, list 
Other   
Effect size reported Yes/no 
ES type type (Cohen’s d, Cohen’s f, etc) 
ES test statistic 
95% CI for ES 95% CI specific to ES 
For categorical data analysis 
for dichotomous data: Think about constructing 
a 2X2 table for each of the four groups; we 
need the # or % who reported the outcome 
("yes" = ex. this would be the 1 group in a 
binary analysis) and the # or % that did NOT 
report the outcome ("no"= ex. this would be 
the 0 group in a binary analysis).  If there are 
multiple outcomes (e.g. reduced UAI, reduced 
substance use), use multiple rows, and list 
study ID# each time. 
Specific outcome variable 
definition specific outcome variable, same as continuous  
N analyzed tx group Instructions same as continuous 
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N analyzed control group Instructions same as continuous 
N analyzed at T1-tx group Instructions same as continuous 
number for tx group at T1 - 
outcome 
If authors reported counts, list number of ppts in tx 
group that reported outcome at T1 (e.g. 50 report 
any UAI).   
number for tx group at T1 - no 
outcome 
If authors reported counts, list number of ppts in tx 
group that reported no outcome at T1 (e.g. 50 
reported zero UAI).   
proportion for tx group at T1 - 
outcome 
If authors reported % or proportion, list number of 
ppts in tx group that reported any outcome at T1 
(e.g. 50% reported UAI).   
proportion for tx group at T1 - 
no outcome 
If authors reported % or proportion, list number of 
ppts in tx group that reported no outcome at T1 (e.g. 
50% reported NO UAI).   
N analyzed at T1- control group same as continuous 
number for control group at T1 
- outcome 
If authors reported counts, list number of ppts in 
control group that reported outcome at T1 (e.g. 50 
report any UAI).   
number for control group at T1 
- no outcome 
If authors reported counts, list number of ppts in 
control group that reported no outcome at T1 (e.g. 
50 reported zero UAI).   
prop. for control group at T1 -
outcome 
If authors reported % or proportion, list % of ppts in 
control group that reported any outcome at T1 (e.g. 
50% reported UAI).   
prop. for control group at T1 - 
no outcome 
If authors reported % or proportion, list % of ppts in 
control group that reported no outcome at T1 (e.g. 
50% reported NO UAI).   
N analyzed at T2-tx group Instructions same as continuous 
number for tx group at T2 - 
outcome 
If authors reported counts, list number of ppts in tx 
group that reported outcome at T2 (e.g. 50 report 
any UAI).   
number for tx group at T2 - no 
outcome 
If authors reported counts, list number of ppts in tx 
group that reported no outcome at T2 (e.g. 50 
reported zero UAI).   
prop. for tx group at T2 - 
outcome 
If authors reported % or proportion, list % of ppts in 
tx group that reported any outcome at T2 (e.g. 50% 
reported UAI).   
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prop. for tx group at T2 - no 
outcome 
If authors reported % or proportion, list % of ppts in 
tx group that reported no outcome at T2 (e.g. 50% 
reported NO UAI).   
N analyzed at T2-control group same as continuous 
number for control group at T2 
- outcome 
If authors reported counts, list number of ppts in 
control group that reported outcome at T2 (e.g. 50 
report any UAI).   
number for control group at T2 
- no outcome 
If authors reported counts, list number of ppts in 
control group that reported no outcome at T2 (e.g. 
50 reported zero UAI).   
prop. for control group at T2 - 
outcome 
If authors reported % or proportion, list number of 
ppts in control group that reported any outcome at 
T2 (e.g. 50% reported UAI).   
prop. for control group at T2 - 
no outcome 
If authors reported % or proportion, list number of 
ppts in control group that reported no outcome at T2 
(e.g. 50% reported NO UAI).   
statistical method used statistical test used 
χ2 list test stats that are reported 
OR Odds ratio 
RR Relative risk 
PR Prevalence ratio 
Risk Diff Risk difference 
CI  95% confidence interval 
Logged OR  Logged Odds Ratio 
p value  Exact p-value 
Other  Other 
effect size reported?  Yes/no 
ES type type (Cohen’s d, Cohen’s f, etc) 
95% CI for ES 95% CI for ES 
NOTES Notes 
Methodological Quality 
Review using PRS Criteria 
Refer to PRS criteria 
http://www.cdc.gov/hiv/dhap/prb/prs/efficacy/rr/cri
teria/index.html 
Is study described as an EBI? Is it reported to be an Evidence-Based Intervention? 
If CDC already classified in 
their 2013 review (studies 
before 2011), list their ranking Use Higa et al (2013) when possible 
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(EBI, positive non-EBI, rigorous 
non-EBI, other non-EBI) 
Refer to PRS GOOD criterion 
for study's intervention level 
(ILI, GLI, CLI): Indicate if study 
met all points for each 
criterion; if no, list failures.  yes/no 
I. Intervention Description yes/no 
II. Quality of Study Design yes/no 
III. Quality of Study 
Implementation and Analysis yes/no 
IV.  Strength of Evidence yes/no 
V.  No demonstrated 
significant negative 
intervention effects yes/no 
VI. Additional Limitations to 
Evaluate yes/no 
Methodological Quality 
Category  
EBI: 
Met PRS criteria for good and 
had positive result yes/no 
Rigorous Non-EBI: 
Met good PRS criteria, but no 
positive result yes/no 
Positive Non-EBI: 
Positive Result, but did not 
meet at least 1 PRS criteria  yes/no 
Other-Non-EBI: 
No positive result, did not 
meet at least 1 PRS criterion  yes/no 
Different from CDC rating, 
when applicable Notes 
NOTES  
DONE! STOP.  
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APPENDIX C 
 
COMPENDIUM OF EVIDENCE-BASED INTERVENTIONS AND BEST PRACTICES 
FOR HIV PREVENTION RISK REDUCTION (RR) CHAPTER  
Last updated December 3, 2014 
 
PRS Efficacy Criteria for Best-Evidence Risk Reduction (RR) Individual-level, Group-
level, and Couple-level Interventions (ILIs/GLIs/CPLs) 
 
Intervention Description  
 Clear description of key aspects of the intervention  
 
Quality of Study Design  
 Prospective study design  
 Appropriate and concurrent comparison arm  
 Random or minimally biased assignment of subjects to study arms  
 
Quality of Study Implementation and Analysis  
 Follow-up assessment ≥ 3-months post completion of intervention for each study arm 
with recall not referring to pre-intervention period)  
 At least a 70% retention rate at a single follow-up assessment for each study arm  
 Comparison between intervention arm and an appropriate comparison arm  
 Analysis of participants subjects in study arms as originally allocated regardless of 
contamination or logistic/implementation issues  
 Analysis of participants regardless of the level of intervention exposure  
 Use of appropriate cluster-level analyses if assigned to study arms by cluster or group  
 Analysis must be based on post-intervention levels or on pre-post changes in measures  
 For pre-post changes used in analysis, measures must be identical, including identical 
recall period  
 Analysis based on an α =.05 (or more stringent) and a 2-sided test  
 With nonrandomized assignment, either no statistical differences in baseline levels of 
the outcome exist or baseline differences are controlled for in the analysis  
 Analytic sample ≥ 50 participants per study arm  
 
Strength of Evidence  
Demonstrated Significant Positive Intervention Effects  
 Positive and statistically significant (p < .05) intervention effect for ≥1 relevant 
outcome measure  
 A positive intervention effect is defined as a greater reduction in HIV/STD incidence 
or risk behaviors or a greater increase in HIV protective behaviors in the intervention 
arm relative to the comparison arm  
 A relevant outcome is defined as a behavior (e.g., abstinence, mutual monogamy, 
number of sex partners, consistent condom use with anal/vaginal sex, unprotected 
anal/vaginal sex, proportion of anal/vaginal sex acts protected, injection drug use, 
sharing or borrowing needles/works) - that directly impacts HIV risk or a biologic 
measure indicating HIV or STD infection (i.e., HIV or STD incidence)  
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 Effect at the follow-up and based on the analyses that meet study implementation and 
analysis criteria  
 
No Demonstrated Significant Negative Intervention Effects  
 No negative and statistically significant (p < .05) intervention effect for any relevant 
outcome  
 A negative intervention effect is defined as a greater increase in HIV/STD incidence 
or risk behaviors or a greater decrease in HIV protective behaviors in the intervention 
arm relative to the comparison arm.  
 No other statistically significant harmful intervention effect  
 For an intervention with a replication evaluation, no significant negative intervention 
effects in the replication study  
 
Additional Limitations to Evaluate  
 No evidence that additional limitations resulted in a fatal flaw: o A fatal flaw has 
occurred when the overall evaluation of limitations indicates they resulted in 
considerable bias, thus substantially reducing the confidence of the findings.  
 Examples of 
within potentially biased subset analyses;  
 Substantial missing data. Missing data plus loss to attrition exceeds acceptable limits 
for retention alone (≥ 40%)  
 Study arm non-equivalence: statistically significant differences between arms in 
important baseline demographics or risk factors  
 Differential retention: (1) significant difference between study arms in characteristics 
among retained or lost-to-follow up participants; OR (2) more than minimal rate of 
differential retention (>10%)  
 Intervention activities did not match with the intervention concepts or guiding theories 
intended to produce the desired outcomes  
 Did not clearly describe issues related to generalizability  
 Too many post hoc analyses (even with Bonferroni corrections)  
 Inconsistent findings  
 
All criteria must be satisfied for an intervention to be considered as a best-evidence 
individual-level, group-level, or couple-level intervention. Source: Lyles et al., (2006) and 
Lyles at al., (2007). 
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PRS Efficacy Criteria for Best-Evidence Risk Reduction (RR) Community-level 
Interventions (CLIs) 
Intervention Description  
 Clear description of key aspects of the intervention  
 
Quality of Study Design  
 Prospective study design  
 Appropriate and concurrent control/comparison arm  
 ≥ 4 communities per arm or appropriate power analysis indicating that a smaller 
number of communities was adequate (i.e., 2 or 3 communities per arm)  
 Select similar communities (units) for assignment  
 To minimize selection bias before assignment regardless of assignment methods 
(randomization or not); use methods such as systematic, a priori approaches to choose 
intervention and control communities that are similar (e.g., matching or stratification 
on factors related to important/appropriate community characteristics)  
 
Quality of Study Implementation and Analysis  
 Sample individuals from assigned communities in acceptable ways (e.g., random, 
systematic) and use identical methods and eligibility criteria for selecting participants 
in each community, study arm, and data collection wave  
 If demographic differences are identified a priori, differential selection (e.g., over-
sampling based on demographics) may be used to achieve equivalence between study 
arms on those factors  
 Follow-up assessment ≥ 3 months post completion of entire time-specific CLI or post 
full implementation of on-going CLI with recall not referring to pre-intervention 
period  
 “Post full implementation of an on-going CLI” means after all components of the CLI 
have been started or put in place in communities  
 If cohort, at least 70% retention rate at a single follow-up assessment for each study 
arm  
 If cohort chart review, ≥ 70% success rate in matching medical records  
 Comparison between intervention arm and an appropriate comparison arm  
 Analysis of communities (units) and analysis of individuals within the communities as 
originally assigned regardless of contamination or logistic/implementation issues  
 Analysis of communities (units) regardless of community level of intervention 
exposure  
 Analysis of individuals within the communities (units) regardless of individual level 
of intervention exposure  
 Use of appropriate cluster-level analyses, e.g., adjusting for ICC  
 Analysis must be based on post-intervention levels or among pre-post changes in 
measures  
 For pre-post changes used in analysis, measures must be identical, including identical 
recall period  
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 Analysis based on an a=.05 (or more stringent) and a 2-sided test; either no statistical 
differences in baseline levels of the outcome exist or baseline differences are 
controlled for in the analysis, regardless of allocation method (e.g., randomization, 
non-randomization)  
 No differences on baseline levels of the outcome means reporting no significant 
difference between groups on BL relevant outcomes or match/stratify/statistically 
adjust participant data by using propensity scores or relevant outcome covariates 
(regardless of assignment methods - RCT or non-RCT)  
 
Strength of Evidence  
Demonstrated Significant Positive Intervention Effects  
 Positive and statistically significant (p < .05) intervention effect for ≥ 1 relevant 
outcome measure  
 A positive intervention effect is defined as a greater reduction in HIV/STD incidence 
or risk behaviors or a greater increase in HIV protective behaviors in the intervention 
arm relative to the comparison arm.  
 A relevant outcome is defined as a behavior (e.g., abstinence, mutual monogamy, 
number of sex partners, consistent condom use with anal/vaginal sex, unprotected 
anal/vaginal sex, proportion of anal/vaginal sex acts protected, injection drug use, 
sharing or borrowing needles/works) that directly impacts HIV risk or a biologic 
measure indicating HIV or STD infection (i.e., HIV or STD incidence)  
 Effect at the follow-up and based on the analyses that meet study implementation and 
analysis criteria  
 
No Demonstrated Significant Negative Intervention Effects  
 No negative and statistically significant (p < .05) intervention effect for any relevant 
outcome  
 A negative intervention effect is defined as a greater increase in HIV/STD incidence 
or risk behaviors or a greater decrease in HIV protective behaviors in the intervention 
arm relative to the comparison arm.  
 No other statistically significant harmful intervention effect  
 For an intervention with a replication evaluation, no significant negative intervention 
effects in the replication study  
 
Additional Limitations to Evaluate  
 No evidence that additional limitations resulted in a fatal flaw: o A fatal flaw has 
occurred when the overall evaluation of limitations resulted in considerable bias, thus 
substantially reducing the confidence of the findings  
 Examples of limitations to check for possible fatal flaw: Group non-equivalence in 
baseline measures of important demographics or risk factors  
 Differential Retention (for cohort studies): (1) association between study arms and 
characteristics related to retention or attrition; OR (2) more than minimal rate of 
differential retention (> 10%) 
 Differential Refusal: At baseline for cohort studies; by wave for serial cross-sectional 
studies: (1) association between study arms and characteristics related to refusal; OR 
(2) more than minimal rate of differential refusal rate (> 100)  
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 Intervention activities did not match with the intervention concepts or guiding theories 
intended to produce the desired outcomes  
 Did not clearly describe issues related to generalizability  
 Effects only found within a potentially biased subset analyses  
 Substantial missing data (> 10% or missing data plus loss to attrition does not exceed 
acceptable limits for retention alone)  
 Too many post hoc analyses (even with Bonferroni corrections)  
 Pilot study or very small sample size per study arm (< 50)  
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PRS Efficacy Criteria for Good-Evidence 
Risk Reduction (RR) Individual-level, Group-level, and Couple-level Interventions 
(ILIs/GLIs/CPLs) 
 
Intervention Description  
 Clear description of key aspects of the intervention  
 
Quality of Study Design  
 Prospective or quasi-prospective study design  
 Appropriate and concurrent comparison arm, or historical comparison (provided it is 
similar to intervention arm with respect to population, setting, and time frame in the 
epidemic, and identical with respect to follow-up interval, recall period, and outcome 
measures)  
 Random, minimally biased, or moderately biased allocation of participants to study 
arms, allowing for selection bias unrelated to the intervention or HIV risk. 
Assignment may be based on pre-established groups or selection into something other 
than the intervention, provided neither is directly related to HIV risk.  
 
Quality of Study Implementation and Analysis  
 Follow-up assessment ≥ 1 month post-completion of intervention for each study arm 
with recall not referring to pre-intervention period  
 At least a 60% retention rate (or medical chart recovery) at a single follow-up for each 
study arm  
 Comparison between intervention arm and an appropriate comparison arm  
 Analysis of participants in study arms as originally allocated, or contaminated 
participants may be excluded if numbers are small, but participants may not be re-
assigned for analytic purposes  
 Analysis of participants may be based on intervention exposure, where participants 
exposed to < 50% of the entire intended intervention may be excluded  
 If participants excluded due to contamination or low exposure (as described above), 
retention rate must include these participants at each follow-up they were assessed  
 Analysis must be based on post-intervention levels or on pre-post changes in measures  
 For pre-post changes used in analysis, measures must be identical, including identical 
recall period  
 Analysis based on an α =.05 and either a 2-sided test or 1-sided test if an a priori 
direction is hypothesized  
 With nonrandomized assignment, either no statistical differences exist in baseline 
levels of the outcome measure, or baseline differences must be controlled for in the 
analysis. If moderately-biased assignment or historical comparison was used, 
differences in baseline demographics also must be controlled for in the analysis.  
 Analytic sample of ≥ 40 participants per study arm  
 
Strength of Evidence  
Demonstrated Significant Positive Intervention Effects  
 Positive and statistically significant (p < .05) intervention effect for ≥ 1 relevant 
outcome measures 
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 A positive intervention effect is defined as a greater reduction in HIV/STD incidence 
or risk behaviors or a greater increase in HIV protective behaviors in the intervention 
arm relative to the comparison arm.  
 A relevant outcome is defined as a behavior (e.g., abstinence, mutual monogamy, 
number of sex partners, consistent condom use with anal/vaginal sex, unprotected 
anal/vaginal sex, proportion of anal/vaginal sex acts protected, injection drug use, 
sharing or borrowing needles/works) that directly impacts HIV risk or a biologic 
measure indicating HIV or STD infection (i.e., HIV or STD incidence)  
 Effect at the follow-up and based on the analyses that meet study implementation and 
analysis criteria 
 
No Demonstrated Significant Negative Intervention Effects  
 No negative and statistically significant (p < .05) intervention effect for any relevant 
outcome  
 A negative intervention effect is defined as a greater increase in HIV/STD incidence 
or risk behaviors or a greater decrease in HIV protective behaviors in the intervention 
arm relative to the comparison arm.  
 No other statistically significant harmful intervention effect  
 For an intervention with a replication evaluation, no significant negative intervention 
effects in the replication study  
 
Additional Limitations to Evaluate  
 No evidence that additional limitations resulted in a fatal flaw: o A fatal flaw has 
occurred when the overall evaluation of limitations indicates they resulted in 
considerable bias, thus substantially reducing the confidence of the findings.  
 Examples of item limitations to check for possible fatal flaw:  
o Effects only found within potentially biased subset analyses  
o Substantial missing data: Missing data plus loss to attrition exceeds 
acceptable limits for retention alone (≥ 40%)  
o Study arm non-equivalence: statistically significant differences between arms 
in important baseline demographics or risk factors  
o Differential Retention: (1) association between study arms and characteristics 
related to retention or attrition; OR (2) more than minimal rate of differential 
retention (> 10%)  
o Intervention activities did not match with the intervention concepts or guiding 
theories intended to produce the desired outcomes  
o Did not clearly describe issues related to generalizability  
o Too many post hoc analyses (even with Bonferroni corrections)  
o Inconsistent findings  
 
 
All criteria must be satisfied for an intervention to be considered as a good-evidence 
individual-level, group-level, or couple-level intervention 
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PRS Efficacy Criteria for Good-Evidence Risk Reduction (RR) Community-level 
Interventions (CLIs) 
Intervention Description  
 Clear description of key aspects of the intervention  
 
Quality of Study Design  
 Prospective or quasi-prospective study design  
 Appropriate and concurrent comparison arm, or historical comparison (provided it is 
similar to intervention arm with respect to population, setting, time frame in the 
epidemic, and identical with respect to follow-up time, recall period, and outcome 
measures)  
 Post hoc selection of comparison is allowed  
 ≥ 1 community per arm  
 1 community per arm is acceptable only if the following conditions are met: (1) there 
is a significant pre- and post-intervention change in the relevant outcome for the 
intervention arm, and (2) the significant pre- and post-intervention change is based on 
appropriate participant-level analysis or repeated-measures analysis.  
 Select similar communities (units) for assignment  
 To minimize selection bias before assignment regardless of random assignment or 
other assignment methods, used methods such as systematic, a priori approaches to 
select intervention and comparison communities that are similar (e.g., matching or 
stratification on factors related to important/appropriate community characteristics)  
 
Quality of Study Implementation and Analysis  
 Sample individuals from assigned communities in acceptable ways (e.g., random, 
systematic) and use identical methods and eligibility criteria for selecting participants 
in each community, study arm, and data collection wave  
 If demographic differences are identified a priori, differential selection (e.g., over-
sampling based on demographics) may be used to achieve equivalence between study 
arms on those factors  
 Follow-up assessment ≥ 1 month post completion of entire time-specific CLI or post 
full implementation of on-going CLI with recall not referring to pre-intervention 
period  
 “Post full implementation of on-going CLI” means after all components of the CLI 
have been started or put in place in communities  
 If cohort, at least 60% retention rate (or medical chart recovery) at a single follow-up 
assessment for each study arm  
 Comparison between intervention arm and an appropriate comparison arm  
 Analysis of communities (units) as originally assigned, or communities may be 
excluded due to contamination or logistic/implementation issues only if dropping no 
more than one community per study arm AND retaining at least two thirds of intended 
communities 
 Analysis of individuals within the communities (units) as originally assigned, or 
contaminated individuals may be excluded if numbers are small, but individuals may 
not be reassigned for analytic purposes  
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 Analysis of communities (units) regardless of community level of intervention 
exposure  
 Analysis of individuals within the communities (units) may be based on intervention 
exposure, where dropping individuals who were not exposed to any intervention 
component (e.g., have not heard of or recognized intervention materials) would retain 
at least 60% of total sample  
 Cluster-level analyses may be provided, but is not required  
 Analysis must be based on post-intervention levels or among pre-post changes in 
measures  
 For pre-post changes used in analysis, measures must be identical, including identical 
recall period  
 Analysis based on an α =.05 and either a 2-sided test or 1-sided test if an a-priori 
direction is hypothesized  
 Either no statistical differences in baseline levels of the outcome exist or baseline 
differences are controlled for in the analysis, regardless of allocation method (e.g., 
randomization, non-randomization)  
 No differences on baseline levels of the outcome means reporting no significant 
difference between study arms in baseline relevant outcome measures, or 
match/stratify/statistically adjust participant data by using propensity scores or 
relevant outcome covariates (regardless of assignment methods – RCT or non-RCT)  
 
Strength of Evidence  
Demonstrated Significant Positive Intervention Effects  
 Positive and statistically significant (p < .05) intervention effect for ≥ 1 relevant 
outcome measure  
 A positive intervention effect is defined as a greater reduction in HIV/STD incidence 
or risk behaviors or a greater increase in HIV protective behaviors in the intervention 
arm relative to the comparison arm  
 A relevant outcome is defined as a behavior (e.g., abstinence, mutual monogamy, 
number of sex partners, consistent condom use with anal/vaginal sex, unprotected 
anal/vaginal sex, proportion of anal/vaginal sex acts protected, injection drug use, 
sharing or borrowing needles/works) that directly impacts HIV risk or a biologic 
measure indicating HIV or STD infection (i.e., HIV or STD incidence)  
 Effect at the follow-up and based on the analyses that meet study implementation and 
analysis criteria  
 
No Demonstrated Significant Negative Intervention Effects  
 No negative and statistically significant (p < .05) intervention effect for any relevant 
outcome  
 A negative intervention effect is defined as a greater increase in HIV/STD incidence 
or risk behaviors or a greater decrease in HIV protective behaviors in the intervention 
arm relative to the comparison arm  
 No other statistically significant harmful intervention effect 
 
Additional Limitations to Evaluate  
 No evidence that additional limitations resulted in a fatal flaw:  
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 A fatal flaw has occurred when the overall evaluation of limitations indicate they 
resulted in considerable bias, thus substantially reducing the confidence of the 
findings  
 Examples of limitations to check for possible fatal flaw:  
 Study arm non-equivalence: statistically significant differences between arms in 
important baseline demographics or risk factors  
 Differential Retention (for cohort studies): (1) association between study arms and 
characteristics related to retention or attrition; OR (2) more than minimal rate of 
differential retention (> 10%)  
 Differential Refusal – at baseline for cohort studies; by wave for serial cross-
sectional studies: (1) association between study arms and characteristics related to 
refusal; OR (2) more than minimal rate of differential refusal rate (> 10%)  
 Intervention activities did not match with the intervention concepts or guiding 
theories intended to produce the desired outcomes  
 Did not clearly describe issues related to generalizability  
 Effects only found within potentially biased subset analyses  
 Substantial missing data (> 10%, or missing data plus loss to attrition exceeds 
acceptable limits for retention alone)  
 Too many post hoc analyses (even with Bonferroni corrections)  
 Pilot study or very small sample size per study arm (< 40)  
 Inconsistent findings 
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